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BRIEF ABSTRACT  
This thesis evaluated the clinical utility of cardiopulmonary computed tomography 
(CT) in patients presenting with chest pain and dyspnoea. 
Studies within this thesis confirmed the following. Firstly, there is a requirement for 
improved diagnostic pathways to minimise patients being discharged without a 
diagnosis, which currently occurs in 30-40% of patients admitted with chest pain and 
dyspnoea.  Historically, CT has been utilised in 32% of admissions with chest pain and 
10% of admissions with dyspnoea.   
Secondly, challenges exist to the wider adoption of cardiopulmonary CT. These include 
patient-related factors, institutional capabilities and guideline restrictions. In acute 
admissions, 11% of patients with dyspnoea and 7% of patients with chest pain and a 
low to moderate likelihood of CAD are suitable for CT. In the RACPC setting, including 
patients across the entire spectrum of CAD likelihood, 18% of patients are suitable for 
CT. NICE CG95 would recommend only 1% of acute chest pain admissions and 2% of 
RACPC attenders for CT.  
Thirdly, NICE CG95 would recommend 51% of acute chest pain admissions and 66% of 
RACPC attenders for discharge without cardiac investigation. In the RACPC population, 
significant CAD is identified in 10% of these patients and a major adverse cardiac event 
in 2%.  
Fourthly, in selected patients with suspected cardiac chest pain, cardiac CT has a 
diagnostic yield of 21% in acute admissions and 13% in RACPC attenders for significant 
CAD. In acute admissions with dyspnoea, cardiopulmonary CT has a diagnostic yield of 
20% for CAD, 20% for pulmonary embolism, nil for aortic dissection and 89% for non-
vascular chest pathology. 
Fifthly, inclusion of CT in diagnostic pathways for chest pain result in fewer patients 
discharged without a diagnosis, fewer invasive angiography procedures and reduced 
diagnostic costs. In patients with dyspnoea, CT provides value to clinicians making 
diagnoses and supports early discharge without detrimental outcomes. 
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CHAPTER 1: GENERAL INTRODUCTION 
1.1 INTRODUCTION 
Over 900,000 patients present to emergency departments in England each year with 
cardiac and respiratory symptoms. Combining emergency and elective admissions, 
cardio-respiratory disease is thought to account for around two and a half million bed 
days per annum{HSCIC, 2014}.  
Most commonly, cardio-respiratory conditions manifest as chest pain and/or 
dyspnoea. The symptoms of cardiac and respiratory disease overlap and elucidating 
the underlying pathology or pathologies in patients presenting to hospital with chest-
related symptoms is a recognised diagnostic challenge, particularly when 
communication may be limited by breathlessness. Chest pain occurs concurrently with 
dyspnoea in a number of conditions, including acute coronary syndrome (ACS), 
pneumothorax, and pulmonary embolism (PE). A significant minority of patients with 
ACS or PE complain of dyspnoea alone. 
Evidence suggests that there is a lack of association between clinical history and 
underlying pathophysiology{Swap, 2005; Lien, 2002}. Diagnosis is even more difficult 
in older patients with multiple co-morbidities and obesity.  This is particularly relevant 
now almost two thirds (65%) of people admitted to hospital are over 65 years old and 
those over 85 years old account for 25% of bed days{Cornwell, 2011} 
Diagnostic uncertainty contributes to misdiagnosis and delays the initiation of 
appropriate therapy. Selection of a treatment strategy based on misdiagnosis may 
even be hazardous to health; for example, β agonist and steroid therapy for suspected 
chronic obstructive pulmonary disease may be detrimental in decompensated 
congestive cardiac failure.  
In patients admitted to the emergency department, any delay within the department 
reduces adherence to recognised treatment algorithms{Diercks, 2007} and increases 
the risk of admission to hospital and short term death{Guttmann, 2011}. Similarly, 
diagnostic uncertainty, delayed diagnosis and delayed admission has the secondary 
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effects of increasing in-hospital adverse events{Kline, 2007}, time to discharge and 
cost of treatment{Huang, 2010}.  
Clinical guidelines are increasing in prevalence and have a role in supporting 
consistent, evidence based and cost effective approaches to diagnosis and 
management. At present, national and international guidelines exist for the 
assessment of patients in whom a provisional diagnosis of cardiac chest pain or 
pulmonary embolism has already been made{Hamm, 2011; Amsterdam, 2014; 
Konstantinides, 2014}. Algorithms for the assessment of patients with acute dyspnoea 
are more broad-based and lack focus{NICE, 2010}. Specific guidance relating to acute 
dyspnoea is currently limited to suspected cardiac failure.  
In part, this relative lack of guidance relates to an absence of robust data fully defining 
the clinical, biochemical and radiological findings of patients presenting with non-
specific chest pain and dyspnoea. The result is that diagnosis remains highly 
dependent on the impression of the admitting physician, based on clinical history and 
examination.  
1.2 CURRENT APPROACH TO THE ASSESMENT OF PATIENTS WITH CHEST PAIN 
Coronary artery disease (CAD) accounts for up to one third of hospital admissions in 
England (around 600,000 admissions per year), while angina affects more than two 
million individuals in the UK{Shaper, 1984}. Although the most common symptom 
attributable to CAD is chest pain, chest pain is often non cardiac in origin{Bosner, 2009; 
Nilsson, 2003}. The prevalence of acute myocardial infarction in patients attending the 
emergency department with undifferentiated chest pain is as low as 4%. Significant 
pulmonary disease such as pneumonia accounts for 11%, with pulmonary embolism 
and aortic dissection diagnosed in around 0.4% and 0.3% of patients with chest pain 
respectively{Kohn, 2005}.  
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Table 1.1: Differential diagnoses for acute chest pain{Stillman, 2007} 
Life threatening Non-life threatening 
Acute coronary syndrome  
Pulmonary embolism  
Aortic dissection  
Intramural haematoma  
Penetrating aortic ulcer  
Aortic aneurysm/rupture 
Oesophageal rupture  
Pericardial tamponade  
Tension pneumothorax  
 
Pneumonia/pulmonary parenchymal 
disease 
Pulmonary, mediastinal, or pleural 
neoplasm 
Musculoskeletal injury or inflammation  
Cholecystitis  
Pancreatitis  
Herpes zoster 
Hiatus hernia/GORD/oesophageal spasm 
Pericarditis/myocarditis  
Simple pneumothorax 
 
Nevertheless, the diagnosis of acute myocardial infarction is missed in between 5 and 
10% of patients and these individuals have worse clinical outcomes{Lee, 1987}.  
Missed diagnoses are more common amongst patients who present atypically; these 
individuals are more likely to be female, aged less than 55 years, non-white, to report 
dyspnoea as their primary complaint and to have a non-diagnostic electrocardiograph 
(ECG){Pope, 2000}. The life threatening nature of myocardial infarction and the time 
imperative for therapeutic intervention has led to a ‘rule out MI’ approach.  
Traditionally, emergency department algorithms for the management of patients with 
chest pain risk have risk stratified individuals based on age, symptoms, ECG changes 
and positive biomarkers of myocardial necrosis{Anderson, 2007}.  Those deemed low 
risk have typically been discharged from hospital while those deemed high risk have 
proceeded to invasive coronary angiography{Antman, 2000}.  
Malpractice fear is a contributing factor for hospitalisation and use of diagnostic 
tests{Katz, 2005}. Due to the limitations of risk stratification and the potential fatal 
consequences of missed ACS, up to 60% of patients eligible for emergency department 
discharge are admitted to hospital for further investigation{Gibbons, 1999}. This 
perceived “intermediate risk” group utilise significant resources, often with prolonged 
observation and multiple investigations. The resulting number of potentially 
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unnecessary hospital days is equal to or greater than 65 per hundred patients{Kaul, 
2004}.  
Conventional assessment of chest pain includes serial measurement of serum 
biomarkers, exercise ECG testing, radionuclide perfusion imaging and ultimately 
invasive coronary angiography. Each of these techniques has recognised limitations.  
1.2.1 BIOMARKERS IN ACUTE CHEST PAIN 
There is broad consensus that cardiac troponin (Tn) I or T is the preferred biomarker 
in clinical practice, however, release occurs only slowly from damaged myocytes and 
peak levels are reached around 12 hours after symptom onset. The need for serial 
sampling to obtain maximum sensitivity results in delays in triage decision making. 
Uncertainties remain regarding the value of high-sensitivity Tn assays, including the 
optimum timings for measurement and the thresholds for normality.  
Other markers used in the triage of patients with acute chest pain include copeptin 
and natriuretic peptides. Some centres continue to rely on less sensitive and less 
specific markers such as myocardium specific creatine kinase (CK-MB). The triad of 
myoglobin-CK-MB-Tn I has a sensitivity of 57% for the detection of acute coronary 
ischaemia, and the combination of ischaemia modified albumin-myoglobin-CK-MB-Tn 
I increases diagnostic sensitivity to 97%{Anwaruddin, 2005}. 
1.2.2 IMAGING IN ACUTE CHEST PAIN  
Non-invasive imaging has a role in the risk stratification, prior to discharge, of stable 
patients who are not selected for urgent cardiac catheterisation. Imaging is often 
performed as an intermediate step and improves confidence in the safety of 
emergency department discharge{Andersen, 2007}.  There is an additional benefit in 
identifying patients with latent ischaemia who may benefit from more aggressive 
revascularisation. Imaging also aids identification of non-coronary causes of chest 
pain.  
Non-invasive cardiac imaging modalities include: chest radiography; multi-detector 
computed tomography (MDCT) used predominantly for the assessment of anatomic 
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CAD; single-photon emission computed tomography (SPECT), positron emission 
tomography (PET) and cardiac magnetic resonance (CMR) used for myocardial 
perfusion imaging; stress echocardiography and CMR used for stress wall motion 
imaging. 
These imaging modalities have varying combinations of availability, portability, and 
ease of applicability to the acute setting. Furthermore, a variety of factors impact the 
quality and breadth of information that the tests provide. Selection of the most 
appropriate imaging modality depends on patient-related factors (e.g. heart rate 
control, hemodynamic stability, renal function, contrast allergy) and institutional 
capabilities (e.g. rapid availability, state-of-the-art technology, and expertise). 
1.2.2.1. Chest Radiography 
Chest radiography is inadequate for the diagnosis or exclusion of significant CAD. It is 
primarily used to exclude conditions that mimic myocardial infarction and to identify 
secondary features such as pulmonary oedema{Buenger, 1988}. In this context, chest 
radiography is highly useful to exclude pneumothorax, with a sensitivity around 40% 
and specificity around 99%{Alrajab, 2013}. Cardiovascular diagnoses, including aortic 
aneurysm, aortic dissection, and pulmonary embolism may be suggested on chest 
radiography but with far lower sensitivity than other imaging modalities such as CT.  
1.2.2.2. Radionuclide Imaging 
In patients with ongoing chest pain, no ischaemic changes on ECG and a negative Tn, 
rest SPECT is useful as a first line investigation{Kontos, 2004; Udelson 2002}. The most 
commonly used SPECT radionuclides are the technetium-based agents, Tc-99m-
sestamibi and Tc-99m-tetrofosmin, and thallium (Tl-201). The absence of a perfusion 
defect during an acute rest study is associated with a very high negative predictive 
value for ACS{Heller, 1998; Candell-Rieraa, 2004}.  If symptoms have abated, 
provocative stress testing may be necessary to exclude obstructive CAD. A perfusion 
defect that becomes apparent or larger during exercise stress or pharmacologic stress 
SPECT defines myocardial ischaemia. Meta-analysis of 79 studies totalling 8,964 
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patients showed an overall diagnostic sensitivity and specificity of SPECT myocardial 
perfusion imaging (MPI) of 86% and 74%, respectively{Underwood, 2004}.  
MPI, using dipyridamole and radiolabelled ammonia (13N-NH3) or rubidium (Rb-82), 
can also be performed using PET. PET is more costly and less available than SPECT but 
appears to be superior in image quality, interpretive certainty, and diagnostic accuracy 
for significant coronary artery stenoses{Bateman, 2006}. 
Both SPECT and PET allow metabolic imaging of the myocardium. Altered glucose and 
fatty acid metabolism in regions of myocardial ischaemia and reperfusion 
(demonstrating ischaemic memory) are detectable using 18F-fluorodeoxyglucose 
(18F-FDG) and 123I-βmethyl-P-iodophenylpentadecanoic acid (123I-BMIPP) 
respectively. Kawai et al. suggest that metabolic imaging may be superior to perfusion 
imaging for identifying CAD as the cause of chest pain{Kawai, 2001}. In a meta-analysis 
of 7 studies and 528 patients, the sensitivity of resting BMIPP imaging for significant 
CAD was 78% with specificity 84%{Inaba, 2008}. Metabolic imaging with FDG and 
BMIPP has also been used for direct ischaemia detection during stress testing{He, 
2003; Dilsizian, 2005}.  
The clinical role for integrated radionuclide and CT imaging and image fusion 
continues to evolve{Flotats, 2010; Dorbala, 2013}. 
1.2.2.3. Cardiac Magnetic Resonance  
Some centres have adopted CMR for the diagnosis of CAD. Approaches include first-
pass gadolinium myocardial enhancement with vasodilator stress and dobutamine 
stress-induced wall motion studies. The strengths of CMR are high resolution imaging 
without soft tissue attenuation artefact, the absence of ionising radiation, and the 
capability to assess valve and ventricular function. Disadvantages include the 
requirement to transport patients out of acute assessment areas, and incompatibility 
with implanted cardiac and other metallic devices. 
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1.2.2.4. Echocardiography 
Two-dimensional echocardiography has a high sensitivity for the diagnosis of ACS 
(91%), and moderate specificity (75%) based on the detection of regional wall 
dysfunction{Kontos, 1998}. Stress echocardiography, using a pharmacologic agent 
(e.g. dobutamine) to induce wall motion abnormalities in regions of ischaemia, is 
equivalent to stress SPECT MPI in the acute setting in low-to-intermediate risk 
patients{Quinones, 1992}. Based on pooled data, in patients with intermediate-to-
high likelihood of CAD, stress echocardiography is equivalent in sensitivity to SPECT 
but superior in specificity{Fleischmann, 1998}.  The often quoted limitations of 
echocardiography are suboptimal image quality (10-15%), lack of quantitation and 
poor identification of single vessel or circumflex disease{Senior, 2005}; however, 
advances in image acquisition, digital display, and the development of harmonic and 
contrast imaging have reduced variability in study acquisition and increased reliability 
and reproducibility. Colour kinesis, tissue Doppler, strain and strain rate imaging allow 
the assessment of segmental arterial function and provide some quantitative analysis 
of the left ventricular response to stress. Using contrast imaging, myocardial perfusion 
can be reviewed in parallel with wall motion imaging. The modality also allows 
detection of left ventricular aneurysms, pseudoaneurysms, effusions, and valvular 
dysfunction. 
1.2.2.5. Computed Tomography (see also section 1.5.1) 
Coronary computed tomographic angiography (CTA) offers direct visualisation of the 
coronary arterial system for the detection of obstructive CAD. The strength of the 
technique is in the detection of CAD in symptomatic patients with either low-to 
intermediate CAD risk or equivocal echocardiographic or SPECT results. In a recent 
European study, the diagnostic accuracy of coronary CTA was significantly greater than 
that of myocardial perfusion imaging and wall motion imaging for detection of 
significant CAD defined invasively{Neglia, 2015}. The absence of obstructive CAD in a 
patient with chest pain is also useful to exclude ACS. Coronary CTA has a very high 
negative predictive value for the detection of coronary atherosclerosis with or without 
significant stenosis{Chow, 2009}. Evaluation of patients with coronary CTA may be 
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limited in patients with high heart rates (>65 beats/min) uncontrolled by beta-blockers 
or other rate-limiting agents, and in patients with intractable dysrhythmias. 
 
Table 1.2: American College of Radiology appropriateness criteria® for the 
investigation of chest pain suggestive of acute coronary syndrome{ACR, 2014) 
Radiologic Procedure Rating Comments RRL* 
SPECT MPI rest and stress 8 This procedure is appropriate for intermediate-
to-high likelihood for coronary artery disease. 
There is abundant literature available on clinical 
utility. 
 
Arteriography coronary 8 This procedure is the gold standard and is 
invasive. 
 
SPECT MPI rest only 7 In the setting of ongoing chest pain, this 
procedure has a high negative predictive value. 
Tc-99m is the most commonly used 
radionuclide agent for this test. RRL may be 
higher if thallium (Tl-201) used. 
 
US echocardiography transthoracic 
stress 
7 Consider this procedure when resting echo and 
cardiac enzymes are normal. 
O 
US echocardiography transthoracic 
resting 
6 This procedure is primarily used for evaluating 
wall-motion abnormalities and aortic dissection. 
O 
CTA coronary arteries with contrast 6 Consider this procedure for those patients with 
low-to-intermediate likelihood for coronary 
artery disease, in the absence of cardiac 
enzyme elevation and ischaemic ST changes. 
 
X-ray chest 5 This procedure is primarily a survey for non-
cardiac aetiologies of chest pain. 
 
CT chest with contrast 5 This procedure is primarily for non-cardiac 
aetiologies such as pulmonary embolism and 
aortic dissection. 
 
MRI heart function with stress 
without and with contrast 
5 For this procedure there is limited experience in 
the clinical setting and lack of availability.  
O 
MRI heart function with stress 
without contrast 
4 For this procedure there is limited experience in 
the clinical setting and lack of availability. 
O 
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Rb-82 PET heart stress 4 For this procedure there is lack of widespread use and 
availability. 
 
MRI heart function and morphology 
without and with contrast 
4 This procedure is primarily for the possibility of aortic 
dissection.  
O 
CT chest without and with contrast 3  
 
MRI heart function and morphology 
without contrast 
3 This procedure is primarily for the possibility of aortic 
dissection. 
O 
US echocardiography transoesophageal 3 This procedure has a relative contraindication for acute 
coronary syndrome. 
O 
CT coronary calcium 2 This procedure is not validated in the acute setting. 
 
MRA coronary arteries without contrast 2 This procedure is technically challenging, and there is a lack of 
widespread use as well as protocol availability. 
O 
MRA coronary arteries without and with 
contrast 
2 This procedure is technically challenging, and there is a lack of 
widespread use as well as protocol availability. 
O 
CT chest without contrast 2  
 
*Relative Radiation Level; Rating scale: 1,2,3 usually not appropriate; 4,5,6 may be appropriate; 7,8,9 usually appropriate 
1.2.3 RATIONALE FOR NON-INVASIVE TESTING 
A sequence of events, known as the ischaemic cascade, occurs when myocardial 
oxygen demand exceeds supply. The first detectable abnormality is regional 
myocardial blood flow heterogeneity between vascular beds supplied by normal and 
stenosed coronary arteries (manifest as areas of perfusion deficit on MPI). 
Subsequently, left ventricular relaxation abnormalities manifest as diastolic 
dysfunction and progress to regional systolic dysfunction (manifest as regional wall 
motion abnormalities). Chest pain and ECG changes are late features of the cascade. 
A rest image during symptoms may be adequate to detect or exclude flow 
heterogeneity (MPI) or regional wall motion abnormalities (echocardiography). If 
symptoms have resolved, provocative stress testing may be indicated. Since 
atherosclerosis, the basis for most acute coronary events, presents initially as artery 
wall thickening and arterial enlargement with luminal narrowing only occurs following 
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plaque rupture, stress tests may be falsely negative in patients with vulnerable plaque 
disease.  
Figure 1.1: Stages of atherosclerosis detectable by invasive and non-invasive 
methods{Erbel, 2012} 
 
Schematic drawing of the development of coronary arteriosclerosis including positive remodelling during plaque burden increase 
and the listing of invasive and non-invasive methods concerning their ability to detect signs of atherosclerosis starting with 
endothelial dysfunction and ending with signs of ischaemia in the ECG  
(EKG – electrocardiograph; PET – positron emission tomography; CT – computed tomography; MRT – magnetic resonance 
tomography; OCT – optical coherence tomography; IVUS – intravascular ultrasound) 
Plaque composition and morphology are key determinants for plaque vulnerability 
and likelihood of rupture.  Features of high risk disease include large plaque volume, 
a lipid-rich core that occupies greater than 40% of the plaque volume, and the 
presence of positive coronary artery remodelling (Figure 1.2). Furthermore, plaque 
distribution impacts on an individual’s likelihood of death with proximal left anterior 
descending artery and multi-vessel disease portending the greatest risk{Min, 2007}. 
Non-invasive detection and analysis of plaques at an early stage, particularly in 
asymptomatic and low risk patients, has the potential to improve risk stratification 
without the need for more invasive procedures.  
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Figure 1.2: Positive remodelling in response to progressive atherosclerosis and 
plaque formation{Glacov, 1987} 
 
1.2.4 INVASIVE CORONARY ANGIOGRAPHY  
Invasive coronary angiography has historically been the ‘gold standard’ investigation 
for CAD.  Coronary artery luminal diameter, estimated by visual inspection of a radio-
opaque lumen during angiography, is used to predict clinical presentation and stress-
induced reductions in coronary blood flow. CAD severity assessment can be optimised 
by the use of quantitative coronary angiography, intravascular ultrasound or the use 
of fractional flow reserve to assess the haemodynamic effects of individual stenosis. 
The usefulness of invasive coronary angiography is limited by its inability to 
demonstrate the nature of atherosclerotic plaques or the presence of coronary artery 
remodelling (Figure 1.2).  Furthermore, the endovascular nature of the test confers a 
1.7% risk of major complications including heart attack, stroke and peripheral embolic 
events and a mortality risk of 0.1%{Scanlon, 1999; Scanlon, 1999}.  
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1.2.5 NICE CLINICAL GUIDELINE CG95 
In March 2010, the National Institute for Health and Care Excellence (NICE) released 
guidelines for the assessment and diagnosis of recent onset chest pain or discomfort 
of suspected cardiac origin{NICE, 2010}. NICE CG95 is subdivided into acute and stable 
chest pain algorithms. The first is intended for patients with acute chest pain who may 
have an acute coronary syndrome (ACS). In this context, ACS is considered to include 
unstable angina, non-ST-segment-elevation myocardial infarction (NSTEMI) and ST-
segment-elevation myocardial infarction (STEMI). The second is for those with 
intermittent stable chest pain who may have stable angina.  
The acute chest pain algorithm states that initial assessment of patients presenting to 
hospital with suspected ACS should focus on clinical history, physical examination, 
resting 12 lead ECG and cardiac biomarker analysis. Patients with findings consistent 
with STEMI should be managed in accordance with NICE CG167(NICE, 2013} and 
considered for urgent coronary reperfusion therapy. Patients with findings consistent 
with unstable angina or NSTEMI should be managed in accordance with NICE 
CG94{NICE, 2010} and considered for ischaemia testing and/or invasive angiography 
prior to hospital discharge. Patients in whom ACS is excluded but myocardial 
ischaemia is still suspected should be investigated according to the stable chest pain 
algorithm. 
Patients admitted to acute assessment units (via referral from general practitioners 
and the emergency department) with suspected cardiac chest pain are most 
commonly those pending investigations to confirm/exclude ACS and those in whom 
ACS has been excluded but a clinical suspicion of CAD persists. Upstream triage means 
that patients with STEMI or low risk of CAD rarely reach this clinical setting. Thus, 
assessment of this population may involve either the acute or stable chest pain 
algorithms of NICE CG95.  
Patients with suspected stable angina in whom hospital admission is not immediately 
warranted are routinely referred to outpatient cardiology services via Rapid Access 
Chest Pain Clinics (RACPCs). Assessment and investigation of these patients should 
follow the stable chest pain algorithm of NICE CG95. CCT has been incorporated into 
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the stable chest pain algorithm, highlighting its increasing role in the acute and 
outpatient settings.  
Figure 1.3: Summary of NICE CG95 
Diagnostic approach for patients with ‘chest pain of recent onset’ 
Subdivided into acute and stable chest pain algorithms. 
 
Patients with suspected stable CAD are risk stratified using a model which amalgamates modified 
Diamond-Forrester criteria{Diamond, 1979} and the Duke clinical score{Pryor, 1993}.  
Patients are assigned within age and sex categories to higher or lower risk according to whether 
they have any of diabetes, hyperlipidaemia or a history of smoking (Table 1.3). 
 
1) Patients with a history of non-anginal chest pain are not routinely recommended for further 
cardiac investigation. 
2) Patients with a history of atypical or typical cardiac chest pain and a likelihood of CAD 
between 10% and 90% should be investigated further. 
a) CCT for those with a likelihood of CAD 10-29% 
b) functional cardiac testing for those with a likelihood of CAD 30–60% 
c) invasive coronary angiography for those with a likelihood of CAD 61–90% 
3) above 90%, it is recommended that patients are treated for angina without further 
diagnostic testing. 
 
CCT in this context comprises coronary calcium scoring with progression to CT coronary 
angiography if calcium score exceeds an absolute total value of 1 and progression directly to 
invasive coronary angiography if calcium score exceeds an absolute total value of 400. 
 
Exercise ECG should not be used to diagnose or exclude stable angina for those without known 
CAD. 
 
1.2.5.1. Risk stratification using NICE CG95 criteria 
Pre-test likelihood of CAD is determined from the nature of chest pain (Figure 1.4) and 
the nomogram below (Table 1.3).  
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Figure 1.4: Clinical classification of chest pain{NICE, 2010} 
1. Sub-sternal chest discomfort of characteristic quality and duration 
2. Provoked by exertion or emotional stress 
3. Relieved by rest and/or GTN 
 
Typical angina (definite) Meets three of the above criteria 
Atypical angina (probable) Meets two of the above criteria 
Non-anginal chest pain Meets one or none of the above criteria 
 
Table 1.3: Estimated percentage likelihood of CAD{NICE, 2010} 
AGE 
(YEARS) 
NON ANGINAL CHEST PAIN ATYPICAL ANGINA TYPICAL ANGINA 
M F M F M F 
LO HI LO HI LO HI LO HI LO HI LO HI 
35 3 35 1 19 8 59 2 39 30 88 10 78 
45 9 47 2 22 21 70 5 43 51 92 20 79 
55 23 59 4 25 45 79 10 47 80 95 38 82 
65 49 69 9 29 71 86 20 51 93 97 56 84 
 For men older than 70 with atypical or typical symptoms, assume an estimate >90%.  
 For women older than 70, assume an estimate of 61–90% EXCEPT women at high risk AND with typical symptoms 
where a risk of >90% should be assumed. 
 Values are per cent of people at each mid-decade age with significant coronary artery disease (CAD). 
 Hi = High risk = diabetes, smoking and hyperlipidaemia (total cholesterol > 6.47mmol/litre). Lo = Low risk = none of 
these three. If there are resting ECG ST-T changes or Q waves, the likelihood of CAD is higher in each cell of the 
table. 
1.3 CURRENT APPROACH TO THE ASSESMENT OF PATIENTS WITH DYSPNOEA 
Dyspnoea is defined by the American Thoracic Society as a ‘subjective experience of 
breathing discomfort that consists of qualitatively distinct sensations that vary in 
intensity’{Parshall, 2012}.  
Dyspnoea is commonly reported by older people in the UK community setting with a 
prevalence of 32.3%{Ahmed, 2012}. Population sampling across fifteen countries 
suggests around 27% of the general population report dyspnoea but prevalence is 
reduced to 16% in those without risk factors or dyspnoea-associated disease. In a 
community based survey of men in Sweden, dyspnoea was reported in 21% of the 
total population and in 70% of patients with angina, highlighting the overlap between 
cardio-respiratory symptoms{Hagman, 1981}. Females report dyspnoea more 
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frequently than males (odds ratio ≈ 2.1){Nielsen, 2013}. Historically, breathlessness 
has been reported in around 25% of patients admitted as medical 
emergencies{Pearson, 1981}.  
Breathlessness is associated with poor functional status, reduced physical and mental 
health. Increasing Medical Research Council (MRC) dyspnoea grade corresponds to 10 
year mortality{Ho, 2001; Ahmed, 2012}. After adjustment for age, gender and 
underlying diseases, dyspnoea is an independent predictor of death{Ahmed, 2012}. 
The physiological mechanisms of dyspnoea are poorly understood but are thought to 
relate to stimulation of respiratory muscle and juxta-capillary mechanoreceptors, 
central and peripheral chemo-receptors, in response to increased work of breathing, 
interstitial fluid and hypoxia/hypercarbia. When forced vital capacity is below 60% of 
predicted, dyspnoea is more likely{Nielsen, 2013}. 
The diagnoses that manifest as acute breathlessness are multi-systemic but around 
two thirds of cases are attributable to cardio-respiratory disease{Gillespie, 1994}.  
Around 85% of cases are attributed to one or more of chronic obstructive pulmonary 
disease, pneumonia, ischaemic heart disease, interstitial lung disease or psychogenic 
manifestation. Acute dyspnoea is multifactorial in up to one third of cases{Michelson, 
1999}.  
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Table 1.4 Differential diagnosis for dyspnoea{Shiber, 2006} 
Mechanical interference with ventilation Abdominal or chest mass 
Asthma, emphysema, bronchitis 
Endobronchial tumour 
Interstitial fibrosis of any cause 
Kyphoscoliosis 
Left ventricular failure 
Lymphangitic tumour 
Obesity  
Obstruction to airflow, central or peripheral 
Pleural thickening  
Resistance to expansion of the chest wall or diaphragm 
Resistance to expansion of the lung 
Thoracic burn with eschar formation 
Tracheal or laryngeal stenosis 
Weakness of the respiratory pump 
 
 
 
 
 
 
Absolute 
Hyperinflation 
Neuromuscular disease 
Obesity 
Pleural effusion 
Pneumothorax  
Previous poliomyelitis  
Relative 
Increased respiratory drive 
 
 
 
 
 
Decreased cardiac output 
Decreased effective haemoglobin 
Hypoxemia of any cause 
Metabolic acidosis 
Renal disease 
Stimulation of intrapulmonary receptors 
Wasted ventilation 
 
Capillary destruction 
Large-vessel obstruction 
Psychological dysfunction 
 
 
 
Anxiety 
Bodily preoccupation, somatization disorder 
Depression 
Secondary gain, malingering 
 
Traditionally, comprehensive clinical assessment has been the foundation for 
diagnosis in patients with acute dyspnoea; however, signs and symptoms are often 
unhelpful{Mueller, 2005} and can lack both sensitivity and specificity, particularly 
when performed by junior staff in noisy or chaotic environments such the emergency 
department. In a study of elderly patients with dyspnoea and acute respiratory failure, 
the accuracy of diagnosis of their admitting emergency department physician ranged 
from 0.76 for cardiogenic pulmonary oedema to 0.96 for asthma. Inappropriate 
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treatment was initiated in almost one third of patients, contributing to increased 
mortality{Ray, 2006}. 
1.3.1. IMAGING IN ACUTE DYSPNOEA 
Chest radiography is the primary imaging modality for the direct assessment of 
patients with dyspnoea although CT is widely used to allay diagnostic uncertainty and 
guide admission decisions{Pandharipande, 2015}. Radionuclide imaging has 
traditionally been used to evaluate myocardial perfusion and systolic function in 
suspected CAD and for the inclusion or exclusion of pulmonary embolism. Peripheral 
ultrasound provides additional information when venous thromboembolism is 
suspected. Bedside echocardiography and CMR are increasingly popular for non-
invasive evaluation of the myocardium, chambers, valves and pericardium when 
cardiac causes of dyspnoea are suspected.  
1.3.1.1. Chest radiography 
The use of diagnostic chest radiography is almost universal and the percentage of 
acute hospital admissions undergoing radiography is often used as a marker of quality 
of acute care{Malnick, 2010}. This is despite evidence that in acute admissions, the 
rate of detection of abnormal x-ray features is less than 50%{Malnick, 2010; Sagel, 
1974; Verma, 2011} and in the absence of an abnormal chest examination or clinical 
indication, admission radiographs contribute to management in less than 4% of 
patients{Malnick, 2010}. The strength of the chest radiograph is its wide availability, 
low risk and suitability for serial assessment. The UK has a lower frequency of x-ray 
examination per capita than other developed countries with an estimated 8.3 million 
chest radiographs performed per annum{DOH, 2002}.   
1.3.1.2 Radionuclide imaging 
Planar ventilation-perfusion (VQ) scanning has long been established as a robust, safe 
investigation for the diagnosis of PE. The investigation is based on an intravenous 
injection of 99m-technetium-labelled albumin particles to allow scintigraphic 
assessment of lung perfusion. Perfusion scans are combined with ventilation studies, 
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for which tracers include 133-xenon gas, 99m-technetium-labelled aerosols, and 99m-
technetium-labelled carbon microparticles. 
Planar VQ has traditionally been limited by challenges in defining the size and precise 
location of thrombus, the use of probabilistic reporting criteria, and a relatively high 
indeterminate rate{PIOPED Investigators, 1990}. As a result, CT pulmonary 
angiography (CTPA), with its binary (positive/negative) reporting approach, has been 
the preferred imaging technique for suspected thromboembolism.  
The use of VQ SPECT imaging techniques, with or without low-dose CT, contributes to 
fewer non-diagnostic scans{Bajc, 2008}. On pooled analysis of study data, VQ SPECT 
has higher sensitivity, specificity and accuracy than planar imaging and a lower 
indeterminate rate{Stein, 2009}. Furthermore, SPECT has superior sensitivity and only 
mildly inferior specificity to CTPA (0.97/0.91 vs 0.86/0.98 respectively){Reinartz, 
2004}. Compared with CTPA, SPECT also offers a lower radiation dose and no contrast-
related complications.  
SPECT is gaining popularity as the first line imaging technique in patients with 
suspected PE and a normal chest radiograph. In the future, SPECT may allow the use 
of automated detection algorithms for PE but large-scale prospective studies are 
needed to validate such approaches{Konstantinides, 2014}.  
1.3.1.3. Computed Tomography (see also section 1.5.2) 
Conventional CT, with or without contrast-enhancement, has a role in the detection 
of pericardial disease and pulmonary causes of dyspnoea (e.g. diffuse parenchymal 
lung disease){Dyer, 2013}. CT is particularly appropriate in patients for whom clinical, 
radiographic, and laboratory studies are non-revealing or non-diagnostic. Compared 
to chest radiography, CT enables more comprehensive assessment of pulmonary 
vascularity in the context of cardiac failure. In many institutions, CT angiography is the 
first-line investigation for the assessment of suspected PE and proximal thoracic aortic 
disease. The strengths of cardiac CT in the dyspnoeic patient are in non-invasively 
differentiating between ischaemic and non-ischaemic causes of cardiomyopathy and 
providing supportive information regarding ventricular volumes and function. 
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Table 1.5: American College of Radiology appropriateness criteria® for the 
investigation of dyspnoea of suspected cardiac origin{ACR, 2010} 
Radiologic Procedure Rating Comments RRL* 
X-ray chest 8  
 
US echocardiography 
transthoracic resting 
8  O 
US echocardiography 
transthoracic stress 
7  O 
SPECT MPI rest and stress 7  
 
PET heart stress 7  
 
MRI heart function and 
morphology with or without 
contrast 
7  O 
CTA coronary arteries 6  
 
CTA coronary arteries with 
advanced low dose techniques 
6  
 
CTA chest (non-coronary) 6  
 
Cardiac catheterization with 
angiocardiography 
6  
 
US echocardiography 
transoesophageal 
5  O 
CT chest with or without contrast 5  
 
Radionuclide ventriculography 4  
 
Tc-99m V/Q scan lung 3  
 
CT coronary calcium 3  
 
Arteriography pulmonary 3  
 
*Relative Radiation Level; Rating scale: 1,2,3 usually not appropriate; 4,5,6 may be appropriate; 7,8,9 usually appropriate 
1.3.2 NON-IMAGING TECHNIQUES  
Non-imaging techniques are more commonly used to aid diagnosis in patients with 
chronic rather than acute dyspnoea. Diagnostic accuracy in chronic dyspnoea 
increases from 55% to 72% when pulmonary function testing is incorporated into an 
algorithm with history and physical examination{Pratter, 2011}. Pulmonary function 
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testing and oximetry are particularly important when asthma or chronic obstructive 
pulmonary disease is suspected. Cardiopulmonary exercise testing, with 
measurement of peak oxygen uptake, anaerobic threshold and breathing reserve, is 
useful when combinations of cardiac and respiratory causes are being 
considered{Maeder, 2009}. 
1.3.3. BIOMARKERS IN ACUTE DYSPNOEA 
Natriuretic peptides are widely used for the diagnosis and exclusion of cardiac failure 
in patients with acute dyspnoea. BNP has additive diagnostic benefit when combined 
with clinical judgement{Januzzi, 2005} and rapid BNP testing within triage protocols 
for acute dyspnoea has been shown to reduce time to diagnosis, length of hospital 
stay, rehospitalisation rates and total cost of treatment{Mueller, 2006; Breidthardt, 
2007; Moe, 2007}.  
BNP is also a powerful prognostic indicator in unselected dyspnoea{Christ, 2007}. 
Increasing levels are associated with intensive care admission in acute exacerbations 
of COPD{Stolz, 2008} and of treatment failure and death in patients with community 
acquired pneumonia{Christ-Crain, 2008}. BNP levels correlate with the pneumonia 
severity index{Christ-Crain, 2008} and, in patients with pulmonary embolism, BNP is a 
significant predictor of unfavourable outcome{Cavallazzi, 2008; Klok, 2008; Coutance, 
2008}. Conversely, BNP has a high negative predictive value for mortality in pulmonary 
embolism and as such may be used to identify low risk patients{Coutance, 2008; 
Vuilleumier, 2009}.  
Individual and multi-marker combinations have a role in the diagnosis of clinically 
challenging overlapping disease states{Maisel, 2012}. Pro-calcitonin (PCT) expression 
in parenchymal tissue is induced by bacterial infection and this biomarker aids the 
diagnosis of pneumonia, particularly in cases with high diagnostic uncertainty{Maisel 
A, 2012}. Pro-adrenomedullin (proADM) is a marker of severity assessment and 
outcome prediction in community acquired pneumonia{Christ-Crain, 2006}. D dimer 
has traditionally been used to exclude pulmonary embolism but there is increasing 
evidence for its use in assessing clot burden{Jeebun, 2010; Ghanima, 2007; Hochuli, 
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2007} and in prognostication{Kline, 2008}.  High sensitivity Tn T also correlates with 
mortality in acute dyspnoea{van Wijk, 2012}. 
1.4 COMPUTED TOMOGRAPHY 
Computed Tomography (CT) is a radiological investigation which utilises x-rays to 
generate detailed cross sectional images of the body. CT was first developed in the 
1970s by Sir Godfrey Hounsfield and Allan Cormack, who received the 1979 Nobel 
Prize in Medicine in recognition of their work. 
1.4.1 THE PHYSICS OF CT 
CT requires an x-ray source rotating within a circular plane and a set of x-ray detectors 
rotating in synchrony. The source and detector elements are housed in a ring shaped 
structure, known as a gantry, with the patient on a motorised table between them.  
The x-ray source acts as a transmitter and produces a narrow, fan-shaped beam of 
radiation, perpendicular to the long axis of the body. As the beam passes through 
tissue, there is variable attenuation along its path, due to absorption and scattering.  
The attenuation of a mono-energetic beam through a homogeneous material may be 
expressed according to Beer’s Law (Figure 1.5). The linear attenuation co-efficient is 
determined by the atomic number and electron density of the tissue through which 
the beam passes. 
Figure 1.5 Beer’s Law 
I = I0e- d  
I = intensity of the transmitted radiation 
I0 = initial radiation intensity 
μ = linear attenuation co-efficient of the tissue being scanned  
d = distance travelled by the radiation through tissue (i.e. tissue thickness) 
The application of Beer’s law in CT is somewhat for convenience, as the x-ray beam 
produced is by no means mono-energetic.  
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X-ray detectors convert incident x-rays into electrical impulses for transmission to a 
data acquisition unit. The resulting series of two-dimensional images are digitally 
reconstructed to produce detailed cross sectional and three-dimensional images of 
the patient.  
Figure 1.6: Diagrammatic representation of a spiral CT scanner 
 
1.4.2 SCANNER TECHNOLOGY 
In traditional axial scanning, the x-ray source and detector rotated 360 degrees around 
the patient with the table being stationary; thereafter the table was advanced for the 
next slice. If movement occurred during data acquisition, image quality was degraded. 
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Axial scanning was therefore only appropriate for imaging organs with no automatism 
function.  
In the 1970s, the development of spiral CT scanning facilitated continuous image 
acquisition as patients advanced through the CT gantry. The gantry performs multiple 
rotations, tracing a spiral of x-rays around the patient to produce a data volume. 
Individual slices are reconstructed from a series of overlapping images to reduce the 
impact of movement artefact seen with traditional axial ‘step and shoot’ scanners. 
Spiral scanning can therefore be used to image organs subject to involuntary motion.  
In the past two decades, CT scanners with multiple-row detectors have been 
developed, which allow simultaneous scanning of several slices, reducing overall 
scanning time. The first multi-slice scanners acquired 4 slices per rotation of the 
gantry. Modern scanners can acquire up to 640 slices per rotation, in as little as 0.2 
seconds. In addition to multiple detectors, scanners have now been developed with 
dual source capability. These allow a full CT slice to be obtained in a half rotation of 
the gantry. 
Short acquisition times mean a longer spiral scan can be acquired in a given time and 
a comparable volume can be scanned in less time with the elimination of motion 
artefact. Through the combination of speed and continuity, complete data sets can be 
obtained within a single breath-hold for thoracic imaging or within a single heartbeat 
for cardiac imaging. The speed of acquisition also facilitates dynamic contrast studies. 
Vessels can be imaged at the point of maximal enhancement and serial images can be 
taken during a single contrast cycle.  
The disadvantage of high speed acquisition is that the quantity of radiation generated 
per rotation is less, resulting in reduced image quality. Furthermore continuous 
movement results in increased slice thickness, associated with an increased likelihood 
of artefact.  
1.4.3 DATA ACQUISITION AND IMAGE PROCESSING  
Each data volume comprises a number of volume elements known as voxels. Voxels 
are three dimensional elements of anatomy represented by the two dimensional 
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pixels. Pixels are therefore two dimensional picture elements that combine to form 
the image matrix.  
The attenuation in each voxel determines the grey-scale of the corresponding pixel in 
the final two-dimensional image.  Attenuation is measured according to the 
Hounsfield scale, derived by linear transformation of the linear attenuation co-
efficient, in which the radiodensity of distilled water at standard pressure and 
temperature (STP) is defined as zero Hounsfield units (HU), and the radiodensity of air 
at STP is defined as -1000 HU{Brooks, 1977}.  
Table 1.6: The Hounsfield Scale  
SUBSTANCE HOUNSFIELD UNITS (HU) 
Air −1000 
Lung −500 
Fat −100 to −50 
Water 0 
Blood +30 to +45 
Muscle +10 to +40 
Soft Tissue, Contrast +100 to +300 
Bone +700 (cancellous bone) to +3000 (dense bone) 
 
Figure 1.7: The Hounsfield scale 
 
Partial volume effect occurs when different tissues are contained within the same 
voxel. Each tissue (e.g. calcified coronary plaque) only partially fills the voxel and is 
therefore a partial volume. When this occurs,  is not representative of a single tissue 
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but instead is a weighted average of the different  values. The thicker the slice on CT, 
the greater the averaging that occurs. 
Modern scanners allow for volumetric data acquisition with isotropic voxel size 
resolution in x, y, and z axes, facilitating multi-planar reformations with no limitation 
to orientation and angulation. 
1.4.4 IMAGE QUALITY 
There have been recent dramatic advances in imaging software that allow virtual 
reality and 3D image reconstruction. Detailed images can now be generated with sub-
millimetre resolution.  Improvements in both spatial and temporal resolution have 
reduced the impact of respiratory motion, tachycardia and dysrhythmia on image 
quality. There remains, however, a compromise between spatial resolution and 
contrast resolution.  
Compared with standard x-ray radiography, CT has significantly worse spatial 
resolution but significantly better contrast resolution. The limiting spatial resolution 
for standard x-ray is approximately 7lp/mm versus 12-20lp/mm for CT. The contrast 
resolution of x-ray is approximately 5% versus 0.5% for CT.   
1.4.4.1 Spatial resolution 
Spatial resolution is a measure of the ability of an imaging system to discriminate 
between discrete, adjacent structures.  Axial spatial resolution (i.e. in the scan plane) 
is inherent to each CT scanner and depends on the distances between the x ray source, 
the centre of rotation and the x ray detector, as well as the focal spot size, the detector 
aperture, and the number of measurements per rotation. Longitudinal spatial 
resolution (i.e. perpendicular to the scan plane) can be optimised by modification of 
CT protocols.  
In conventional CT, longitudinal spatial resolution is entirely determined by slice 
thickness. Slice thickness impacts on voxel size; the smaller the voxel size, the greater 
the spatial resolution.  Slice thickness is typically between 5 and 10mm, but may be as 
thin as 1mm. Reducing slice thickness improves spatial resolution and minimises 
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partial volume effect but requires a higher radiation dose to maintain image quality. 
Radiation burden may be a concern if there is a large anatomical area to be scanned, 
necessitating a high number of slices. 
1.4.4.2 Contrast resolution 
Contrast resolution indicates the ability of CT to detect differences in image density. 
It is a measure of the details that are just visible at a given x-ray dose. Increased visual 
noise reduces the visibility of low-contrast objects. The better the signal to noise ratio, 
the greater the visibility of detailed structures of a given size and contrast. Image noise 
results from variation in attenuation coefficients between voxels of identical tissue.  
Filters selected during the image reconstruction process can be used to control noise. 
1.4.4.3 Temporal resolution 
Motion free imaging of organs with an automism function requires high temporal 
resolution, where temporal resolution is effectively the ability of CT to deliver image 
detail in the smallest ‘window’ of time. This is particularly relevant for cardiac imaging, 
for which a temporal resolution of 250ms is required to achieve motion free imaging 
during diastole. As heart rate increases, so temporal resolution must also increase.  
Temporal resolution increases with the number of x-ray detectors present and with 
increased gantry speed. Temporal resolution can be further enhanced by the use of 
ECG gated protocols, segmentation and tailored reconstruction algorithms.  
1.4.5 ECG GATED TECHNIQUES  
Cardiac motion is at its least during diastole, when passive filling of the ventricles 
occurs.  Cardiac gating is used to optimise imaging during diastole and may be 
prospectively or retrospectively applied.  
In prospective gating, ECG triggering ensures x-ray generation and data acquisition 
during diastole. The scanner estimates the start of the diastolic phase by analysis of 
the preceding 3-7 heartbeats. This approach is less useful in patients with tachycardia 
and dysrhythmia.  
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In retrospective gating, the CT volume set is acquired simultaneously with a surface 
ECG recording. X-ray detection must occur from every area of the heart for the 
duration of the cardiac cycle.  Reconstruction algorithms assign data to phases of the 
cardiac cycle, relative to the R wave.  This approach allows faster cardiac volume 
coverage and functional analysis throughout the cardiac cycle. The trade-off is a higher 
radiation dose than for prospective gating.  
Figure 1.8: Tube current application during retrospective and prospective CT 
acquisition{Courtesy of Dr. Nadeem Hussain, University of South Alabama} 
 
a Retrospective gating;  b Prospective gating 
With prospective gating, the tube current is in force for a predefined portion of the cardiac cycle (shown here as 40%, but can be 
as short as 10% of the cardiac cycle). Arrows marks 100% of the cardiac cycle.  
 
1.4.6 RADIATION DOSING 
Publications in the lay and medical press have raised concerns about the health risks 
associated with increasing medical radiation exposure, particularly related to 
cardiovascular imaging{Brenner, 2007}. Data from Europe and the US demonstrated 
that in 2007 CT scanning constituted 5–10% of all imaging procedures, but contributed 
40–67% of the total radiation burden{Sadetzki, 2007}.  
The effective dose, expressed in Sieverts (Sv), is a generic estimate of the overall harm 
to the patient caused by the radiation exposure and allows rough comparison 
between different CT scenarios. Cardiac CT examinations may deliver effective doses 
in excess of 20mSv, versus 3-9mSv for other CT examinations of the chest{Mayo, 
a 
b 
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2009}. The absence of evidence-based standard cardiac acquisition protocols mean 
there is wide variation in radiation doses for the same examination (5-
30mSv){Hausleiter, 2009}. Nevertheless, where CT negates the requirement for 
additional radiological investigations, such as myocardial perfusion scanning or 
invasive coronary angiography, the overall patient radiation dose may be reduced.  
The relationship between radiation dose and CT tube current in milliamperes (mA) is 
linear. Methods proposed for achieving radiation dose reduction during cardiac CT 
include body mass-based modulation of tube current, ECG correlated modulation of 
tube current during retrospectively gated acquisitions{Jakobs, 2002}, prospective axial 
gating{Earls, 2008; Maruyama, 2008}, tube voltage reduction{Bischoff, 2009}, 
reducing scan length/volumes{Gopal, 2009} and combinations of the 
above{Hausleiter, 2006}. Dose minimisation technologies built into scanning 
equipment include grids, collimators and filters to shield scattered radiation, define 
scan slice and absorb low-energy x-rays. 
For cardiac imaging, lowering the heart rate by beta-blocker administration not only 
reduces motion artefacts but also stabilises sinus rhythm to allow consistent use of 
ECG dependent dose reduction algorithms. The use of high pitch data acquisition 
(resulting in x-ray tubes and detectors rotating around the patient without overlap) 
has (to date) been limited to patients with heart rates lower than 65 bpm. 
When imaging the lungs, current as low as 40mAs can be used to obtain high 
resolution images, although higher doses may be required for the assessment of 
ground glass opacity, sub-pleural lines and in obese patients.   
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Table 1.7: Typical radiation doses resulting from cardio-pulmonary imaging{IAEA, 
2014}  
 PROCEDURE EFFECTIVE RADIATION DOSE (mSV) 
Background radiation per annuma   2.4 
Chest radiograph 0.02 
MDCT thorax 3-11 
CT calcium scoring by MDCT 1-5 
CT coronary angiography by MDCT 8-30 
Comprehensive cardiopulmonary CT 8-22 
Ventilation perfusion scan 7 
Invasive coronary angiography 3-10 (up to 22) 
a global average 
Figure 1.9: Radiation exposure using different CCT protocols{Weustink, 2009} 
 
a Helical CT coronary angiography (CTA) without ECG tube modulation. 
b Retrospectively gated helical CTA with ECG tube modulation (10-20mSv; 64-slice CT).  
c Prospectively gated axial CTCA or step-and-shoot algorithm (2-3mSv; 64-slice CT). 
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1.5 COMPUTED TOMOGRAPHY IN CLINICAL PRACTICE 
Technological advancement, increased availability and the perception that imaging 
can meaningfully affect medical decision making has resulted in an upsurge in the use 
of CT. There has been a 140%  increase in the number of scans performed in the UK 
since 1997, with in excess of 3.4 million scans performed per annum{Hart, 2008}.   
A significant proportion of these scans relate to the diagnosis and early triage of 
patients with acute medical conditions and over 31% are lung imaging.  Rates of 
growth in the use of CT are highest for abdominal pain, flank pain, chest pain and 
shortness of breath. Reports suggest CT use in the emergency department may be 
increasing at a greater rate than in other clinical areas.  
The ability to perform non-invasive angiography is one of the greatest attributes of CT. 
Like invasive angiography, CT scanning allows direct visualisation of emboli, but is 
safer and cheaper than invasive angiography, and more widely available. 
Advanced computer systems now offer the capability for a growing number of non-
invasive virtual endoscopy procedures to be performed. CT virtual endoscopy has 
been used to evaluate pathologic processes of the nasopharynx, larynx, and 
tracheobronchial tree{Thomas, 2009}. In comparison with virtual colonoscopy, virtual 
bronchoscopy requires no prior preparation of the patient and images are generated 
as part of post-processing, with no additional radiation burden. The advantages of 
virtual procedures include the capability to access small structures, to view non-
traditional perspectives, to provide volumetric analyses and to apply automatic 
pathology detection software.   
In recent years, MDCT has been combined with PET and SPECT in hybrid imaging 
approaches that assimilate cellular signalling (functional) and anatomical information. 
The combination of CT calcium scoring and cardiac SPECT with Tl-201 for myocardial 
viability and Tc-99m-sestamibi for myocardial perfusion is an attractive possibility. 
SPECT-CT also offers the opportunity to anatomically define the lobes of the lungs so 
that lobar function can be assessed semi-automatically from V/Q images in patients 
being considered for lung volume reduction surgery{Beyer, 2011}. 
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1.5.1 CARDIAC COMPUTED TOMOGRAPHY 
The primary indication for cardiac CT (CCT) is in the risk assessment of patients with 
potential or suspected CAD.  The key elements of the investigation are coronary 
calcium assessment and coronary CT angiography (CTA). CCT may also be used to 
characterise coronary artery plaque, to evaluate cardiac function, myocardial 
perfusion, infarction, malignancy, pericardial pathology, and congenital 
anomalies{Desjardins, 2004}.  
1.5.1.1 Coronary calcium scoring  
Coronary artery calcification occurs as part of the process of atherosclerosis and is 
absent in the normal vessel wall{Stary, 1995}. Unenhanced CT is a sensitive method 
for the detection of coronary calcium{Greenland, 2007; Carr, 2005} and the coronary 
calcium score (CCS), which quantifies coronary calcification, correlates closely to 
global atherosclerotic plaque volume on autopsy{Rumberger, 1995}.  
Figure 1.10: Example of coronary calcium imaging{Agatston, 1990} 
 
 
 
 
 
 
 
Left coronary artery main 
stem 
Proximal left anterior 
descending artery 
Mid left anterior 
descending artery 
CCS increase with age, reflecting progressive atherosclerosis, and are typically higher 
in male patients{Hoff, 2001; McClelland, 2006}.  Scores are reported as absolute 
values (Agatston score equivalent) and as percentiles of calcification relative to an age 
and sex-matched population. Agatston scores are determined from measurements of 
the area and density of calcified plaque. A typical report provides an Agatston score 
for each individual coronary artery and a total score.  
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There is a well-documented association between CCS and the occurrence of 
cardiovascular events. Similarly, in patients with a CCS of zero, the likelihood of 
coronary events is low{Shareghi, 2007}. Evidence suggests that CCS is independently 
predictive of outcome, irrespective of traditional cardiac risk factors{Greenland, 
2007}. 
Table 1.8: Correlation between coronary calcium score and angiographically 
documented stenosis in patients with suspected CAD {Haberl, 2001} 
TOTAL CORONARY CALCIUM 
SCORE 
DIAGNOSIS CLINICAL INTERPRETATION 
0 No identifiable atherosclerotic 
plaque 
A negative examination. 
>97% chance of being free 
from CAD 
Very low cardiovascular risk. 
1-10 Minimal plaque burden Significant CAD very unlikely 
11-100 Mild plaque burden Likelihood of mild-mod non-
obstructive CAD 
101-400 Moderate plaque burden High likelihood of moderate 
non-obstructive CAD 
>400 Extensive plaque burden High likelihood of at least one 
significant coronary stenosis 
The diagnostic utility of CCS was initially validated using electron beam computed 
tomography (EBCT){Rumberger, 1995; O’Rourke, 2000}. In more recent years, EBCT 
and MDCT scanners have been demonstrated to have equivalent reproducibility for 
measuring coronary artery calcium, supporting the adoption of MDCT in this 
role{Detrano, 2005}.  
In symptomatic patients, CCS <100 are typically associated with a low probability of 
abnormal perfusion on myocardial perfusion testing (<2%){Berman, 2004} or 
significant arterial obstruction on invasive coronary angiography (<5%; where 
significant obstruction is taken as stenosis >50%){Haberl, 2001}. The sensitivity of CCS 
for significant atherosclerotic obstruction exceeds 95% but specificity is limited.  
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The strength of CCS is its high negative predictive value (96-100%){Haberl, 2001; Knez, 
2004}, meaning the investigation can be used to exclude coronary artery disease with 
a high level of confidence. A degree of caution is; however, recommended in 
symptomatic patients in whom 5-15% with a CCS of zero have 1 or more stenoses 
>50% on CT coronary angiography due to non-calcified lesions{Jarreau, 2007}. In a 
study of high risk patients with suspected ACS, 39% of patients with CCS zero still had 
obstructive disease, highlighting the importance of considering pre-test 
probability{Henneman, 2008}. In symptomatic patients with a CCS of zero, obstructive 
CAD is associated with an increased incidence of cardiovascular events{Villines, 2011}. 
The main limitation of CCS is its inability to detect the location of significant lesions in 
individuals with a high score or the likelihood of those with a high score having a 
coronary event. International guidelines discourage the use of CCS for coronary artery 
disease screening in patients with a high risk profile as these patients should be 
commenced directly on primary preventive therapy{Greenland, 2007; NICE, 2010}.  
Whether a coronary calcium scan can be used alone to exclude ACS reliably or to 
provide added value to coronary CTA in emergency department patients with acute 
chest pain remains a subject of debate. In a recent study, a CCS of zero was found not 
to exclude ACS, nor did a high CCS preclude interpretation of coronary CTA in most 
patients. The authors concluded that the decision to perform a coronary calcium scan 
should be balanced against the additional radiation exposure required{Pursnani, 
2015}. 
1.5.1.2 Coronary CT angiography  
ECG gating techniques maximise temporal resolution and minimise imaging artefacts 
caused by cardiac motion to allow coronary artery visualisation. With newer 
generations of MDCT scanners the proportion of non-assessable segments has 
decreased{Vanhoenacker, 2007}. Coronary CTA still does not provide the same degree 
of image quality or diagnostic accuracy for the quantification of stenosis as invasive 
coronary angiography but may be superior for identifying cumulative calcified, non-
calcified and mixed plaque burden{Butler, 2007}. Sensitivity for the detection of 
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significant coronary segment stenosis (≥50%) is 90-93% with specificity 93-
97%{Vanhoenacker, 2007; Mowatt, 2008}. In pooled study results, the positive 
predictive value for significant CAD was 93% and negative predictive value 
100%{Mowatt, 2008}.  
Evidence suggests that CTA performs best in ruling out obstructive CAD in patients 
with a low likelihood of CAD and a low CCS, and in patients across the range of CAD 
likelihood with a CCS of zero. Conversely, CTA is less effective for this purpose in 
patients with a high likelihood of CAD, known CAD or extensive coronary 
calcification{Arbab-Zadeh, 2012}. CTA does not provide additional relevant diagnostic 
information in symptomatic patients with a high estimated pre-test probability of CAD 
{Meijboom, 2007}.  
Table 1.9: Pre and post-test probability for a positive CTA based on likelihood of 
CAD{Adapted from Meijboom, 2007}  
 LOW PRE-TEST 
LIKELIHOOD 
(<30%) 
INTERMEDIATE PRE-TEST 
LIKELIHOOD 
(30-69%) 
HIGH PRE-TEST 
LIKELIHOOD 
(>70%) 
 CT-Y CT-N CT-Y CT-N CT-Y CT-N 
Pre-test 
probability 
13 53 87 
Post-test 
probability 
68 0 88 0 96 17 
 
CTA is the only non-invasive investigation to allow detection of vulnerable plaque 
disease through the characterisation and quantification of coronary plaque. Adverse 
characteristics detectable using CTA include low attenuation plaque, positive 
remodelling and spotty calcification{Nakazato, 2013}; proximal left anterior 
descending artery and multi-vessel involvement also suggest high risk disease{Min, 
2007}. Intravascular ultrasound (IVUS) is the standard reference for the assessment of 
plaque composition/progression and direct comparison of CTA with IVUS suggests 
non-inferiority of CTA{Voros, 2011; Nakazato, 2013}.  
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CTA, without adjunctive functional testing, is limited by its inability to identify clinically 
significant CAD. It is assumed that there is a threshold above which a stenosis causes 
significant reduction in coronary blood flow but in reality all stenoses are of unknown 
significance following purely anatomical assessment.  
Figure 1.11: Progression of CAD to flow limiting stenosis{Gould, 2009} 
 
More advanced CAD is associated with dense coronary calcification and reduced 
coronary luminal diameters that have historically been considered detrimental to 
image interpretation. Similarly, CTA is of limited value in the assessment of in-stent 
stenosis and coronary artery bypass grafts. Depending on stent type, there is a high 
variability of artefacts and lumen visibility{Maintz, 2006}. Graft visualisation may be 
obscured by movement and surgical clip artefacts{Heye, 2014}. In the future CTA may 
have a role in the non-invasive diagnosis of in-stent restenosis and occlusion{Oncel, 
2007} but at present, the strength of the technique is in the exclusion of coronary 
artery disease where none is present.   
CCT can also be used to assess for acute myocardial infarction, detectable as hyper-
enhancement on delayed acquisition scanning{Lardo, 2006; Gerber, 2006}. The 
transmural extent of this hyper-enhancement correlates well with findings on 
radionuclide imaging{Sato, 2008; Habis, 2007}. Precise and reproducible 
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measurements of ventricular volumes, wall thickness, and regional contraction 
abnormalities are achievable but CCT should not be considered a first line 
investigation for evaluating cardiac function. The technique also provides detailed 
information on wider cardiovascular and thoracic pathology. Effusions and pericardial 
calcification are readily detected.  
The technique has been used in the acute setting to exclude coronary stenosis in 
selected patients with chest pain{Vanhoenacker, 2007}, and when the diagnosis 
remains uncertain despite clinical evaluation and simple non-invasive 
testing{Hoffmann, 2006}. In symptomatic patients with suspected CAD, CTA adds 
incremental benefit to CCS for discrimination of individuals at risk of death or MI{Al-
Mallah, 2014}.  
With appropriate patient selection, CCT has been demonstrated to reduce diagnostic 
time, costs and requirement for repeat evaluation for recurrent chest pain{Goldstein, 
2007}, and has been shown to be more cost effective than exercise testing and stress 
echocardiography in the triage of emergency department patients with acute chest 
pain{Khare, 2008}. Furthermore, CCT can preclude the need for invasive 
angiography{Schroeder, 2005; Dorgelo, 2005}.  
The multi-centre PROMISE trial recently confirmed CCT as a viable alternative to 
functional testing{Douglas, 2015}. In symptomatic patients with suspected CAD, a 
strategy of initial CTA was associated with fewer catheterisations showing no 
obstructive CAD and a lower median cumulative radiation exposure per patient. There 
was no statistically significant difference between the costs of first receiving CCT 
versus a functional test over three years of follow-up{Douglas, 2015}.  
Patients with normal study findings have excellent clinical outcomes and can be safely 
discharged from hospital{Rubinshtein, 2007; Rubinshtein, 2007; Hollander, 2009; Litt, 
2012}. In patients with low-intermediate risk of CAD, negative CCT may be used to 
support hospital discharge without major adverse cardiac events (MACE) for up to five 
years {Laudon, 2010; Rubinshtein, 2007; Rubinshtein, 2007; Hollander, 2009}.  
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1.5.2 THORACIC COMPUTED TOMOGRAPHY 
Developments in CT technology, particularly multi-detector CT, now allow coverage of 
the entire thorax with sub-millimetre resolution, within a single breath-hold (less than 
10s). The appearance of most lung diseases on CT has already been described. The 
advantages of CT over standard chest radiography for diagnosis are widely recognised, 
and CT is increasingly used for monitoring disease progression.  
1.5.2.1 CT pulmonary angiography 
CT pulmonary angiography (CTPA) is the initial imaging modality of choice for stable 
patients with suspected pulmonary embolism{Remy-Jardin, 2007}. Modern CT 
scanners enable the evaluation of pulmonary vessels down to sixth order 
branches{Patel, 2003}. The sensitivity of CTPA for pulmonary embolism is around 83% 
and specificity around 96%{Stein, 2006}. The negative predictive value of a normal 
CTPA exceeds 98%, regardless of whether there is underlying lung disease{Tillie-
Leblond, 2002}. CTPA also allows a quantitative assessment of clot burden, measured 
by pulmonary artery obstruction index, which correlates with clinical severity{Wu, 
2004; van der Meer, 2005}.  
Quantitative assessment of ventricular dimensions by CT is also useful as a marker of 
right ventricular dysfunction (RVD){Becattini, 2011; Bach, 2005}. There is an 
association between RVD detected by CT and other markers of cardiac dysfunction 
(elevated serum BNP and Tn I){Jimenez, 2014}. Right to left ventricular dimensional 
ratio on CT correlates well with echocardiography for the assessment of RVD in 
patients with acute pulmonary embolism{Becattini, 2011; Henzler, 2012}; however, 
recent literature does not currently support an association between CT detected RVD 
and 30 day mortality{Jimenez, 2014}.  
By imaging the lung parenchyma, pleura and great vessels, CTPA offers additional 
information not provided by V/Q scintigraphy or pulmonary angiography. In one 
study, CTPA identified pleural or parenchymal abnormalities that explained 
indeterminate defects on V/Q scans in 57% of patients{van Rossum, 1996}. In other 
studies, alternative intra-thoracic findings were identified in 11% to 85% of patients 
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undergoing CTPA{Kanne, 2004}. Using CTPA as the primary diagnostic test in 
suspected pulmonary embolism leads to alternative diagnoses in up to 25% of 
patients{Van Strijen, 2003}. CTPA can also differentiate causes of pulmonary 
hypertension such as chronic thromboembolic disease, underlying lung pathology, 
and their sequelae.  
1.5.2.2 Conventional CT chest 
Conventional chest CT provides continuous axial cross-sectional imaging in a cranio-
caudal direction. The image window extends from the lung apices to costophrenic 
angles.  With current MDCT technology, slices are usually reconstructed at 2.5–5mm. 
Thinner reconstructions can be used to evaluate fine morphological detail such as the 
lung parenchyma.  Contrast enhanced images are acquired in a similar manner to non-
enhanced images but follow the administration of intravenous iodinated contrast 
medium.  
Selection of different processing algorithms generates mediastinal and lung windows. 
Mediastinal windows are used to assess the chest wall, pleura and mediastinal 
structures, usually with intravenous contrast so that vascular structures in the 
mediastinum can be differentiated from enlarged lymph nodes or other masses. Lung 
windows allow the pulmonary parenchyma and vasculature to be seen in detail, while 
the mediastinal and chest wall structures are essentially obscured.  
1.5.2.3 High resolution CT chest 
HRCT images were traditionally acquired as non-contiguous 1–2mm slices, 20–30mm 
apart. MDCT offers the capability to reconstruct the entire chest into contiguous 1mm 
slices and therefore HRCT is often no longer performed as a separate investigation. 
Continuous, helical MDCT detects significantly more pulmonary abnormalities and has 
better inter-observer agreement than conventional interrupted (axial) HRCT{Dodd, 
2008; Dodd, 2006}.  
The use of high spatial resolution reconstruction algorithms enhance the detection of 
small structures and subtle pathological changes. The smallest anatomic unit 
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detectable on HRCT is the secondary pulmonary lobule{Murata, 1986; Webb, 1988}. 
Inter-lobular septae are not usually seen unless their diameter exceeds 0.2mm. Intra-
lobular acinar arteries have a diameter of 0.5mm and are highly visible, as are the 
pulmonary arteries supplying each lobule with a diameter of 1mm. Bronchi are usually 
visible, but bronchioles, which have a wall diameter of 0.15mm, are at the limit of CT 
resolution and are rarely seen{Webb, 1988}.    
HRCT images are used to demonstrate the lung parenchyma. The clinical indications 
for HRCT are to detect and evaluate bronchiectasis, to evaluate suspected interstitial 
lung disease when standard chest radiography is unremarkable, to delineate 
abnormalities identified on standard chest radiography to aid diagnosis, to evaluate 
disease activity, to predict treatment response and to guide interventional procedures 
(e.g. biopsy){Kazerooni, 2001} 
Diagnoses with pathognomonic features on HRCT include bronchiectasis, emphysema, 
Langerhan’s cell histiocytosis, lymphangioleiomyomatosis, idiopathic interstitial 
pneumonias, lymphangitis carcinomatosis, pneumoconiosis and sarcoidosis. Thus, CT 
may obviate the need for a histological diagnosis. The role of HRCT imaging in the 
emergency setting is limited but may be useful to help assess the cause of pulmonary 
consolidation.  
1.5.3 COMPREHENSIVE CARDIO-PULMONARY COMPUTED TOMOGRAPHY (CPCT) 
CT angiography of the coronary arteries, pulmonary arteries, and thoracic aorta are 
increasingly used in the non-invasive workup of suspected low to intermediate-risk 
CAD, pulmonary embolism, and thoracic aortic disease associated with aortic valve 
dysfunction, respectively. 
Dedicated coronary CT protocols allow excellent assessment of the coronary arteries 
and proximal ascending aorta but are less suitable for assessment of the pulmonary 
vasculature, and should not be used to exclude pulmonary embolism{Dodd, 2008 }. By 
contrast, the main differential diagnoses for pulmonary embolism, namely aortic 
aneurysm/dissection and coronary artery disease manifest on thoracic CT. 
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Comprehensive cardio-pulmonary CT (CPCT) protocols for the complete assessment 
of thoracic vessels and adjacent intra-thoracic structures, aim to opacify the 
pulmonary and coronary arteries and the aorta during a single breath-hold acquisition. 
These so called ‘triple rule out’ protocols are currently being used predominantly in 
the assessment of patients presenting with acute chest pain to the emergency 
department, although there are concerns about excess radiation and contrast burden 
relative to dedicated angiographic protocols{Ayaram, 2013}. 
 
Figure 1.12: Example of an image generated using a CPCT protocol 
 
The challenge of CPCT is in achieving 3 separate diagnostic quality examinations in a 
single CT, with peak contrast enhancement 10-12 seconds apart for the pulmonary 
arteries (>200HU) and aorta/coronary arteries (>300HU). One method is to increase 
the volume of intravenous contrast administered and CPCT requires larger contrast 
volumes than CTPA. Split bolus protocols have also been trialled.   
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Figure 1.13: Peak arterial enhancement using a CPCT contrast 
protocol{Frauenfelder, 2009} 
 
CPCT requires simultaneous, homogenous, and high contrast attenuation (>250 HU) of the pulmonary arteries, the aorta, and 
the coronary arteries. Dedicated contrast-medium application protocols must take into account the transit time between the 
pulmonary and aortic/coronary opacification (typical duration 11s) 
The literature suggests diagnostic enhancement of the pulmonary arteries is more 
easily achieved than for the coronary arteries{Halpern, 2009}, nevertheless, with ECG 
gating, coronary artery images are comparable in quality to dedicated cardiac 
studies{Halpern, 2009}. Simultaneous evaluation of coronary arteries in high-pitch 
dual-source CT of the thorax for non-cardiac purposes is consistently diagnostic in 
patients with low heart rates and heart rate variability (such as can be achieved with 
β-blockade){Scharf, 2011}. 
CPCT protocols make use of a larger field of view than cardiac protocols. Causes of 
chest pain which manifest in this wider view include pneumonia, pleural effusion,  
intra-thoracic masses, pericardial effusion, pericarditis, hiatus hernia, oesophageal 
rupture, pancreatitis and bone fractures{Thoongsuwan, 2002}. The sensitivity of 
comprehensive CPCT for identifying the cause of chest pain is estimated between 
93%{Johnson, 2007} and 87%, with a specificity of 96%{White, 2005}. 
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The larger volume of anatomy to scan for CPCT necessitates a longer breath hold and 
an increased radiation burden. The increase in tube current necessary for coronary 
artery imaging and use of retrospective ECG gating mean the effective dose with CPCT 
is higher than for examination of the pulmonary arteries or thoracic aorta alone. The 
effective dose for CPCT is around 50% greater than for cardiac CT.  
The role for CPCT in the emergency department remains controversial. Supporting the 
finding that CCT may increase diagnostic sensitivity and specificity in patients 
presenting with acute chest pain{Rubinshtein, 2007}, Takakuwa et al. found that CPCT 
eliminated the need for further diagnostic testing in over 75% of low to moderate risk 
patients{Takakuwa, 2008}. By contrast, Madder et al. found CPCT resulted in higher 
radiation exposure than CCT, but was not associated with improved yield, reduced 
clinical events, or diminished downstream resource use. The composite diagnostic 
yield was 14% with CPCT, and 16% with CCT. CPCT patients had a 50% higher effective 
dose, a higher incidence of subsequent emergency attendance, and more 
downstream CTPA scans{Madder, 2011}.  
The application of CPCT in patients with acute dyspnoea has yet to be fully evaluated, 
despite the fact that many of the pathologies causing dyspnoea are common with 
those that cause chest pain. A single study by Rogers et al. looked at efficiency of 
comprehensive CT examination in patients presenting to the emergency department 
with undifferentiated chest pain/discomfort, or dyspnoea. Patients were randomised 
to receive CPCT or a dedicated CCT. While CPCT was feasible, with similar diagnostic 
yield to CCT, it did not reduce length of stay, rates of subsequent testing or cost. The 
authors concluded that CPCT may be helpful in the evaluation of select 
patients{Rogers, 2011}. 
To date, the consensus appears to be that CPCT can be useful and potentially cost-
effective when used appropriately, but further clarity is required regarding protocols 
to avoid overuse of this technique. 
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1.6 AIMS OF THESIS  
This aims of this thesis were:  
 To evaluate the characteristics of patients attending hospital with 
undifferentiated chest pain and dyspnoea  
 To evaluate the role for cardiopulmonary computed tomography in the 
diagnosis and prognostication of these patients  
 To review the use of this imaging modality within the framework of existing 
UK guidance  
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CHAPTER 2: GENERAL METHODOLOGY 
During the course of this thesis, I personally undertook the duties of study design, 
ethical approval and funding acquisition, patient identification, recruitment, 
preparation for CT scanning (including relevant phlebotomy, cannulation and 
administration of beta-blockade), follow-up, data entry and analysis.  
I was supported by a team including clinicians (study design and image interpretation), 
research nurse specialists (patient identification, follow-up and data entry), data 
analysts (power analyses and statistical outcome analyses) and the Chelsea and 
Westminster Research and Development (R&D) Support Office.  
2.1 PATIENT SELECTION FOR CT SCANNING INVOLVING CARDIAC PROTOCOLS: 
Inclusion criteria for each of the studies in this thesis are detailed in their respective 
chapters. The exclusion criteria were, however, universal for all studies involving CCT 
and are listed below. 
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Table 2.1: Exclusion criteria for cardiac CT protocols 
CRITERIA DETAILED DEFINITION 
Age <40years  
Features of acute myocardial infarction 
 
 Consistent ECG: ST elevation/new left bundle 
branch block 
 Ongoing chest pain with dynamic ECG changes 
 Elevated serum troponin I: ≥3µg/ml 
Haemodynamic or respiratory instability  Systolic blood pressure ≤90mmHg 
 SpO2 ≤92% on supplemental oxygen 
 
Previous percutaneous coronary intervention  Coronary arerty stent or bypass grafting 
Resting heart rate >70bpm  Including after pharmacologic treatment 
Contraindication to negative chronotropic agents if 
resting HR >70bpm 
 Allergy or previous intolerance 
 Established on verapamil 
 Sick sinus syndrome, 2nd/3rd degree heart block, 
history of transient loss of consciousness 
 Severe aortic stenosis 
 Restrictive cardiomyopathy 
Contraindication to contrast enhanced CT  Allergy or previous intolerance of iodinated 
contrast  
 Renal dysfunction: serum creatinine >150 µmol/l  
 Pregnancy or childbearing potential 
Inability/disinclination to provide written informed 
consent 
 
2.2. MDCT SCANNING PROTOCOLS 
All CT scans undertaken for this thesis were performed using a 128-slice, single source 
scanner (Somatom Definition AS+, Siemens Healthcare, Germany). The features of this 
specific scanner are a gantry rotation of 0.3s, temporal resolution 150ms and spatial 
resolution 0.33mm for each individual image. A 2m (whole body) scan can be achieved 
in around 10s.   
Three acquisition protocols were used; coronary calcium acquisition, coronary CTA 
and a combined CPCT acquisition. Scan parameters are detailed in Table 2.2. All scans 
were performed during inspiratory breath hold. Patients were familiarised with the 
breath-holding technique prior to scanning.   
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2.2.1 CORONARY CALCIUM PROTOCOL 
Coronary calcium acquisition was undertaken using prospective ECG gating and an 
unenhanced CT protocol. ECG pulsing interval was at 70% of the R-R interval.  
2.2.2 CORONARY CT ANGIOGRAPHY PROTOCOL 
Coronary CTA was undertaken using retrospective ECG gating. Images were acquired 
from the level of the carina to just inferior to the diaphragm. 
Angiography was preceded by coronary calcium acquisition for all patients undergoing 
CTA. Thus, patients underwent an initial scan without contrast and a further scan 
following triple phase intravenous contrast injection.  
Acquisition delay time was determined by the injection of a 15ml test-bolus of contrast 
at 6ml/sec followed by 40ml saline chaser at 6ml/sec. The time to peak test-bolus 
enhancement plus three seconds was used as scan delay time. A non-ionic contrast 
medium (Omnipaque 350; GE Healthcare) was infused via an ante-cubital intravenous 
catheter at rates as per Table 2.2. 
Patients with a heart rate exceeding 70 bpm and no contraindications to beta-blockers 
received metoprolol tartrate on the scanner table. A starting dose of 5mg was 
administered by intravenous injection over one minute, followed by a saline flush, 
with re-administration of the same dose every 2-5 minutes until heart rate was 
controlled (≤65bpm) or a total dose of 30mg was reached. Heart rate was monitored 
continuously via an ECG on the CT scanner console. Blood pressure was recorded 
before and after the administration of beta-blockers and at 15 minute intervals 
thereafter.  
Although rate control agents other than beta-blockers exist, neither calcium channel 
blockers nor ivabradine were used in the course of the studies in this thesis, in 
accordance with national guidance{RCP/BSCI/RCR, 2014}. 
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2.2.3 COMPREHENSIVE CARDIOPULMONARY CT PROTOCOL 
CPCT was undertaken using retrospective ECG gating. The protocol differed from the 
CTA protocol, having a larger field of view to include the entire chest and scanning in 
a caudal-cranial direction to ensure prompt imaging of the heart post intravenous 
contrast.  
The contrast protocol dispensed with the injection of the contrast-saline mixture used 
for coronary CTA to avoid dilution of contrast in the right heart for optimum 
pulmonary arterial opacification. 
As per coronary CTA, patients with a heart rate exceeding 70bpm and no 
contraindications to beta-blockers received metoprolol prior to scanning. Up to six 
5mg doses were administered by intravenous injection.  
Table 2.2: Scanning parameters for coronary calcium acquisition, CTA and CPCT 
CT PARAMETER CCS CTA ONLY CPCT 
Tube voltage (kV) 120 120 120 
Tube current (mA) 30 500 600 
Field of view (mm) 400/250 250 400/250 
Collimation (mm) 60x0.6mm 0.60x0.6mm 60x0.6mm 
Direction Cranial-caudal Cranial-caudal Caudal-cranial 
Time (sec)  8-12 14-15 
Test bolus injection  N/A 15ml contrast @ 6ml/sec 
40ml saline @ 6ml/sec 
15ml contrast @ 6ml/sec 
40ml saline @ 6ml/sec 
Contrast: Scan acquisition 
injection protocol 
N/A 65ml contrast @ 6ml/sec 
40 ml saline @ 6ml/sec 
85ml contrast @ 6ml/sec 
60 ml saline @ 6ml/sec 
 
2.2.4 RADIATION DOSE REDUCTION STRATEGIES 
When possible, prospective ECG gating was used. Dose modulation outside of the 
acquisition window was adopted for retrospectively gated scanning. Scan ranges were 
tailored to patient dimensions.   
2.2.5 DATA ACQUISITION 
All CT data sets were transferred to a dedicated workstation. Images for coronary 
calcium scoring were reconstructed as 3mm contiguous slices. Images were 
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reconstructed at an effective thickness of 0.6mm every 0.5mm for CTA and 0.75mm x 
0.5mm for CPCT. Using retrospective analysis of R wave timing, scanning phases were 
reconstructed to allow coronary assessment in the phase of minimal cardiac motion.  
Phases were reconstructed at 10% increments throughout the cardiac cycle (from 
10%-90% of the R-R interval). The best mid-late systolic (20-40% of R-R interval) or 
mid-late diastolic (50-70% of R-R interval) data set was chosen for final image 
interpretation. 
2.2.6 IMAGE ANALYSIS 
All images were analysed and processed by two experienced radiologists in consensus. 
Any disagreements were settled by consensus, with a third experienced clinician 
mediating.  
2.2.6.1 Coronary artery image analysis 
Images of the heart and coronary arteries were reconstructed with a small field of 
view (120-190 mm), and a medium-smooth convolution kernel (B 26f).  
Coronary calcification was identified using a 130 Hounsfield Unit threshold and 
calculated as an Agatston Score Equivalent. All calcific lesions with an area greater 
than 1mm2 were considered significant for scoring purposes. Total coronary calcium 
scores were recorded as absolute values and as categories (ASE 0; 1-100; 101-400; 
>400).  
Coronary CTA analysis was performed using a cardiac software package (Syngo.via; 
Siemens Healthcare, Germany). Axial data sets were supplemented by 3D volume-
rendered images, maximum intensity projection, curved multi-planar formats and 
automated lumen detection algorithms, as indicated.  
Coronary anatomy was divided into 16 segments, using a modified version of the 
traditional 15 segment model{Austen, 1975}, to allow for separate assessment of the 
intermediate coronary artery, should it exist. Coronary segments were reported as 
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having no stenosis, non-significant stenosis (<50% luminal narrowing) or significant 
stenosis (>50% luminal narrowing). 
Coronary artery stenosis >50% was chosen as a diagnostic threshold because patients 
with this degree of obstruction on CT are generally referred for non-invasive or 
invasive testing to characterise their disease further.   
2.2.6.2 Extra-cardiac image analysis 
For the evaluation of extra-cardiac pathology, images were reconstructed with a large 
field of view (>300 mm). Images were reviewed in axial, coronal, and sagittal planes, 
using a mediastinal window (width: 400, level: 40), lung window (width: 1,500, level: 
-500), and bone window (width: 3,700, level: 700) for all examinations. 
Based on existing models {Kirsch, 2007; Lazoura 2010}, extra-cardiac findings were 
classified as benign, indeterminate or of clinical significance at the time of image 
evaluation. Benign findings were those of minimal clinical significance requiring no 
follow-up. Indeterminate findings were those of potential clinical significance, 
requiring correlation with the patient’s history or a follow-up study. Clinically 
significant findings were those requiring immediate clinical assessment or 
intervention.  Findings of clinical significance were classified according to ICD-10.  
Recognised criteria were used for the assessment of specific extra-cardiac findings. 
Pulmonary nodules were classified according to Fleischner Society criteria published 
at the time{MacMahon, 2005}. We accept the limitations of these guidelines in the 
consideration of sub-solid nodules, both solitary and multiple, which have been 
addressed in a more recent Statement of the Fleischner Society{Naidich, 2013}. 
Nodules of less than 8mm diameter with features concerning for malignancy were also 
considered clinically significant. 
Low attenuation areas were labelled as emphysema, while high attenuation areas 
were labelled as ground glass opacification or consolidation. Interstitial lung disease 
was characterised by interlobular septal thickening in the absence of evidence of 
congestive cardiac failure. Pulmonary embolism was characterised by one or more 
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filling defects in the pulmonary arterial system and a diagnosis of pulmonary 
hypertension was made if there was dilatation of a main pulmonary artery to a 
diameter of ≥29mm.   
Aortic aneurysm was defined by the diameter of the ascending aorta exceeding 4cm 
or the diameter of the abdominal aorta exceeding 3.5cm. Lymphadenopathy was 
considered significant if a node measured ≥1cm in diameter in its short axis. Liver 
lesions were labelled as cysts if they were smooth and non-enhancing, with the 
attenuation of water. Nodular, peripherally enhancing liver lesions were labelled as 
haemangiomas.  
2.3 STATISTICAL ANALYSIS 
Statistical analysis was performed using Graphpad Software (Prism 6, Instat, StatMate:  
GraphPad Software, Inc., La Jolla, California USA).  
2.3.1 ASSESMENT OF NORMAL DISTRIBUTION (D'Agostino-Pearson test) 
There are multiple tests for normal distribution, including the D'Agostino-Pearson test, 
the Shapiro Wilk test, the Kolmogorov-Smirnov test and the Chi-squared goodness-of-
fit test. In this thesis, the D'Agostino-Pearson test was used to compute a single P-
value for the combination of the coefficients of Skewness and Kurtosis. D'Agostino 
developed several normality tests. The one used by Graphpad Prism is the Omnibus 
K2 test. 
2.3.2 TESTS OF DIFFERENCE/MEASUREMENT OF AGREEMENT 
For parametric data, the T-test was used to compare mean values for two independent 
groups or against hypothesised values and analysis of variance (ANOVA) was used to 
compare means for multiple groups. 
For non-parametric data, the Mann Whitney U test was used to compare the median 
values for two independent groups (e.g. the distribution of CAD likelihood categories 
between two groups) and the Wilcoxon signed rank test was used for discrete, paired 
data as the non-parametric analog to the paired t-test. The Chi square test was used 
to test goodness of fit to a hypothesis or to determine the relationship between 
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categorical variables (e.g. gender, frequency of cardiac risk factors, nature of chest 
pain, likelihood of CAD, and frequency of MACE). Fisher’s exact test was used instead 
of the Chi square test when one or more cells had an expected frequency of ≤5. 
2.3.3 SIGNIFICANCE TESTING  
The P value represents the probability of getting the results obtained, in the event of 
the null hypothesis being true. Conventional significance is taken as P<0.05 and for the 
purpose of this thesis P<0.05 was deemed statistically significant. The P value does not 
measure the measure the importance of an effect; therefore in large studies a small P 
value may occur in the context of a minimally significant clinical effect, while in small 
studies, P may not reach significance even for clinically relevant effects. 
2.4 ETHICAL CONSIDERATIONS 
All patients involved in prospective research were required to give written informed 
consent to participate.  
As the benefits of CT in patients presenting with acute chest symptoms are not fully 
known, and there are appreciable risks with regard to radiation and intravenous 
contrast exposure, age criteria were used to exclude patients from undergoing CT 
scanning where the technique was less likely to be useful. The incidence of COPD, lung 
malignancy and coronary artery disease all rise above the age of forty years; aged less 
than forty these conditions are rare{Chaitman, 1981; Raherison, 2009; ONS 2013}. 
Patients aged less than forty years were therefore excluded from undergoing CT.  
Recently published data suggests that around 1 in 20 patients aged under 45 years 
undergoing cardiac CT for the investigation of suspected CAD have evidence of 
obstructive disease{Otaki, 2015}. Whilst the nature of disease in this sub-population, 
and pathways for appropriate investigation and management warrant further 
investigation, this was not within the remit of this thesis. 
All female patients aged forty to sixty years were required to give the date of their last 
menstrual period. If uncertain, a urinary pregnancy test was carried out and the result 
documented in writing.  
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2.4.1 EFFECTIVE RADIATION DOSE 
There is considerable debate regarding the significance of repeated low-level radiation 
exposure. Stochastic risks of radiation-induced malignancy and heritable genetic 
disease are the principal concerns. With increasing radiation doses, acute tissue 
reactions (deterministic effects) become more important. 
At a cellular level, exposure to ionising radiation results in the formation of free 
radicals with the potential to cause chemical damage to DNA. Cells respond by 
undergoing cell cycle arrest to allow DNA repair. A single unrepaired or misrepaired 
double strand break can result in DNA mutation or cell death via necrosis or apoptosis. 
Reactive oxygen species and reactive nitric oxide species also induce cellular stress 
responses and inflammation with the release of cytokines, growth factors and 
chemokines. These responses are thought to account for damage occurring in cells not 
directly irradiated, the so-called ‘bystander effect’. 
It has been proposed that radiation-induced DNA repair, apoptosis, terminal cell 
differentiation and immune activation may be adaptive responses to reduce genomic 
instability and the number of mutated cells in tissues; however, adaptive protection 
diminishes at radiation doses above 100-200mGy and is not observed following acute 
exposures in excess of 500mGy{Feinendegen, 2005}. Where radiogenic damage 
induction occurs unchecked there is increased susceptibility to malignancy, supporting 
a threshold or hormesis for cancer risk.  
There is a paucity of epidemiological data demonstrating excess cancer risk below 
100mSv. Since the effective dose from a single cardio-pulmonary CT is lower than this, 
the potential risk can only be estimated by assuming a dose-response relationship.   
The International Committee on Radiological Protection (ICRP) estimates that the 
radiogenic fatal cancer risk for an adult population is about 5%/Sv or (by using the 
linear non-threshold dose-response hypothesis) 0.005%/mSv (Table 2.3). Potential 
radiation risks can be compared to the spontaneous fatal cancer risk (about 20%) and 
the spontaneous cancer incidence (about 40%). With modern scanners, the 
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theoretical risk of radiation-induced cancer is therefore low compared with the 
intrinsic risk of developing cancer{Perisinakis, 2012}.  
Table 2.3: Estimation of cancer risk based on radiation exposure{IAEA, 2012} 
APPROXIMATE EFFECTIVE DOSE(MSV) APPROXIMATE RISK PER SCAN OF FATAL RADIOGENIC 
CANCERA 
1 mSv 0.005% 
2 mSv 0.01% 
3-5 mSv 0.015-0.025% 
10 mSv 0.05% 
25 mSv 0. 125% 
aRadiogenic cancer incidence is approximately twice the fatal risk. 
It is implicit that every possible effort should be made to use low radiation dose 
protocols. Retrospectively gated CTA is associated with a radiation dose not greater 
than 15mSv. Prospectively gated late pass acquisition typically delivers a radiation 
dose around 4mSv. Non-cardiac images acquired simultaneously with cardiac images 
do not contribute further radiation. The maximum total radiation exposure for 
patients enrolled in CT studies within this thesis was therefore predicted to be 19mSv.  
In actuality, the effective dose for CCT performed at Chelsea and Westminster Hospital 
was found to be in the range 4-6mSv. Using the accepted ICRP risk factor of 0.005% 
per mSv for risk of fatal cancer induction{ICRP, 1991}, the maximum excess risk of fatal 
cancer induction was 0.03% (1 in 3,333), increasing the risk of fatal cancer from 1 in 
4.000 to 1 in 3.998.  
In the course of studies for this thesis the risk of radiation-induced tissue reactions 
(e.g. acute radiation syndrome, reproductive impairment, dermatologic lesions, 
cardiovascular and cerebrovascular disease, and cataract formation) was judged to be 
negligible as the IRCP have concluded there is no convincing evidence of their 
occurrence at the effective doses detailed above{ICRP, 2012}.  
2.4.1.1 Radiation dose for CPCT versus dedicated angiographic protocols  
Although radiation and contrast exposure with CPCT exceed dedicated CT 
angiographic studies (mean difference in radiation 4.84mSv (95% CI 1.65-8.04mSv) 
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and contrast 38.0 mL (95% CI 28.1-48.0 mL)){Ayaram, 2013}, CPCT offers additional 
diagnostic information in patients with symptoms concerning for ACS, acute aortic 
syndrome and PE and may reduce total radiation burden by reducing the requirement 
for serial investigations{Halpern, 2009}.  
In patients with acute dyspnoea, CPCT was hypothesised to facilitate more rapid 
detection or exclusion of significant pathology, reduce time to diagnosis, initiation of 
appropriate treatment and hospital discharge; also to reduce re-admission rates and 
improve long-term mortality by facilitating targeted treatment of underlying disease. 
In the context of falling radiation doses with advances in CPCT technology and 
practice{Takakuwa, 2009}, the overall risk:benefit ratio of CPCT was judged likely to 
be favourable. 
2.4.2 INTRAVENOUS CONTRAST ADMINISTRATION 
Omnipaque (350) or an equivalent intravenous contrast medium was used for vascular 
delineation during CT scanning. As with all contrast media, Omnipaque may be 
associated with serious, life threatening, anaphylactoid or cardiovascular reactions. 
Literature produced by GE Healthcare, the manufacturer of Omnipaque, states that 
approximately 95% of adverse reactions are mild to moderate in degree. Incidence of 
shock is estimated at one per twenty thousand patients (0.05%) and incidence of 
death is reported as less than one per ten thousand patients (less than 0.01%).  
2.4.3 INCIDENTAL FINDINGS 
Clinically significant non-cardiac incidental findings are detected in between 
2.8%{Hunold, 2001} and 45.6%{Cademartiri, 2007} of patients undergoing CCT. In one 
of the largest studies (n = 503), Onuma et al. identified 31 cases of pneumonia, 7 aortic 
aneurysms, 1 aortic dissection, 2 lung cancers, and 2 breast cancers{Onuma, 2006}. 
The detection rate is higher for a large field of view, encompassing the entire thorax, 
versus a small ‘cardiac’ field of view.  
CTPAs requested for the exclusion of pulmonary embolism have a high yield of cardiac 
abnormalities{Foley, 2010}. Few reports of non-coronary findings are available for 
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CPCT. In a study of 69 patients investigated with CPCT, relevant non-coronary 
diagnoses were found in three patients, including pericarditis, pneumonia, and 
pulmonary embolism{White, 2005}. More recently, CPCT evaluation of low to 
moderate risk ACS patients presenting to the emergency department identified a non-
coronary diagnosis that explained the presenting complaint in 11% of 
patients{Takakuwa, 2008}. All patients undergoing CT during the studies detailed in 
this thesis were informed that further investigation and follow-up of incidental 
findings may be required.  
2.4.4 ETHICAL APPROVAL 
All studies within this thesis went through a process of local review and internal 
authorisation via the Chelsea and Westminster R&D Support Office and the Trust 
acted as the Sponsor for all studies.  
Research Ethic Committee approval was required and successfully obtained for the 
following studies: 
 Prospective assessment of the utility of CCT in patients admitted with chest 
pain to the acute medical setting (Chapter 4) 
o Cambridgeshire 1 REC: reference number 09/H0304/64 
 Prospective assessment of the utility of CCT in patients presenting with chest 
pain to the cardiac outpatient setting (Chapter 6) 
o North London REC 1: reference number 10/H0717/33 
 Prospective assessment of the utility of CPCT in patients admitted with 
dyspnoea to the acute medical setting (Chapter 9) 
o North West London REC 1: reference number 10/H0722/12 
2.5 FUNDING CONSIDERATIONS 
My salary throughout the duration of this thesis was funded by a Research Fellowship 
Award from the Defence Postgraduate Medical Deanery. In addition, I obtained 
funding to the total value of £63,600 through a Joint Research Committee Fellowship 
Award, a Joint Research Committee Small Grant and a Special Award from the Chelsea 
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and Westminster Health Charity. These funds financed my research activities 
(including radiology costs) and covered the cost of employing a research nurse 
specialist for a period of two years.  
 
 
 
  
74 
 
CHAPTER 3: DEMOGRAPHIC ANALYSIS OF PATIENTS ADMITTED TO HOSPITAL WITH 
UNDIFFERENTIATED CHEST PAIN AND DYSPNOEA 
3.1. INTRODUCTION 
With the increasing economic pressures in healthcare, there is a drive to improve the 
efficiency of care for patients with chest pain and dyspnoea, to minimise delays in 
targeted therapy, to avoid unwarranted hospital admission or inappropriate discharge 
and to reduce total costs. Any measures to streamline the patient journey must take 
into account the prevalence of underlying disease, patient characteristics and the 
nature of existing clinical practice{Solinas, 2003}. 
One of the recognised challenges in generating robust diagnostic algorithms for 
patients admitted with undifferentiated chest pain and dyspnoea is an absence of 
information delineating the demographic, biochemical and radiological characteristics 
of these populations. Furthermore, there is a lack of available information regarding 
the investigations undertaken and the ultimate diagnoses of these patients. Medical 
literature tends to focus on definitive diagnosis of patients in whom a preliminary 
diagnosis or series of differentials has already been proposed.  
3.1.1 CHEST PAIN 
Chest pain accounts for approximately 1% of general practice attendances{Bosner, 
2009}, 6% of emergency department attendances (around 700,000 patient 
attendances per annum in the UK){Goodacre, 2005} and 20–30% of emergency 
medical admissions.  
Gastrointestinal causes of pain, musculoskeletal problems and psychopathology are 
identified more frequently in general practice{Klinkman, 1994}; and serious lung 
diseases and cardiovascular diseases in the hospital attenders{Buntinx, 2001}. 
Compared with patients with cardiac chest pain, patients with non-cardiac pain are 
usually younger, less likely to have typical symptoms and more likely to have a normal 
resting ECG{Sekhri, 2007}.  
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3.1.2 DYSPNOEA 
Studies have documented the prevalence of dyspnoea in different settings with widely 
variable results. In the community prevalence ranges from 3-25%, in general practice 
consultations 4%, in medical outpatient clinics 4%, in the emergency department 3%-
4% and in acute hospital admissions 15-25%{Mulrow, 1993}. Factors associated with 
increased prevalence include increasing age, raised body mass index, smoking history 
and lower socio-economic status{Mulrow, 1993}.  
Across the various medical settings, the most common causes of dyspnoea are cardiac 
or pulmonary in origin{Gillespie, 1994}. In elderly patients presenting to the 
emergency department, congestive cardiac failure (43%), community-acquired 
pneumonia (35%), exacerbation of chronic respiratory disease (32%), pulmonary 
embolism (18%) and acute asthma (3%) are the leading diagnoses{Ray, 2006}.  A study 
of 599 patients attending the emergency department found 209 (35%) had a final 
diagnosis of cardiac failure, 31 (5%) had an ACS and amongst patients with acute 
cardiac failure, 12 (6%) had a concomitant acute myocardial infarction{Januzzi, 2005}. 
Up to one third of patients have more than one aetiology underlying their 
breathlessness. Pulmonary dysfunction, particularly COPD, and the use of pulmonary 
medication often coincides with unrecognised heart failure{McCullough, 2003; 
Rutten, 2005} 
3.1.3 CLINICAL CODING AT CHELSEA AND WESTMINSTER HOSPITAL 
The hospital employs non-medical staff to undertake centralised clinical coding duties. 
The coding team includes 6 qualified and non-qualified clinical coding officers and 2 
qualified clinical coding trainers/auditors. Each coding officer is expected to code for 
multiple, random medical and surgical specialties.  
Coding officers use alpha-numeric codes, known as Read Codes, to record clinical 
conditions and procedures for finished consultant episodes in the emergency 
department and in-patient admissions. Code selection is based on information from 
the Full Medical Record (hard copy) and Electronic Patient Record (EPR). A number of 
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separate systems are accessible to coding staff including radiology, laboratory and 
endoscopy systems{Chelwest, 2014}.  
Accurate maintenance of the Full Medical Record and EPR is the responsibility of 
medical, nursing and allied health professionals. Within the EPR, medical staff are 
expected to record working diagnoses for patients admitted via the emergency 
department and final diagnoses for patients discharged from hospital.  
Clinical coding data are validated by regular internal audit and the Payment by Results 
data assurance framework.  
3.2. AIMS 
This aims of this study were to:  
 Identify the frequency of admissions to Chelsea and Westminster Hospital with 
undifferentiated chest pain or dyspnoea  
 Review the investigative pathways, length of stay and final diagnoses for these 
patients 
3.3 PATIENTS AND METHODS 
Chelsea and Westminster Hospital coding data were analysed for the 5 years 
preceding February 2012. All patients aged over eighteen years admitted to hospital 
via the emergency department with a primary diagnosis of non-specific chest pain or 
dyspnoea were identified. Diagnosis was determined according to the Read codes 
detailed in Table 3.1.  
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Table 3.1: Read codes for patients with undifferentiated dyspnoea and chest pain 
 DESCRIPTOR READ CODE ICD CODE 
CHEST PAIN retrosternal chest pain R065011 R074 
 chest discomfort R065600 R073 
 chest pain NOS R065Z00 R074 
 chest pain, unspecified R065000 R074 
 chest tightness R065800 R073 
 pleuritic pain R065400 R073 
 other chest pain RYU0460 R073 
    
DYSPNOEA breathlessness R060D00 R068 
 dyspnoea R060A00 R060 
 shortness of breath R060800 R060 
When it became apparent that the number of patients admitted with non-specific 
dyspnoea was significantly lower than predicted, a second survey was undertaken to 
identify all patients discharged over the same five year period with discharge Read 
codes compatible with respiratory disease and/or symptoms of acute dyspnoea (>500 
Read codes; Appendix – Tables 1 and 2).   
The medical records of all patients admitted with non-specific dyspnoea were 
reviewed. Data were collated regarding the diagnostic investigations performed 
during the index admission, hospital length of stay and primary discharge diagnosis for 
each patient. Discharge diagnoses recorded by hospital coding (Read codes) were 
compared with those entered by the responsible clinician in the EPR.  
A sample of patients with non-specific chest pain, randomly selected using a 
computerised number generator, and equal in number to the number of patients with 
non-specific dyspnoea, was compared with the dyspnoea group. 
3.4 STATISTICAL ANALYSES 
This study was conceived as a scoping exercise in advance of studies detailed later in 
this thesis. As such, it was not powered to achieve statistical significance.  
Patients with chest pain and dyspnoea were compared using descriptive analyses. 
Clinical and demographic characteristics were summarised as frequency distributions 
(absolute and as percentages).  Comparisons between the groups were performed for 
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age and length of stay using the independent samples t-test following assessment for 
normality by the D'Agostino-Pearson test. Gender and frequency of investigations 
were compared using Chi-square or Fisher’s exact tests as appropriate. Length of stay 
was compared using the Mann Whitney U test.  
3.5 RESULTS 
According to primary diagnosis coding in the emergency department, a total of 3,907 
patients were admitted to Chelsea and Westminster Hospital with undifferentiated 
chest pain and 38 patients were admitted with undifferentiated dyspnoea over a five 
year period (Table 3.2). Analysis of discharge coding over the same period 
demonstrated in excess of 4,600 patients with symptoms of dyspnoea, diagnoses or 
radiological features with the potential to cause dyspnoea.  
Table 3.2: Number of patients admitted with undifferentiated dyspnoea and chest 
pain (Feb 2008 - Feb 2012) 
 DESCRIPTOR READ CODE NUMBER OF PATIENTS 
(% of total) 
DYSPNOEA (n =38) breathlessness R060D00 4 (10.5) 
 dyspnoea R060A00 5 (13.2) 
 shortness of breath R060800 29 (76.3) 
    
CHEST PAIN (n = 3097) retrosternal chest pain R065011 1 (0.03) 
 chest discomfort R065600 1 (0.03) 
 chest pain NOS R065Z00 3085 (99.6) 
 chest pain, unspecified R065000 6 (0.19) 
 chest tightness R065800 2 (0.06) 
 pleuritic pain R065400 1 (0.03) 
 other chest pain Ryu0460 1 (0.03) 
    
Demographic and clinical information for all patients with dyspnoea and a randomised 
sample of patients with chest pain is shown in Table 3.3. Although no statistically 
significant differences were found in the age, gender and length of stay of patients in 
the two groups, patients with dyspnoea were, on average, older than those with chest 
pain, with a mean difference of 7.11 years (95% CI -1.172 to 15.382 years; P=0.091) 
and remained in hospital for longer with a mean difference 3.63 days (95% CI -6.7 to -
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0.56 days; P=0.066; skewed by 7 patients with dyspnoea who remained in hospital for 
>15 days). 
Table 3.3: Study population characteristics (n=76) 
CHARACTERISTIC  DYSPNOEA (%) CHEST PAIN (%) P VALUE 
No. of patients  38 (100.0) 38 (100.0)  
     
Gender Male 18 (47.4) 22 (57.9) 0.491 
 Female 20 (52.5) 16 (42.1)  
     
Age (years) Mean ± s.d. 63.9 ± 19.2 56.8 ± 16.9 0.091 
 Median 68 57  
 Range 22-96 25-94  
     
Length of stay (days) Mean ± s.d. 5.4 ± 9.0 1.8 ± 2.9 0.066 
 Median 1 1  
 Range 0-33 0-15  
Investigation profiles for both groups are shown in Table 3.4. Routine blood tests (full 
blood count, renal function and liver function) were performed in over 95% of all 
patients. There was no statistical difference between the use of D dimer in the two 
groups (P=0.100) but troponin and CK were measured more frequently in the chest 
pain group (p≤0.001 for both). 76% of patients with dyspnoea and 97% of patients 
with chest pain underwent biomarker analysis for at least one of D dimer, troponin or 
CK.  Imaging with chest radiography was performed in over 90% of patients but CT was 
used significantly more often in the dyspnoea group (32% vs 11%; P=0.047).  
 
  
80 
 
Table 3.4: Diagnostic investigations performed during index admission (n=76) 
CHARACTERISTIC  DYSPNOEA (%) CHEST PAIN (%) P VALUE 
No. of patients  38 (100.0) 38 (100.0)  
     
LABORATORY FBC 
U&E  
LFT  
CRP 
ESR 
D Dimer 
BNP 
Troponin 
CK 
GLU 
Lipid profile 
ANY LABORATORY 
37 (97.4) 
37 (97.4) 
37 (97.4) 
34 (89.5) 
2 (5.3) 
19 (50.0) 
0 (0) 
14 (36.8) 
7 (18.4) 
9 (23.7) 
1 (2.6) 
37 (97.4) 
38 (100.0) 
38 (100.0) 
37 (97.4) 
33 (86.9) 
1 (2.6) 
11 (28.9) 
0 (0) 
32 (84.2) 
24 (63.2) 
16 (42.1) 
7 (18.4) 
38 (100) 
1.000 
1.000 
1.000 
1.000 
1.000 
0.0997 
1.000 
<0.001 
<0.001 
0.142 
0.056 
1.000 
BLOOD GAS Arterial 9 (23.7) 1 (2.6) 0.007 
MICROBIOLOGY Sputum culture 
Pleural fluid culture 
Blood culture 
Viral screen 
TB screen 
Atypical pneumonia screen 
ANY MICROBIOLOGY 
6 (15.8) 
1 (2.6) 
2 (5.3) 
1 (2.6) 
1 (2.6) 
3 (7.9) 
10 (26.3) 
1 (2.6) 
0 (0) 
1 (2.6) 
2 (5.3) 
0 (0) 
1 (2.6) 
5 (13.2) 
0.108 
1.000 
1.000 
1.000 
1.000 
0.615 
0.249 
CARDIOLOGY ECG 
ETT 
ECHO 
Functional testing 
Angiography 
ANY CARDIOLOGY 
16 (42.1) 
0 (0) 
9 (23.7) 
2 (5.3) 
0 (0) 
22 (57.9) 
32 (84.2) 
2 (5.3) 
6 (15.8) 
1 (2.6) 
1 (2.6) 
32 (84.2) 
<0.001 
0.493 
0.566 
1.000 
1.000 
0.022 
RESPIRATORY Lung function 
Bronchoscopy 
ANY RESPIRATORY 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
1.000 
1.000 
1.000 
OTHER OGD 0 (0) 0 (0) 1.000 
IMAGING CXR 
CT 
VQ scan 
MRI 
Doppler 
USS other 
ANY OTHER IMAGING 
35 (92.1) 
12 (31.6) 
0 (0) 
0 (0) 
2 (5.3) 
2 (5.3) 
35 (92.1) 
36 (94.7) 
4 (10.5) 
1 (2.6) 
2 (5.3) 
0 (0) 
1 (2.6) 
36 (94.7) 
1.000 
0.047 
1.000 
0.493 
0.493 
1.000 
1.000 
Based on discharge coding, no diagnosis was recorded for 63% of patients admitted 
with chest pain (Table 3.5); the most common diagnoses were coronary artery disease 
(16%) and musculoskeletal pain (5%). Similarly, in patients admitted with dyspnoea, 
no diagnosis was recorded for 32% (Table 3.6); the most common diagnoses were 
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respiratory tract infection (24%), cardiac failure (18%), asthma (5%) and pulmonary 
embolism (5%). Based on the EPR, 32% of patients with chest pain and 39% of patients 
with dyspnoea were discharged without a formal diagnosis.  
Compared with coding records, the EPR documented a statistically greater proportion 
of patients as having ‘nil abnormal detected’ (dyspnoea P=0.025, chest pain P=0.025) 
but was also more likely to make no attempt to define the reason for admission 
(dyspnoea P=0.001, chest pain P=0.113). Coding records were more likely to 
document symptoms without attributing them to a diagnosis (dyspnoea P=0.014, 
chest pain P<0.001).  
Table 3.5: Discharge diagnoses for patients with undifferentiated chest pain (n=38) 
DISCHARGE DIAGNOSIS  READ CODE EPR P VALUE 
Cardiac disorders Angina 2 (5.3) 8 (21.1)  
 Acute coronary syndrome 4 (10.5) 0 (0)  
 NSTEMI 0 (0) 1 (2.6)  
 Drug induced coronary 
spasm 
0 (0) 1 (2.6)  
 Pericarditis 1 (2.6) 0 (0)  
 Cardiac failure 0 (0) 2 (5.3)  
Musculoskeletal 
disorders 
 2 (5.3) 2 (5.3)  
Respiratory disorders Respiratory tract infection 1 (2.6) 3 (7.9)  
 Asthma/bronchospasm 0 (0) 0 (0)  
 COPD 1 (2.6) 0 (0)  
 Bronchiectasis 1 (2.6) 0 (0)  
 Pulmonary embolism 0 (0) 1 (2.6)  
GI disorders  GORD 1 (2.6) 0 (0)  
 Oesophagitis 0 (0) 1 (2.6)  
 GI malignancy 1 (2.6) 0 (0)  
 Hepatitis 0 (0) 1 (2.6)  
No diagnosis Symptoms not attributed 
to disease process 
21 (55.3) 3 (7.9) <0.001 
 
 No entry recorded 3 (7.9) 9 (23.7) 0.113 
Nil abnormal detected  0 (0) 6 (15.8) 0.025 
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Figure 3.1: Discharge diagnoses for patients with undifferentiated chest pain (n=38) 
 
 
Table 3.6 Discharge diagnoses for patients with undifferentiated dyspnoea (n=38) 
DISCHARGE DIAGNOSIS  READ CODE EPR P VALUE 
Respiratory disorders Respiratory tract infection 9 (23.7) 7 (18.4)  
 Asthma/bronchospasm 2 (5.3) 1 (2.6)  
 COPD/emphysema 0 (0) 2 (5.3)  
 Interstitial lung disease 1 (2.6) 1 (2.6)  
 Pulmonary embolism  2 (5.3) 0 (0)  
 Pneumothorax/pneumomedi
astinum 
0 (0) 0 (0)  
 Pleural effusion 0 (0) 1 (2.6)  
Thoracic oncology Malignant neoplasm  0 (0) 1 (2.6)  
Cardiac disorders Coronary artery disease  1 (2.6) 1 (2.6)  
 Cardiac failure 7 (18.4) 2 (5.3)  
GI disorders  Gastritis 0 (0) 1 (2.6)  
Other Anaemia 1 (2.6) 0 (0)  
 Alcohol withdrawal 1 (2.6) 0 (0)  
 Ankle effusion 1 (2.6) 0 (0)  
 Blocked urinary catheter 1 (2.6) 0 (0)  
No diagnosis Symptoms not attributed to 
disease process 
9 (23.7) 1 (2.6) 0.014 
 Radiologic features not 
attributed to disease process 
1 (2.6) 0 (0) 1.000 
 No entry recorded 2 (5.3) 14 (36.8) 0.001 
Nil abnormal detected  0 (0) 6 (15.8) 0.025 
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Figure 3.2: Discharge diagnoses for patients with undifferentiated dyspnoea (n=38) 
 
 
3.6 DISCUSSION  
This analysis of historical trends in the admission and assessment pathways of patients 
with undifferentiated chest pain and dyspnoea confirms the routine application of 
biomarker profiling, x-ray imaging and to a lesser extent CT imaging.  Although 
disparities exist between clinical coding and discharge summary records, this study 
suggests at least 30-40% of patients with chest pain and dyspnoea are discharged 
without a formal diagnosis.   
In Chelsea and Westminster Hospital, around 52 patients per month (12 patients per 
week) were admitted via the emergency department with chest pain and no working 
diagnosis. Despite evidence suggesting that the prevalence of dyspnoea in acute 
medical admissions is around half that of chest pain{Mulrow, 1993; Skinner 2010}, this 
study identified fewer than 1 patient per month admitted via the emergency 
department with undifferentiated dyspnoea.  Review of medical discharge coding 
records suggested the low number of documented admissions was not a true 
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reflection of clinical practice, given that around 77 patients per month were 
discharged from hospital with symptoms, radiological features or diagnoses 
compatible with dyspnoea. 
The results indicate a greater tendency for treating clinicians to commit to an early 
working diagnosis for patients with dyspnoea than for those with chest pain (i.e. 
before transfer from the emergency department). This is interesting given the 
potentially life threatening outcomes of incorrect diagnoses in both groups and may 
reflect the so called ‘rule out MI’ approach to chest pain, which commonly results in a 
period of up to twelve hours surveillance with serial ECGs and Tn testing before 
differential diagnoses are considered.  
Analysis of the investigations performed suggests that baseline haematology and 
biochemistry testing were almost universal. Although diagnosis appeared to occur at 
an earlier stage for patients with dyspnoea, there was still a reliance on biomarkers to 
support diagnosis with CRP, D dimer and troponin performed in 90%, 50% and 37% of 
dyspnoeic patients respectively.  Given the evidence supporting the use of BNP in the 
evaluation of dyspnoea (and the prognostication of ACS and PE){Davis, 1994; Januzzi, 
2005; Maisel, 2004}, it was perhaps surprising that BNP was not requested for any 
patients with undifferentiated dyspnoea.  This may reflect the high cost and prolonged 
laboratory turnaround time when the test was introduced, limiting its role in the acute 
setting.  
Recognising the role of biomarkers to complement clinical assessment and ECG in the 
diagnosis, risk stratification, triage, and management of patients with suspected 
ACS{Mueller, 2014}, this study confirmed a high frequency of Tn in use the chest pain 
group (performed in 84%). The lesser uptake of Tn and ECG testing in the dyspnoea 
group raises concern for missed CAD, as the EuroHeart data set indicates up to 26% of 
patients with ACS report predominant breathlessness{Hamaad, 2004} and in a large 
series of patients referred for evaluation of dyspnoea, 42% of those with dyspnoea 
alone had ischaemia on stress echocardiography versus 19% of those with chest 
pain{Bergeron, 2004}. 
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Given the importance of rapid diagnosis and treatment for conditions such as 
myocardial infarction, prompt availability of investigation results impacts upon patient 
satisfaction but also patient safety{Dierks, 2007; Kline, 2007; Guttman, 2011}. The 
reliance on biomarkers in this study highlights a potential role for bedside biomarker 
analysis to aid prompt acquisition of results. The Biosite ProfilER (Biosite INC, USA) 
shortness of breath multi-marker panel is an example of the commercially available 
options and is used to measure levels of BNP, troponin I, CK-MB, myoglobin and D 
dimer. 
In this study, patients with dyspnoea were more likely to undergo CT during their acute 
admission than patients with chest pain (P=0.047). The lower use of CT in the chest 
pain group is likely to reflect the era in which these patients were admitted, when CCT 
was in its infancy. Nevertheless, the small numbers of patients with chest pain 
undergoing exercise testing, functional cardiac testing and invasive angiography 
suggests acute admission episodes were used to risk stratify patients safe for 
discharge to the community rather than to complete full inpatient cardiac workup.  
NICE CG95 supports this practice of risk stratification based on Bayesian analysis, while 
recognising an increasing role for CCT. 
Comparison between patient outcomes based on Read codes and EPR discharge 
summaries demonstrated discrepancies between the two data sets. A recent report 
on the quality of clinical coding in the NHS highlighted tight deadlines, vacant posts 
and inexperienced staff as potential causes of coding error that impact on the accuracy 
of data capture{Capita, 2014}. Our experience was that non-medical coding staff 
appeared reticent to attribute disease causality. Errors in coding definitive diagnoses 
may also arise when the quality of source documentation is poor{Capita, 2014} and in 
this study around one quarter of EPR discharge summary entries were inadequately 
completed. The implication is that neither method in isolation provided an accurate 
overview of diagnoses in the study population.  
The high proportion of study patients discharged without a diagnosis mirrors recent 
European findings that one quarter of acute medical admissions leave hospital without 
the cause of their symptoms being identified{Vest-Hansen, 2014}. If extrapolated to 
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the 700,000 emergency department admissions for chest pain and approximately 
350,000 admissions for dyspnoea, failure to diagnose even one third of these 
individuals would equate to 346,500 patients per annum at risk of anxiety, delayed or 
inappropriate investigation and management, hospital re-presentation and 
ultimately, increased mortality{Pope, 2000; Ray, 2006}.  
Evidence-based assessment algorithms have a role in minimising potential 
harms{Woolf, 1999}. Deficiencies in existing coding systems go part way to explaining 
the current lack of large scale epidemiological data to support the development and 
optimisation of algorithms for undifferentiated chest pain and dyspnoea to date. It is 
important that the NHS continues to improve the quality of its data in a way that 
benefits patients and improves patient care.  
3.7 LIMITATIONS 
This study was performed at a single site over a period during which there were 
significant advances in biomarker and imaging technology, plus the publication of 
National guidance for the assessment and management of suspected CAD{NICE, 
2010}. Furthermore, the number of cases reviewed was small and the dyspnoea cases 
were non-randomised. While the number of cases of undifferentiated dyspnoea is 
likely to be underestimated, the number of patients with undifferentiated chest pain 
may be an over-estimate given the tendency of coding to under-attribute causality. 
Extrapolation of the results should therefore be with caution. 
3.8 LEARNING POINTS 
 Over 95% of patients with chest pain and over 75% of patients with dyspnoea 
undergo biomarker profiling which could be performed using a bedside multi-
marker panel. Bedside biomarker analysis may support more rapid diagnosis 
and treatment in these patients. 
 Computed tomography is integral to the assessment of patients with 
undifferentiated dyspnoea, being performed in around one third of patients. 
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 Computed tomography is performed in around ten percent of patients 
assessed for undifferentiated chest pain. This figure may increase with 
advances in CCT technology and the support of NICE CG95. 
 Challenges with the accuracy of medical coding currently limit the role of 
Hospital Episode Statistics in supporting the development and optimisation of 
assessment algorithms for patients with undifferentiated chest pain and 
dyspnoea. 
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CHAPTER 4: PROSPECTIVE ASSESMENT OF THE UTILITY OF CARDIAC CT IN PATIENTS 
ADMITTED WITH CHEST PAIN TO THE ACUTE MEDICAL SETTING 
4.1 INTRODUCTION 
In the past twenty five years the number of general and acute medical beds has fallen 
by a third{Imison, 2012}  while the last decade alone has seen a 37% increase in 
emergency admissions{HES, 2012}. Hospitals have coped with this increase by 
reducing average lengths of stay. High event rates and finite facilities for the invasive 
management of ACS emphasise the clinical and logistical importance of risk 
stratification in selecting patients safe for discharge. 
At present, patients presenting to hospital with chest pain with low likelihood of CAD 
are often discharged without further investigation while those with high likelihood 
often proceed directly to invasive coronary angiography. Stratification of patients with 
intermediate likelihood of CAD remains an important clinical issue as these individuals 
are at greatest risk of diagnostic uncertainty which may lead to inappropriate 
discharge or investigation . 
CCT is a non-invasive diagnostic test with the ability to detect CAD quickly and 
accurately{Hamon, 2007, Mowatt 2008, Miller 2008}. A potential role for CCT has been 
identified in the risk stratification of patients presenting to hospital with chest pain. 
To date, evidence supporting the early use of CCT has been largely based on studies 
undertaken in emergency departments in the American healthcare system{Goldstein 
2007; Rubinshtein, 2007; Hoffman, 2009; Hoffman, 2012}.  
At the time of this study, the value of CCT in acute chest pain was unexplored in the 
UK setting, where patients with suspected CAD are often managed in acute 
assessment units whose referrals originate from both general practitioners and 
emergency departments.  
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4.2 AIMS 
This prospective pilot study was undertaken to assess the feasibility and clinical utility 
of CCT as an early triage tool in patients admitted to an acute assessment unit with 
suspected cardiac chest pain and low-intermediate likelihood of CAD.  
Specific aims of the study were to:  
 Assess the practical challenges of incorporating early CCT into routine care for 
the target population. 
 Assess the impact of CCT-based assessment, relative to standard assessment, 
on  
o Diagnosis or exclusion of clinically significant CAD 
o Downstream cardiac investigation burden (inpatient and outpatient) 
o Hospital attendances and admissions with chest pain 
o Incidence of major adverse cardiovascular events (MACE)a  
a Major Adverse Cardiac Events defined as any of unstable angina, acute myocardial infarction, urgent coronary revascularisation, 
life threatening dysrhythmia, stroke, and cardiac death 
4.3 PATIENTS AND METHODS  
Patients who presented to the acute assessment unit of Chelsea and Westminster 
Hospital with suspected cardiac chest pain over a four month period from November 
2009 were screened for entry to the study.  
Chest pain was categorised as non-anginal, atypical or typical for angina  (see Chapter 
2). Pre-test likelihood of CAD was determined using a nomogram based on modified 
Diamond-Forrester criteria (Table 4.1){Diamond, 1979}. Low pre-test likelihood was 
defined as <10%, intermediate 10-90% and high likelihood >90%, in accordance with 
the ACC/AHA 2002 Guideline Update for Exercise Testing{Gibbons, 2006}. Patients 
with a high likelihood of CAD or Tn I ≥3µg/ml at 12 hours were excluded from the 
study. 
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Table 4.1: Percentage likelihood of CAD according to modified Diamond-Forrester 
criteria{Diamond, 1979} 
 TYPICAL ANGINA ATYPICAL ANGINA NON-ANGINAL 
Age (years) male female male female male Female 
30–39 67 26 22 4 5 1 
40–49 87 55 46 13 14 3 
50–59 92 80 59 32 22 8 
60–69 94 91 67 54 28 19 
Additional standard exclusion criteria for studies including CCT are detailed in Chapter 
2. Patients were also excluded if CCT could not occur within 24 hours of admission. 
Thus, recruitment was based on a convenience sample of patients admitted between 
10am on Sunday and 4pm on Friday each week.  
Eligible patients were discussed with the cardiology team and excluded from scanning 
if CCT was felt not to be in the patients’ best interests (e.g. patients with non-cardiac 
chest pain or a high risk of CAD based on the cardiologist’s clinical impression). 
Enrolled patients underwent CCT, comprising CCS and CTA, according to the protocol 
detailed in Chapter 2. CCT results were made available to the cardiology team, who 
were solely responsible for further management. 
An age and sex-matched historical cohort was selected from patients attending the 
acute assessment unit with suspected cardiac chest pain and no history of 
percutaneous cardiac intervention in the year prior to the study, for whom 
investigation did not include CCT. Where there was no exact age match, a patient as 
close as possible in age was selected.  
The two cohorts were classified as CCT-Y (patients who underwent CCT) and CCT-N 
(the historical cohort). 
Data relating to clinical presentation, demographics, risk factor profiles (i.e. diabetes 
mellitus, smoking history, hyperlipidaemia and hypertension) and clinical course were 
collated for all patients. Medical records were reviewed to obtain results of all 
diagnostic tests performed during the hospital admission and in the 3 months post 
admission. Downstream investigations were defined as all cardiac tests occurring from 
admission to completion of follow-up. 
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Final diagnosis and diagnosis of MACE was based on the judgment of 2 clinicians with 
access to all clinical and laboratory data, including the results of conventional serial 
troponin measurements, stress tests and invasive angiography, through 3 months of 
follow-up.  
Following publication of NICE CG95 in March 2010, post-hoc risk stratification was 
performed for all patients to determine likelihood of CAD based on NICE criteria.  
4.4 STATISTICAL ANALYSIS 
The study was conceived as a feasibility study and was therefore not powered to 
achieve statistical significance. It was intended that the study would recruit 20 patients 
over a three month period. Although the recruitment period was extended to four 
months, the recruitment target was not met.  
The two cohorts were compared using descriptive analyses. Clinical and demographic 
characteristics were summarised as frequency distributions (absolute and as 
percentages). Following assessment for normality by the D'Agostino-Pearson test, 
comparisons between the two groups were performed for age using the independent 
samples t-test. Gender, nature of chest pain, likelihood of CAD, frequency of cardiac 
risk factors, and frequency of cardiac investigations and MACE were compared using 
Chi-square or Fisher’s exact tests as appropriate. Additionally, the overall distribution 
of the CAD likelihood categories between the two groups and length of stay were 
compared using the Mann-Whitney U test.  
4.5 RESULTS 
4.5.1. Patient population 
A total of 198 patients with suspected cardiac chest pain were screened during the 
enrolment period (Table 4.2). Exclusion criteria were identified in 106 (54%). A further 
78 patients (39%) were either selected to pursue standard clinical care by the 
cardiology team (n=37), declined to participate (n=18), or could not complete the CCT 
examination (n=23). Ultimately, 14 patients (7%) were scanned.  
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Table 4.2: Recruitment analysis (n=198) 
Number of patients screened (% of total) 198 (100.0) 
Number of patients found to be ineligible (% of total) 106 (53.5) 
Reasons for ineligibilitya (% of total)  
 age <40yrs 12 (6.1) 
 likelihood of CAD >90% 33 (16.7) 
 features of AMI 20 (10.1) 
 haemodynamic/respiratory instability 4 (2.0) 
 previous coronary intervention 44 (22.2) 
 resting heart rate >70bpm 9 (4.5) 
 allergy/intolerance of iodinated contrast 3 (1.5) 
 renal dysfunction 7 (3.5) 
 pregnancy 4 (2.0) 
 unable to provide written consent 16 (8.1) 
Number of potentially eligible patients not scanned (% of total) 78 (39.4) 
Reasons for non-scanning (% of total)  
 excluded by cardiologist 37 (18.7) 
 CCT not possible within 24 hours/prior to discharge 23 (11.6) 
 declined written consent 18 (9.1) 
Number of patients recruited (% of total) 14 (7.1) 
a often more than one factor per patient - 42 patients with >1 exclusion criteria 
Reasons for exclusion by the cardiology team were a clinical diagnosis of non-cardiac 
chest pain (n=24) or a perceived high risk of significant CAD (n=13) warranting invasive 
angiography as first line management, based on clinical acumen.   
Reasons for declined consent were self-discharge from hospital (n=7), unwillingness 
to undertake inpatient investigations (n=5), inability to decide whether to have CCT 
(n=2), and concerns regarding radiation (n=3) and intravenous contrast exposure 
(n=1).  
13 patients were discharged from hospital before they could undergo CCT and 
scanning was not possible within 24 hours of admission for a further 10 patients. The 
limitations to scanning within 24 hours included delays in troponin result availability, 
delays in the availability of past medical records and CCT scanner non-availability. The 
mean time from admission to CCT was 1218 ± 249mins (20hrs 18min; range 815-
1623mins).  
Demographic information for the CCT-Y and CCT-N cohorts is detailed in Table 4.3.  
There were no statistical differences between the cohorts with respect to age, gender, 
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risk factor profiles or likelihood of CAD (measured by both Diamond-Forrester and 
NICE criteria). 
Table 4.3: Study population characteristics (n=28) 
CHARACTERISTIC  TOTAL CCT-Y CCT-N P VALUE 
No. of patients  28 (100.0) 14 (100.0) 14 (100.0)  
      
Gender Male 16 (57.1) 8 (57.1) 8 (57.1) 1.000 
 Female 12 (42.9) 6 (42.9) 6 (42.9)  
      
Age Mean ± s.d. 63.5 ± 12.03 63.5 ± 12.28 63.5 ± 12.23 1.000 
 Median 62.5 62.5 62.5  
 Range 42-85 42-85 42-85  
      
Cardiac risk factors   NICE risk factorsa 25 (89.3) 12 (85.7) 13 (92.9) 1.000 
  Hypertension 19 (67.9) 9 (64.3) 10 (71.4) 1.000 
  Reported CAD 4 (14.3) 3 (21.4) 1 (7.1) 0.596 
  Family history of 
CAD  
12 (42.9) 6 (42.9) 6 (42.9) 1.000 
      
Nature of chest pain Non-anginal 12 (42.9) 4 (28.6) 8 (57.1) 0.252 
  Atypical angina 14 (50.0) 10 (71.4) 4 (28.6) 0.057 
  Typical angina 2 (7.1) 0 (0.0) 2 (14.3) 0.482 
      
Likelihood of CAD – 
Diamond-Forrester (%) 
 
<10 
 
2 (7.1) 
 
1 (7.1) 
 
1 (7.1) 
 
1.000 
  10-90 24 (85.7) 13 (92.9) 11 (78.6) 0.596 
  >90 2 (7.1) 0 (0.0) 2 (14.3) 0.482 
      
Likelihood of CAD - NICE 
(%) 
10-29 3 (10.7) 2 (14.3) 1 (7.1) 1.000 
 30-60 10 (35.7) 5 (35.7) 5 (35.7) 1.000 
 61-90 13 (46.4) 5 (35.7) 8 (57.1) 0.450 
 >90 2 (7.1) 2 (14.3) 0 (0.0) 0.482 
      
Length of stay (hrs) Mean ± s.d. 63.32 ± 80.0 73.5 ± 101.4 53.14 ± 52.23  
 Median 31 29 32 0.944 
 Range 0-388 16-388 0-186  
      
Downstream 
investigations 
ETT 3 0 3 0.222 
 CCS 14 14 0 <0.001 
 CTA 13 13b 0 <0.001 
 Functional  2 2 0 0.482 
 IC A 9 3 6 0.420 
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 Total  41 32 9 <0.001 
      
0-3 months post admission Re-presentation to 
ED with chest pain 
4 2 2 c 1.000 
  Re-admission with 
chest pain 
3 2 1 1.000 
      
 MACE  0 0 0 1.00 
      
Adjudicated diagnosis CAD diagnosed 7 (25.0) 4 (28.6) 3 (21.4) 1.00 
 CAD excluded 18 (64.3) 10 (71.4) 8 (57.1) 0.694 
 Inconclusive 3 (10.7) 0 (0.0) 3 (21.4) 0.222 
aCardiac risk factors used to define patients at high risk for CAD using the NICE algorithm are any one of diabetes mellitus, smoking 
or hyperlipidaemia (total cholesterol >6.47mmol/l). 
b One patient underwent CCS without CTA; decision undertaken by radiologist based on elevated CCS. All scans were of diagnostic 
quality. 
c One patient attended the emergency department on two occasions 
4.5.2 Clinical outcomes 
CAD was diagnosed in 29% (n=4) and excluded in 71% (n=10) of the CCT-Y cohort. 75% 
of patients with clinically significant CAD had abnormal findings on CCT.  The diagnostic 
yield with CCT was 21%. Imaging demonstrated 29% (n=4) had no evidence of CAD, 
43% (n=6) had mild plaque burden but no significant stenosis, 14% (n=2) had mild 
plaque burden with significant stenosis, and 7% (n=1) had significant plaque burden 
with significant stenosis (one patient with significant plaque did not complete CTA).  
CAD was diagnosed in 21% (n=3) and excluded in 57% (n=8) of patients investigated 
without CCT, leaving 21% (n=3) without a definitive diagnosis. Statistical analysis 
demonstrated no difference in the diagnostic ability of CCT-based assessment, relative 
to standard assessment (P=0.222). 
Over the three month follow-up period, no patients suffered a MACE.  
Figure 4.1: Incidental clinical findings (ICFs) identified on CCT 
 2 ICFs identified in a single patient undergoing CCT (n=1/14; 7%)  
 chronic unilateral pleural effusion: no action required 
 calcified pulmonary nodule: no action required 
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4.5.3 Resource utilisation 
Downstream investigations are detailed for each cohort in Tables 4.4 and 4.5. None of 
the CCT-Y cohort underwent ETT versus 21% of the CCT-N cohort (P=0.222). Half as 
many patients in the CCT-Y cohort underwent invasive angiography as in the CCT-N 
cohort (21% versus 43%; P=0.420). Both these difference were non-significant.  
Table 4.4: Individual demographics, investigations and diagnostic outcomes for 
CCT-Y cohort (n=14) 
Patient 
No 
Age Gender Likelihood 
of CAD 
CCS CTA  In-
patient 
ix 
Discharge 
diagnosis 
Out-
patient 
Ix 
Final 
diagnosis 
1 42 M 14 0 NAD - Non-CAD - Non-CAD 
2 47 F 3 0 NAD - Non-CAD - Non-CAD 
3 52 M 59 3.9 NAD - Inconclusive Functional Non-CAD 
4 57 M 22 3.4 NAD - Non-CAD - Non-CAD 
5 59 M 22 1 NAD - Non-CAD - Non-CAD 
6 60 M 67 114 Significant - CAD ICA CAD 
7 62 F 54 6.1 NAD - Non-CAD - Non-CAD 
8 63 M 67 36.4 NAD ICA CAD - CAD 
9 65 F 54 0 NAD - Non-CAD - Non-CAD 
10 69 F 54 0 NAD - Non-CAD - Non-CAD 
 
11 
 
70 
 
F 
 
>54 9 
Non-
Significant 
 
- 
 
Non-CAD 
 
- 
 
Non-CAD 
12 79 F >54 45 Significant ICA CAD - CAD 
13 79 M >67 946 - - Inconclusive Functional Non-CAD 
14 85 M >67 3847 Significant - CAD - CAD 
(Ix – investigations; CCS - coronary calcium score; CTA – CT angiography; ETT – exercise tolerance test; ICA – invasive coronary 
angiography) 
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Table 4.5: Individual demographics, investigations and diagnostic outcomes for 
CCT-N cohort (n=14) 
Patient  Age Gender Likelihood 
of CAD 
In-patient 
ix 
Discharge 
diagnosis 
Out-patient 
Ix 
Final diagnosis 
1 42 M 14 ICA CAD - CAD 
2 48 F 3 - Inconclusive - Inconclusive 
3 51 M 59 ETT + ICA Non-CAD - Non-CAD 
4 57 M 22 ETT Non-CAD - Non-CAD 
5 59 M 22 ICA CAD - CAD 
6 60 M 28 ETT Non-CAD - Non-CAD 
7 62 F 91 - Inconclusive - Inconclusive 
8 63 M 28 - Non-CAD - Non-CAD 
9 65 F 54 ICA CAD - CAD 
10 68 F 91 - Inconclusive ICA Non-CAD 
11 72 F >54 ICA Non-CAD - Non-CAD 
12 79 F >54 - Non-CAD - Non-CAD 
13 78 M >28 - Inconclusive - Inconclusive 
14 85 M >28 - Non-CAD - Non-CAD 
(Ix – investigations; ETT – exercise tolerance test; ICA – invasive coronary angiography) 
Despite significantly fewer investigations performed overall in the CCT-N cohort 
(P<0.001), the high cost of invasive angiography meant investigation costs per capita 
were higher in this cohort. The relative decrease in cost using a CCT approach was 14% 
(Table 4.6). 
Table 4.6: Investigation costs per capita{NICE, 2010} 
INVESTIGATIONS TOTAL POPULATION 
(cost £) 
CCT-Y 
(cost £) 
CCT-N 
(cost £) 
ETT (£66) 198 0 198 
Ca SCORE (£103)a 1442 1442 0 
Functional (£293) 586 586 0 
ICA (£850) 7650 2550 5100 
Total cost  9876 4578 5298 
Cost per capita 352.71 327.00 378.43 
a counting either or both of CCS and CTA as single entity 
The use of early CCT neither prolonged nor reduced length of stay significantly. Mean 
length of stay appeared longer for the CCT-Y cohort but median values for the two 
cohorts were comparable, highlighting the impact of a single patient who remained in 
hospital for 388hrs on the CCT-Y mean.  
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There was no significant difference between the two cohorts regarding the frequency 
of subsequent emergency department attendance (P=1.000) or admission with chest 
pain (P=1.000).  
4.6 DISCUSSION 
This small scale pilot study highlighted clinical and logistical challenges to the 
introduction of CCT in the acute medical setting. Although the study did not 
demonstrate a statistically significant clinical or resource benefit to the use of early 
CCT, clinically relevant CAD was ultimately diagnosed or excluded in a greater 
proportion of patients undergoing CCT. There was increased diagnostic testing 
amongst the CCT cohort but costs were less than for standard assessment. These 
results were achieved without a detected increase in MACE.  
Despite broad study inclusion criteria, around half of patients presenting to the acute 
assessment unit were ineligible for CCT and fewer than 10% reached the scanner. The 
most common reasons for ineligibility were a history of known CAD with previous 
coronary intervention (22%), a high pre-test likelihood of CAD (>90% likelihood based 
on modified Diamond-Forrester criteria) (17%), or features of acute myocardial 
infarction (10%).  The findings suggest a degree of risk stratification occurred upstream 
of the acute assessment unit (i.e. in the emergency department) and that patients who 
were admitted were those at higher risk of significant cardiac pathology. There may 
also have been some misjudgement of risk using the Diamond-Forrester model which 
overestimates the prevalence of CCT-detectable disease in European populations, 
especially in women{Cheng, 2011; Genders, 2011}. 
Traditionally, patients with likelihood of CAD 0-90% have been considered low-
intermediate risk and there are data to support the use of CCT to triage these 
patients{Athappan, 2010; Singer, 2012; Samad, 2012}; however, NICE CG95 concludes 
there is insufficient evidence to recommend CCT for the intermediate population over 
better established functional testing methods and invasive coronary angiography.  
While adoption of NICE CG95 may have the beneficial effect of minimising diagnostic 
test selection based on clinical acumen and personal preference, the proportion of 
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patients eligible for CCT using NICE criteria may be even lower than this study would 
suggest.   
Logistic barriers to the introduction of CCT in acute admissions, highlighted in this 
study, may be overcome by allowing patients unkeen for inpatient investigations, 
discharged from hospital or unable to be scanned within 24 hours to return for 
outpatient scanning within a limited time period. In the emergency department 
setting, CCT within 72 hours of discharge has been shown to be safe{Raju, 2014}. In a 
non-research context, a CCT service may also have dedicated time slots available for 
acute admissions, to facilitate timely scanning of these patients.  
Tackling CCT non-availability is an important challenge. Although CCT services are 
becoming more widespread, they are by no means universal and tend not to be 
operational outside working hours. A recent emergency department study, performed 
in a unit with standard business hours CCT availability, demonstrated CCT was 
associated with shorter length of stay amongst low-risk chest pain patients (p < 
0.0001) but only for patients presenting to hospital between 8 and 12 am{Mahler, 
2013}. Thus, CCT availability may impact on the clinical utility of the investigation.   
In our study population, compared with standard care, a diagnostic approach 
incorporating CCT resulted in a greater proportion of patients for whom CAD was 
either diagnosed or excluded (100% versus 79%; P=0.222). The strength of CCT 
appeared to be in the exclusion of CAD, although this was not confirmed statistically 
(P=0.694). The findings suggest clinicians acknowledged the strong negative predictive 
value of CCT but were less inclined to exclude CAD on the basis of standard 
assessment, potentially due to concerns regarding the specificity of traditional 
investigations or the fear of under treatment.  
Prior to recent advances in CCT technology, including the development of CT 
myocardial perfusion imaging and CT fractional flow reserve, CCT was limited to 
providing anatomical but not functional assessment; however, information on the 
presence of anatomical CAD is still relevant to clinical decision making about invasive 
angiography{Shreibati, 2011; Hoffman, 2012, Douglas, 2015}. This study 
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demonstrated a non-significant reduction in invasive angiography following CCT but 
an increased frequency of functional imaging, potentially reflecting clinician 
uncertainty in the hemodynamic significance of a positive CCT result. Consistent with 
published data suggesting early CCT leads to increased downstream testing{Hoffman, 
2012}, a greater total number of investigations were performed in the CCT cohort; 
however, fewer invasive angiography procedures resulted in lower cardiac 
investigation costs per capita (16% decrease; £327.00 versus £378.43).  
Average length of stay appeared greater in the CCT cohort but median length of stay 
was comparable for the two approaches, highlighting the impact of a single patient in 
the CCT cohort who remained in hospital for a prolonged period. The absolute rate of 
MACE in the study population, over a three month period of follow-up, was zero, 
suggesting patients managed with a CCT approach were no more likely to experience 
MACE than those receiving standard care. Similarly, there were very few hospital re-
attendances or re-admissions with chest pain meaning the study did not have the 
statistical power to support the conclusion that hospital readmission may be reduced 
after CCT-based evaluation. 
Finally, this study was conceived and completed prior to the release of NICE CG95. A 
separate study, based on the same, well-defined population, was subsequently 
performed to evaluate the consequences of adopting NICE CG95 on the uptake of CCT 
in acute cardiac admissions (Chapter 5). 
4.7 LIMITATIONS  
The primary limitation of this study was that it analysed a small patient population in 
a single centre using a convenience sample. In part, this reflects its origins as a 
feasibility study but also, obstacles to recruitment which led to termination of the 
study before the intended number of patients were recruited. 
Furthermore, CCT enrolment occurred only during weekday daytime hours when all 
imaging testing was available, with radiographers and readers on site, to allow rapid 
reporting and triage decision making. In reality, testing and interpretation are not 
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accessible around the clock and there is likely to be a resultant impact on the timing 
of decisions to discharge patients. 
As such, caution is advised when considering the generalisability of the results to 
similar care settings. Large scale diagnostic studies are needed to provide a definitive 
answer as to whether CCT has a role within an integrated diagnostic strategy for 
patients admitted acutely to hospital with chest pain and the health economic 
implications of such a strategy. Extending the period of study follow-up beyond early 
discharge and more broadly exploring the downstream effects of CCT (e.g. the 
composite financial contribution of evaluation, monitoring, full investigation and 
therapy and the impact on quality-adjusted-life-years) is necessary to recognise 
scenarios in which CCT does, and does not, add ‘value’. 
Given the limitations of the Diamond-Forrester model of risk stratification, future 
studies may be better served using the extended predictive models of Genders et 
al.{Genders, 2011} or the assessment and early management models proposed by 
NICE CG95 and the European Society of Cardiology{Montalescot, 2013}. The adoption 
of such evidence-based models may also serve to minimise bias arising from variation 
in practice between individual cardiologists, encourage clinicians to keep patients in 
hospital to undergo CCT where indicated and encourage patients to undergo 
recommended investigations, avoiding the high rates of drop out seen in this study.  
Restrictions on local recruitment may be addressed through engagement in multi-
centre trials. 
4.8 LEARNING POINTS 
 Up to 50% of patients admitted to the acute assessment unit with low-
intermediate likelihood of CAD are potentially eligible for CCT.  
 For CCT to add incremental benefit to the data available to clinicians, 
investment to provide a 24 hour a day, seven day a week scanning and 
interpretation service should be considered, even though the number of 
patients scanned may be relatively small. 
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 CCT within 72 hours post discharge may negate logistical issues surrounding 
inpatient scanning. 
 A diagnostic algorithm incorporating CCT may enhance the ability of clinicians 
to diagnose or exclude CAD relative to standard assessment. 
 A diagnostic algorithm incorporating CCT may lead to increased diagnostic 
testing but without an associated increase in cost. 
 Locally agreed, evidence-based protocols will minimise under- and over-
utilisation of the technique. In the future, it is likely these protocols will be 
based around NICE guidance.  
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CHAPTER 5 RETROSPECTIVE ANALYSIS OF THE UTILITY OF CARDIAC CT IN THE ACUTE 
MEDICAL SETTING IN ACCORDANCE WITH NICE GUIDELINE CG95  
 
5.1 INTRODUCTION 
Chapter 4 elaborated upon the potential benefits and challenges of adopting CCT in 
the UK acute medical setting, based upon a broad inclusion policy with patient 
selection guided by the acumen of cardiologists on the ground.  NICE CG95, published 
in March 2010 sought to formalise the risk stratification of patients with suspected 
CAD, to support a unified cost-effective and evidence-based approach to investigation, 
incorporating CCT for selected patients.   
NICE CG95 is primarily intended for the management of patients with suspected CAD 
in the outpatient setting but is also applicable to patients with acute chest pain in 
whom ACS is excluded but myocardial ischaemia is still suspected (a common scenario 
on the acute assessment unit). The guideline is subdivided into acute and stable chest 
pain algorithms.  
NICE CG95 advocates risk stratification of patients with suspected stable CAD using an 
amalgamation of the modified Diamond-Forrester (DF) criteria described previously 
and the Duke clinical score that incorporates the presence of diabetes mellitus, 
smoking history and hyperlipidaemia. 
Patients with a history of non-anginal chest pain are not routinely recommended for 
further cardiac investigation. Those with a history of atypical or typical cardiac chest 
pain and a likelihood of CAD between 10 and 90% should be investigated further.  
CCT is recommended for a patients with a likelihood of CAD in the range 10-29%; 
effectively 1) men aged 40-49 years with atypical angina and no cardiac risk factors, 2) 
women aged 50-69 years with atypical angina and no cardiac risk factors, or 3) women 
aged less than 50 years with typical angina and no cardiac risk factors. CCT in this 
context comprises CCS with progression to CTA if there is a significant calcified plaque 
burden. 
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At the time of this study, there were no published data regarding the impact of the 
NICE CG95 on acute cardiac investigation services and the requirement for acute CCT 
provision to meet NICE CG95 was unproven.  
5.2 AIMS 
This retrospective study reviewed the demographic and clinical characteristics of 
patients admitted to the acute assessment unit with suspected cardiac chest pain, to 
evaluate the impact of NICE CG95 on our local population. 
Specific aims of the study were to: 
 Determine the distribution of CAD likelihood amongst acute medical 
admissions with suspected cardiac chest pain, according to NICE CG95 criteria.  
 Review the investigation burden on inpatient cardiac services if NICE CG95 
were applied to this population. 
5.3 PATIENTS AND METHODS 
Patients who presented to the acute assessment unit of Chelsea and Westminster 
Hospital with suspected cardiac chest pain over a four month period from November 
2009 were screened as detailed in Chapter 4.  
Data relating to clinical presentation, demographics, risk factor profiles (i.e. diabetes 
mellitus, smoking history, hyperlipidaemia and hypertension) and clinical course were 
collated for all screened patients. The data set was used as the basis of analysis for the 
current study, in which NICE CG95 was applied retrospectively to the population. 
Patients with evidence of ACS (positive troponin I, ischaemic ECG changes) or a history 
of known CAD with previous coronary intervention were excluded from further 
analysis.   
Chest pain was categorised as non-anginal, atypical or typical for angina. Pre-test 
likelihood of CAD was determined using a nomogram based on NICE CG95. Patients 
were deemed eligible for investigation if they had typical or atypical anginal chest pain 
and a likelihood of CAD in the range 10-90%; those in the range 10-29% (i.e. low risk) 
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were eligible for CCT; those in the range 30-60% (i.e. intermediate risk) were eligible 
for functional testing and those in the range 61-90% (i.e. high risk) were eligible for 
invasive coronary angiography in accordance with NICE CG95.  
5.4 STATISTICAL ANALYSES 
Clinical and demographic characteristics were summarised as frequency distributions 
(absolute and as percentages).  
5.5 RESULTS 
A total of 198 patients with suspected cardiac chest pain (median age 63 years, range 
21-96 years, male: female ratio 1.3:1) were screened over the four-month period. 
Demographic and clinical information is shown in Table 5.1. The distribution of CAD 
likelihood according to nature of chest pain, gender, risk and age is shown in Table 5.2.  
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Table 5.1: Study population characteristics (n=198) 
CHARACTERISTIC  TOTAL 
No. of patients  198 (100) 
   
Gender Male 113 (57.1) 
 Female 85 (42.9) 
   
Age Mean ± s.d. 63.54 ± 16.52 
 Median 63 
 Range 21-96 
   
Cardiac risk factors   NICE risk factorsa 155 (78.3) 
  Hypertension 119 (60.1) 
  Reported CAD 91 (46.0) 
  Family history of CAD 47 (23.7) 
   
Nature of chest pain Non-anginal 100 (50.5) 
  Atypical angina 55 (27.8) 
  Typical angina 43 (21.7) 
   
Likelihood of CAD – NICE (%) <10 21 (10.6) 
 10-29 27 (13.6) 
 30-60 52 (26.3) 
 61-90 55 (27.8) 
 >90 43 (21.7) 
   
Recommended cardiac investigations - NICE No investigation 144 (72.2) 
 ETT 0 (0.0) 
 CCS/CTA 2 (1.0) 
 Functional  12 (6.1) 
 IC A 17 (8.6) 
a Cardiac risk factors used to define patients at high risk for CAD using the NICE algorithm are any one of diabetes mellitus, 
smoking or hyperlipidaemia (total cholesterol >6.47mmol/l). 
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Table 5.2: Distribution of study population according to age, sex and nature of 
chest pain (n=198) 
Age 
(years) 
Non Anginal Atypical Typical 
M F M F M F 
Lo Hi Lo Hi Lo Hi Lo Hi Lo Hi Lo Hi 
<30 2 3 1 - - 1 - - - - - - 
30-39 2 3 - - - - - - - - - - 
40-49 3 10 4 2 1 2 1 - - 6 - - 
50-59 4 11 1 2 1 4 1 5 1 5 2 2 
60-69 1 3 4 8 1 6 - 7 - 9 1 3 
>70 6 12 7 11 1 10 3 11 1 4 2 7 
White:  Not routinely recommended for further investigation  
Dark grey: Likelihood of CAD 10-29% - recommended for CCT 
Mid grey: Likelihood of CAD 30-60% - recommended for functional cardiac testing 
Light grey: Likelihood of CAD 61-90% - recommended for invasive angiography 
33% (n=65) would have been excluded from the NICE stable chest pain algorithm by a 
raised troponin I or ischaemic ECG changes. A further 22% (n=44) would have been 
excluded as a result of previous coronary intervention. 
51% (n=101) of patients would have been recommended for no routine cardiac 
investigation based on pain classified as non-anginal (n=80), a likelihood of CAD <10% 
(n=1) or both (n=20).  21.7% (n=43) would have proceeded directly to treatment 
without investigation, based on a likelihood of CAD >90%. 
1% (n=2) of patients would have been recommended for CCT (Figure 5.1), 6% (n=12) 
for functional cardiac testing and 9% (n=17) for invasive coronary angiography. If the 
criteria for CCT had been broadened to include patients at intermediate risk of CAD, 
with a likelihood 10–60%, 7% (n=14) of patients admitted would have been eligible for 
the investigation. 
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Figure 5.1: Eligibility for CCT in patients admitted with suspected cardiac chest pain  
 
 
5.5 DISCUSSION 
NICE CG95 currently recommends CCT only for those patients with atypical or typical 
angina and a low risk of CAD with pre-test likelihood in the range 10-29%. These 
criteria alone would have excluded over 95% of patients admitted with suspected 
cardiac chest pain and potentially undervalued CCT as a diagnostic tool. Although 
there is evidence to support the broadening of CCT inclusion criteria to include 
patients at intermediate risk of coronary artery disease{van Werkhoven, 2009; Gopal, 
2009}, NICE favour functional testing and invasive coronary angiography. In our local 
population, uptake of functional cardiac testing would have been around six times 
higher and invasive coronary angiography around nine times higher than for CCT.  
NICE CG95 predicts that ‘around’ 29% of patients have a likelihood of CAD <10%, 11-
17% have a likelihood 10-29%, 17-18% have a likelihood 30-60%, 15% have a likelihood 
60-90% and 6-9% have a likelihood >90%{NICE, 2010}. These figures are based on 
outpatient data and it is unsurprising that they underestimated the risk of CAD in our 
population of acute medical patients. Almost half of patients in this study had a 
likelihood of CAD exceeding 60%, indicating a high risk of significant CAD and 
2
Patients eligible for CCT
55
Likelihood of CAD outside range 10-29% n=53
133
Non-anginal chest pain n=78
198
Evidence of acute coronary syndrome n=65
Patients admitted with suspected cardiac chest pain
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corroborating the observation in Chapter 4 that triage occurs upstream of acute 
assessment units .  
Over three quarters of patients admitted had at least one cardiac risk factor 
recognised by NICE (i.e. diabetes mellitus, smoking or hyperlipidaemia), almost half 
reported a history of previously diagnosed CAD and one fifth had a history of 
revascularisation. Nevertheless, over half of patients admitted to the acute 
assessment unit had chest pain categorised as non-anginal. The high percentage of 
patients with non-anginal symptoms despite clinically suspected ischaemia highlights 
the challenge of diagnosis in the acute medical population, who are often elderly with 
multiple co-morbidities{Cornwell, 2011}.  
NICE CG95 recommends patients with non-anginal pain should not routinely undergo 
cardiac investigation. Exercise ECG testing is widely used in this population at present 
but is not supported by NICE{Timmis, 2010}. There is apprehension that the NICE 
model focusses on anatomical diagnosis at the expense of functional 
assessment{Underwood, 2010} and it remains to be seen whether UK cardiologists will 
persist in using exercise ECG testing, including in place of anatomical imaging such as 
CCT.  
In total, 51% of patients admitted with suspected cardiac chest pain would have been 
excluded from further cardiac testing on the basis of NICE criteria, raising concern for 
missed cardiac diagnoses and implicit mortality risk{Pope, 2000}. 1% of the study 
population would have been recommended for CCT, 6% for functional cardiac testing 
and 9% for invasive coronary angiography. If the criteria for CCT had been broadened 
to include patients at intermediate risk of CAD, 7% of patients admitted would have 
been eligible for the investigation. NICE have requested further cost-effectiveness 
studies before reviewing their current guideline for amendments. 
Differences between the proportion of patients predicted to fall into each CAD 
likelihood category and the proportion of patients ultimately recommended for each 
investigation further highlights the hazard of cardiac service development based 
exclusively on the NICE CG95 predictions.  
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Computed tomography is universally available in NHS hospitals that admit acute 
medical patients and, with appropriate software and training, a CCT service can be 
established to provide rapid diagnostic assessment of patients with suspected CAD. By 
comparison, functional and invasive cardiac testing are less available. Increasing the 
number of patients requiring these services is likely to result in delays to diagnosis and 
increased duration of hospital admission with resultant cost implications. Investment 
may be better justified in functional and invasive cardiac testing than in the 
development of CCT services for acute medical admissions, to meet NICE CG95 
demands.  
5.7 LIMITATIONS 
Due to the retrospective nature of this study, typicality of chest pain was judged from 
notes review, and observer interpretation of the nature of chest pain may have 
skewed the likelihood of CAD. Retrospectively confirming a history of CAD was another 
challenge.  Traditionally, significant CAD has been defined by a history of myocardial 
infarction, ‘positive’ angiography or coronary revascularisation. For the purposes of 
risk stratification, all patients were considered to have undifferentiated chest pain 
unless there was a history of coronary revascularisation. This approach more 
realistically reflects the situation facing acute physicians meeting patients for the first 
time, especially in London, where inter-hospital mobility of patients adds to the 
difficulty of maintaining complete records of hospital admissions and cardiac 
investigations. 
5.8 LEARNING POINTS 
 NICE CG95 recommends CCT only for use in patients with atypical or typical 
angina and a low likelihood of CAD (range 10-29%). 
 Adoption of NICE CG95 in the acute medical setting may result in fewer than 
five percent of patients admitted with suspected cardiac chest pain being 
recommended for CCT. 
 Adoption of NICE CG95 is likely to result in a greater number of patients 
undergoing functional and invasive testing than CCT.  
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 The results do not support large scale investment in CCT services within the 
acute medical setting to meet NICE CG95.  
 Investment may be more appropriate if NICE broaden the criteria for CCT 
eligibility to include patients with an intermediate likelihood of CAD.  
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CHAPTER 6: PROSPECTIVE ASSESMENT OF THE UTILITY OF CARDIAC CT IN PATIENTS 
PRESENTING WITH CHEST PAIN TO THE CARDIAC OUTPATIENT SETTING 
6.1 INTRODUCTION 
Rapid access chest pain clinics (RACPCs) have been established in the majority of 
hospitals across the UK, in accordance with the National Service Framework for 
coronary heart disease{DOH, 2000}. Their aim is to provide out-patients with 
suspected cardiac chest pain with prompt investigation and targeted management. 
Referrals come from general practitioners, consultant cardiologists (when new 
patients meet the referral criteria) and emergency departments (when patients 
present with typical symptoms but ECGs and troponin levels do not suggest an acute 
coronary event).  
RACPCs have proven successful in identifying high risk patients with coronary heart 
disease; however, coronary heart disease continues to be under-diagnosed and 
patients judged to have non‐cardiac pain are not immune from major adverse cardiac 
events{Sekhri, 2007}. There is a requirement for better diagnostic accuracy and risk 
stratification in patients attending RACPCS, particularly amongst patients aged <65 
years{Boyle, 2007}. 
A diagnosis of angina pectoris due to coronary heart disease requires a history 
consistent with angina and the presence of obstructive CAD. The strength of CCT is in 
the detection or exclusion of CAD but the technology has yet to be fully evaluated in 
its application to stable outpatients attending RACPCs. A health technology 
assessment, including a systematic review of 64-slice CTA, has identified a 
requirement for research into the usefulness of CTA in patients with suspected 
CAD{Mowatt, 2008}. Subsequently, as part of NICE CG95, NICE have called for research 
into the clinical and cost-effectiveness of CTA compared with functional testing in the 
diagnosis of angina. 
Although recently published studies have gone some way to addressing these research 
questions{Yerramasu, 2014; SCOT-HEART Investigators, 2015; Douglas, 2015}, the 
benefits of using CCT to diagnose patients with new-onset stable angina and the 
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effects of CCT use on subsequent management and clinical outcomes remained 
unexplored in the UK setting at the time of this study. 
6.2 AIMS 
This prospective pilot study was undertaken to assess the feasibility and clinical utility 
of early CCT as a diagnostic tool in patients referred to a RACPC with suspected cardiac 
chest pain.  
Specific aims of the study were to:  
 Assess the practical challenges of incorporating early CCT into routine care for 
the target population. 
 Assess the impact of CCT-based assessment, relative to standard assessment, 
on  
o Diagnosis or exclusion of clinically significant CAD 
o Downstream cardiac investigation burden (inpatient and outpatient) 
o Outpatient clinic reviews prior to discharge 
o Hospital attendances and admissions with chest pain 
o Incidence of major adverse cardiovascular events (MACE)a  
a Major Adverse Cardiac Events defined as any of unstable angina, acute myocardial infarction, urgent coronary revascularisation, 
life threatening dysrhythmia, stroke, and cardiac death 
6.3 PATIENTS AND METHODS  
Consecutive patients referred to the RACPC at Chelsea and Westminster Hospital, with 
chest pain of suspected cardiac origin over a twelve month period from November 
2010 were screened for entry to the study. Standard exclusion criteria for studies 
including CCT are detailed in Chapter 2.  
Enrolled patients were randomised (1:1) to undergo early CCT or to continue with 
standard practice, using a statistician-designed randomisation tool. For patients 
randomised to CCT, an outpatient scan comprising CCS and CTA, (according to the 
protocol detailed in Chapter 2) was arranged within one week of receipt of referral, 
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prior to scheduled RACPC review. CCT results were made available to clinicians in the 
RACPC, who were solely responsible for further management.  
Data relating to clinical presentation, demographics, risk factor profiles and clinical 
course were collated for all patients. Medical records were reviewed to obtain results 
of all diagnostic tests performed in the six months post RACPC referral. Downstream 
investigations were defined as all cardiac tests occurring from referral to completion 
of follow-up. Data were corroborated by a standardised telephone survey of patients 
and their general practitioners at six months. 
Final diagnosis and diagnosis of MACE was based on the judgment of two clinicians 
with access to all clinical and laboratory data, including the results of conventional 
serial troponin measurements, stress tests and invasive angiography, through six 
months of follow-up.  
Post-hoc risk stratification was performed for all patients to determine likelihood of 
CAD based on NICE criteria.  
6.4 STATISTICAL ANALYSES 
Based on audit data collated from the RACPC in the preceding twelve months, the total 
sample size required to achieve power of 0.80 at statistical significance level 0.05 was 
calculated as n=75 patients{Zhao, 2008}. A calculation of sample size using the relative 
asymptotic efficiency of Wilcoxon-Mann-Whitney test with respect to Student’s t test 
gave a consistent result. A sample size of 100 patients was selected to enable the 
detection of smaller, but relevant, differences between the distributions.  
Comparisons between the two cohorts were performed for age and number of 
outpatient clinic appointments using the independent samples t-test following 
assessment for normality by the D'Agostino-Pearson test. Gender, frequency of 
cardiac risk factors, nature of chest pain, subsequent hospital attendances/admissions 
with angina, likelihood of CAD, and frequency of MACE were compared using Chi-
square or Fisher’s exact tests as appropriate. Additionally, the overall distribution of 
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the CAD likelihood categories between the two cohorts was compared using the 
Mann-Whitney U test. 
All analyses were intention to treat, and patients were analysed in the group they were 
allocated to, irrespective of compliance with scanning. 
6.5 RESULTS 
6.5.1. Patient population 
A total of 484 patients with suspected cardiac chest pain were screened during the 
enrolment period (Table 6.1). Exclusion criteria were identified in 399 (82%). 
Ultimately, 85 patients were recruited to the study (median age 59 years, range 40-92 
years, male: female ratio 0.85:1).  
Table 6.1: Recruitment analysis (n=484) 
Number of patients screened (% of total) 484 (100.0) 
Number of patients screened but not recruited (% of total) 399 (82.4) 
Number of patients recruited (% of total) 85 (17.6) 
Reasons for non-recruitment (% of total)  
 age <40yrs 59 (12.2) 
 no history of chest pain 8 (16.5) 
 features of AMI 1 (0.2) 
 haemodynamic/respiratory instability 4 (0.8) 
 previous coronary intervention 21 (4.3) 
 resting heart rate >70bpm - 
 allergy/intolerance of iodinated contrast - 
 renal dysfunction 5 (1.0) 
 pregnancy - 
 unable to provide written consent 
  Language barrier 
  psychiatric disturbance/confusion 
  Hearing impairment 
38 (7.9) 
28 
8 
2 
 declined written consent 
  Lack of time 
  Concerns regarding radiation 
  Contrast 
  Other 
50 (10.3) 
25 
6 
1 
18 
 CCT not possible prior to OPD appointment 147 (30.4) 
 Patient non-response 61 (12.6) 
Cardiac CT within preceding 3 months 4 (0.8) 
Enrolled in parallel study 1 (0.2) 
a i.e. last minute booking into clinic slot, CT scanner non-availability, recruitment team non-availability   
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40 patients were randomised to undergo early CCT, of whom 9 did not complete the 
scan (withdrawal of consent (n=4), failure to attend (n=2), acute illness (n=1), elevated 
creatinine (n=1), logistical issues (n=1)). The remaining 45 patients were randomised 
to standard practice. Demographic information for the early CCT and standard care 
cohorts is detailed in Table 6.2.  Patients randomised to early CCT were, on average, 
significantly younger, with a mean difference of 5.08 years (95% CI 9.78 to -0.38; 
P=0.034). There were no significant differences between the cohorts in their gender 
distribution, frequency of cardiac risk factors or likelihood of CAD (P=0.271).  
Table 6.2: Study population characteristics (n=85) 
Characteristic TOTAL (%) EARLY CCT (%) STD PRACTICE (%) P VALUE 
No. of patients 85 40 (47.1) 45 (52.9)  
     
Gender     
  Male 39 (45.9) 17 (42.5) 22 (48.9) 0.664 
 Female 46 (54.1) 23 (57.5) 23 (51.1)  
     
Age     
 Mean ± s.d. 59.16 ± 11.10 56.48 ± 9.83 61.56 ± 11.72 0.034 
 Median 59 57 61  
 Range 40 - 92 40 - 79 40 - 92  
     
Cardiac risk factors  
  NICE risk factorsa 
 
66 (77.6) 
 
29 (72.5) 
 
37 (82.2) 
 
0.309 
 Hypertension 34 (40.0) 20 (50.0) 14 (31.1) 0.120 
 Reported CAD 4 (4.7) 2 (5.0) 2 (4.4) 1.000 
 Family history of CAD  50 (58.8) 27 (67.5) 23 (51.1) 0.185 
     
Nature of chest pain     
 Non-anginal 40 (47.1) 16 (40.0) 24 (53.3) 0.278 
 Atypical angina 26 (30.6) 13 (32.5) 13 (28.9) 0.815 
 Typical angina 19 (22.4) 11 (27.5) 8 (17.8) 0.309 
     
Likelihood of CAD -  NICE (%)a     
 <10 7 (8.2) 5 (12.5) 2 (4.4) 0.250 
 10-29 17 (20.0) 7 (17.5) 10 (22.2) 0.787 
 30-60 23 (27.1) 11 (27.5) 12 (26.7) 1.000 
 61-90 28 (32.9) 14 (35.0) 14 (31.1) 0.818 
 >90 10 (11.8) 3 (7.5) 7 (15.6) 0.322 
     
Downstream investigations     
 ETT 
 CCSb 
32  
48 
9  
31  
23 
17 
0.008 
<0.001 
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 CTAb 
 Functional  
 ICA 
44 
24 
14 
31  
9  
6  
13 
15  
8  
<0.001 
0.337 
0.777 
 Total 162 86 76 0.057 
     
Number of clinic attendancesc     
 Mean ± s.d. 1.47 ± 0.72 1.33 ± 0.76 1.60 ± 0.65 0.077 
 Median 1 1 2  
 Range 0 - 4 0 – 4 1 - 3  
     
Presentation to ED with chest pain 3 1 2 1.000 
Admission with chest pain 3 1 2 1.000 
     
MACEd     
 Total no. of cases  3 (3.5) 1 (2.5) 2 (4.4) 1.000 
          MI 2 (2.4) 1 (2.5) 1 (2.2)  
 CVA 0 0 0  
  Emergency revascularisation 3 (3.5) 1 (2.5) 2 (4.4)  
 Death 0 0 0  
     
Adjudicated diagnosis      
 CAD diagnosed 18 (21.2) 8 (20.0) 10 (22.2) 1.000 
 CAD excluded 61 (71.8) 31 (77.5) 30 (66.7) 0.337 
 Inconclusive 6 (7.1) 1 (2.5) 5 (11.1) 0.207 
aCardiac risk factors used to define patients at high risk for CAD using the NICE algorithm are any one of diabetes mellitus, 
smoking or hyperlipidaemia (total cholesterol >6.47mmol/l). 
b* 9 patients in the early CCT cohort did not complete CCT 
c 2 patients in the early CCT cohort were not seen in clinic (DNA n=1; direct admission from CCT n=1) 
d Two of the three patients who underwent emergency revascularisation also had another MACE (MI) 
6.5.2 Clinical outcomes 
The distribution of disease identified on CCT, for both cohorts, is detailed in Table 6.3. 
Although CTA appeared more sensitive than CCS for the detection of significant CAD, 
this was not confirmed statistically (P=0.110).   
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Table 6.3: Distribution of CCT outcomes  
CALCIUM SCORE: TOTAL (%) 
n=48 
EARLY CCT (%) 
n=31 
STD PRACTICE (%) 
n=17 
Zero 
1-400 
>400 
26 (54.2) 
19 (39.6) 
3 (6.3) 
17 (54.8) 
13 (41.9) 
1 (3.2) 
9 (69.2) 
6 (35.3) 
2 (11.8) 
OCCLUSIVE CAD ON CTA: TOTAL (%) 
n=44 
EARLY CCT (%) 
n=31 
STD PRACTICE (%) 
n=13 
Normal appearance 
Non-occlusive CAD (<50% stenosis) 
Occlusive CAD (≥50% stenosis) 
13 (29.5) 
23 (52.3) 
8 (18.2) 
9 (29.0) 
18 (58.1) 
4 (12.9) 
4 (30.8) 
5 (38.5) 
4 (30.8) 
Early CCT did not statistically increase the likelihood of a subsequent positive cardiac 
investigation (Table 6.4), even when patients in the early CCT cohort who failed to 
complete CCT were excluded from analysis (Table 6.5).  
Table 6.4: Likelihood of a positive test result 
INVESTIGATIONS TOTAL EARLY CCT STD PRACTICE P VALUE 
Number + result  
(% +) 
Number + result  
(% +) 
Number + result  
(% +) 
ETT 
CCSa 
CTAb 
Functionalc  
ICAd 
32 
48 
44 
24 
14 
7 (21.2) 
3 (6.3) 
8 (18.2) 
10 (41.7) 
11 (73.3) 
9 
31 
31 
9 
6 
1 (11.1) 
1 (3.2) 
4 (12.9) 
3 (33.3) 
5 (83.3) 
23 
17 
13 
15 
8 
6 (26.1) 
2 (11.8) 
4 (30.8) 
7 (46.7) 
6 (75.0) 
0.640 
0.283 
0.711 
0.679 
1.000 
a Taken as ASE >400, b Taken as >50% stenosis, c Taken as presence of inducible ischaemia, d Taken as ≥ 70% stenosis on ICA 
 
Table 6.5: Likelihood of a positive result excluding patients randomised to early 
CCT who did not undergo CCT 
INVESTIGATIONS EARLY CCT STD PRACTICE P VALUE 
Number + result (% +) Number + result (% +) 
ETT 
CCSa 
CTAb 
Functionalc  
ICAd 
5 
31 
31 
5 
4 
0 (0) 
1 (3.2) 
4 (12.9) 
2 (40.0) 
3 (75.0) 
23 
17 
13 
15 
8 
6 (26.1) 
2 (11.8) 
4 (30.8) 
7 (46.7) 
6 (75.0) 
0.553 
0.283 
0.711 
1.000 
1.000 
a Taken as ASE >400, b Taken as >50% stenosis, c Taken as presence of inducible ischaemia, d Taken as ≥ 70% stenosis on ICA 
Statistical analysis demonstrated no difference in the diagnostic ability of an early CCT 
approach, relative to standard practice (P=0.207). Clinically significant CAD was 
diagnosed in 20% (n=8) and excluded in 78% (n=31) of the early CCT cohort leaving 3% 
(n=1) without a definitive diagnosis. CAD was diagnosed in 22% (n=10) and excluded 
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in 67% (n=30) of patients in the standard practice cohort, leaving 11% (n=5) without a 
definitive diagnosis.  
Over the six month follow-up period, 3 patients suffered a MACE (event rate 3.5%). All 
episodes of MACE occurred in patients with functional imaging or invasive coronary 
angiography indicative of occlusive CAD. None of these patients had undergone prior 
CCT. 
Figure 6.1: Incidental clinical findings identified on CCT  
 ICFs identified in 16 patients in CCT cohort and 5 patients in the standard practice cohort who underwent CCT (i.e. 
21 of 48 scanned; 44%) 
 Mean ICFs per patient 1.38 ± 0.80; median 1; range 1-4.  
 14 patients with thoracic ICFs, 3 with abdominal ICFs and  4 with both 
 ICFs include: emphysema (4 patients), pulmonary nodules (9 patients), bronchiectasis (1 patient), chest wall lesion (1 
patient), hiatus hernia (2 patients), renal lesions (1 patient), liver lesions (4 patients), polysplenia (1 patient), 
dextrocardia (1 patient), suspected VSD (1 patient), aortic valve calcification (1 patient), aberrant RCA (1 patient) 
6.5.3 Resource utilisation 
Reflecting routine practice at the time, patients in the standard practice cohort were 
significantly more likely to undergo ETT (P=0.008) and significantly less likely to 
undergo CCT (both CCS and CTA) (P<0.001). Although fewer patients in the CCT cohort 
underwent functional imaging (-48%) and invasive coronary angiography (-19%), these 
findings were not statistically significant.  
Patients randomised to early CCT underwent a greater total number of investigations 
(P=0.057), but their investigation costs per capita were lower (£288.10 versus £321.42, 
relative reduction 10.4%).  
Table 6.6: Investigation costs per capita{NICE, 2010} 
INVESTIGATIONS: TOTAL COHORT (COST £) CCT (COST £) STD PRACTICE (COST £) 
ETT (£66) 2,112 594 1,518 
Ca SCORE (£103)a 4,944 3,193 1,751 
Functional (£293) 7,032 2,637 4,395 
ICA (£850) 11,900 5,100 6,800 
Total cost  25,988 11,524 14,464 
Cost per capita 305.74 288.10 321.42 
a counting either or both of CCS and CTA as single entity 
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Patients randomised to early CCT attended fewer clinics, on average, than those 
randomised to standard practice although the difference was not statistically 
significant (P=0.077).  There was no significant difference in the number of emergency 
department attendances or hospital admissions with chest pain between the two 
cohorts over a six month period.  
6.6 DISCUSSION 
This pilot study was the first to explore the use of CCT in the RACPC setting. The study 
highlighted clinical and logistical challenges to the introduction of early CCT into 
assessment pathways. Although the study did not demonstrate a statistically 
significant clinical or resource benefit to the use of early CCT, clinically relevant CAD 
was ultimately diagnosed or excluded in a greater proportion of patients undergoing 
the investigation. Incorporation of early CCT into patient assessment led to increased 
diagnostic testing but a tendency towards a reduction in functional imaging and 
invasive angiography, resulting in lower investigation costs and a reduced number of 
outpatient review appointments. These results were achieved without a detected 
increase in MACE.  
A strength of this study was that it included patients representative of the spectrum 
of individuals referred to the RACPC, with no limitations based on patient body mass 
index, atrial fibrillation, pre-test likelihood of CAD or the presence of elevated 
coronary calcium scores, as has been the case with previous studies of CCT. 
Furthermore, the study did not dictate the use or withholding of cardiac investigations 
in either cohort (including CCT (CCS and CTA)), allowing the triage potential of early 
CCT to be explored, rather than adopting a head to head analysis of CCT versus other 
diagnostic modalities. Finally, the study focussed on patient and clinician centred 
outcomes, rather than the diagnostic accuracy of CCT, which has already been 
extensively reported in the literature.  
Fewer than 20% of the screened population were recruited. The primary limitations 
to recruitment were logistic, relating to CCT or patient non-availability prior to RACPC 
attendance (43%). In an established RACPC-CCT service logistic concerns may be less 
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relevant if scanning and reporting can be facilitated on the day of RACPC attendance. 
Secondary limitations were patient factors including an absence of a history of chest 
pain (17%) and age less than forty years, highlighting inappropriate RACPC referrals 
exploiting the prompt availability of a cardiology opinion for patients in whom angina 
was clinically unlikely.  
Nevertheless, 45% of the recruited study population had a likelihood of CAD exceeding 
60%, suggesting a high risk of CAD amongst patients referred to RACPCs. 21% of the 
study population were subsequently diagnosed with clinically significant CAD, 
supporting published data that the NICE CG95 nomogram may overestimate risk in 
outpatients{Khan, 2014}. The frequency of CAD diagnosis was not affected by the 
incorporation of early CCT into patient assessment but the frequency of CAD exclusion 
increased, resulting in fewer patients with inconclusive outcomes.  
Prior to recent advances in CCT technology, including the development of CT 
myocardial perfusion imaging and CT fractional flow reserve, CCT was limited to 
providing anatomical but not functional assessment. Thus, patients ‘diagnosed’ with 
obstructive disease on CCT have often required further investigation. A role for CCT 
has been proposed in targeting these investigations{Chow, 2009; SCOT-HEART 
Investigators, 2015}. This study demonstrated a trend towards a reduction in both 
functional imaging and invasive angiography following early CCT but failed to 
demonstrate a statistically significant reduction in the proportion of negative 
functional studies or catheterisations. The results contrast with published data, 
suggesting a greater number of invasive procedures are performed after CCT than 
after standard evaluation or an initial functional imaging approach{Shreibati, 2011; 
Douglas, 2015}.  
The early CCT approach resulted in a greater number of diagnostic investigations per 
capita but investigation costs were 10% lower than with standard practice (£288.10 
versus £321.42). The trend towards fewer clinic follow-up appointments with early 
CCT also supported the finding that an early CCT approach may be cost effective in 
RACPCs, particularly when extrapolated to the 500,000 NHS outpatient appointments 
for CAD per annum {Stewart, 2003}.  
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The absolute rate of MACE in the study population, over a six month period of follow-
up, was low at less than 4%. The results suggest that patients randomised to early CCT 
were no more likely to experience MACE and the trend towards earlier clinic discharge 
did not result in missed diagnoses. Similarly, there were very few hospital attendances 
or admissions with chest pain, and it was not possible to comment on whether hospital 
attendance may be affected by uncertainty regarding the presence of CAD.  
A recent study prospectively evaluated the role of CCT in the RACPC setting, narrowing 
the eligible population to include only those with patients’ pre-assessed as having 
stable chest pain symptoms and a low likelihood (10-29%) of underlying obstructive 
CAD, as per NICE CG95{Yerramasu, 2014}. In the immediate future, it is likely that CCT 
will be targeted to this population.  
6.7 LIMITATIONS 
Recruitment to this study was a significantly greater challenge than was initially 
predicted. Despite the recruitment of sufficient patients to achieve statistical power, 
patient factors including acute illness, deranged biochemistry and study withdrawal 
meant that around one quarter of patients randomised to undergo early CCT did not 
undergo either CCS or CTA. Analyses were performed on an intention to treat basis. 
While this situation may reflect ‘real life’ uptake of early CCT if this becomes 
incorporated into routine clinical practice, it means the clinical and financial impact of 
early CCT is likely to have been underestimated in this study.  
Inherent in the study design was a lack of blinding to the intervention, with 
consequent bias in decision making towards earlier clinic discharge in the CCT group. 
For both cohorts of patients, however, clinical decision making was the responsibility 
of experienced clinicians not directly associated with the study whose decisions were 
subject to the same imperatives to provide high-quality, personalised care.  
Although this study provided outcome information for a period of six months post 
RACPC referral, a prolonged period of follow-up with a wider exploration of patient 
and economic outcomes (e.g. the composite financial contribution of evaluation, 
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monitoring, full investigation and therapy and the impact on quality-adjusted-life-
years) may have facilitated greater understanding of the risks and benefits of an early 
CCT strategy, relative to standard practice.  
6.8 LEARNING POINTS: 
 At the time of this study, standard RACPC assessment was based around 
exercise tolerance testing as the first line investigation and CCT was less 
commonly performed. 
 Early CCT may improve clinical decision making for patients presenting to 
RACPCs with suspected cardiac chest pain, resulting in fewer patients in whom 
CAD is neither diagnosed nor excluded.  
 Early CCT may result in an increase in diagnostic testing but a decrease in the 
total cost of investigations. 
 Early CCT may result in the need for fewer outpatient clinic appointments.  
 An assessment pathway incorporating early CCT does not appear to have any 
detrimental effects on cardiovascular outcomes. 
 In the immediate future, the use of CCT is RACPCs is likely to be in accordance 
with NICE CG95.  
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CHAPTER 7: RETROSPECTIVE ANALYSIS OF THE UTILITY OF CARDIAC CT IN THE 
CARDIAC OUTPATIENT SETTING IN ACCORDANCE WITH NICE GUIDELINE CG95 
 
7.1 INTRODUCTION  
Chapter 6 prospectively evaluated the logistical, clinical and financial implications of a 
model incorporating early CCT into the assessment of RACPC patients, based upon a 
broad inclusion policy.  
In NICE CG95, NICE propose their own model for the risk stratification and 
investigation of patients with suspected CAD, with the intention of supporting a 
unified cost effective and evidence-based approach to investigation. The target 
audience for NICE CG95 are general practitioners and cardiology specialists in RACPCs.  
NICE CG95 uses the nature of a patient’s chest pain and their pre-test likelihood of 
CAD to guide recommendations for further investigation. NICE have predicted the 
distribution of patients across a spectrum of CAD likelihood, based upon personal 
communication from two of their authors and detailed in Chapter 5{Skinner, 2010}.  
Study findings from Chapter 5 and the published literature suggest NICE 
underestimate the proportion of higher risk patients presenting to RACPCs, 
emergency departments and acute assessment units{Fox, 2010} and taking the NICE 
predictions on trust may lead to inaccurate estimates of the cardiac investigation 
burden and inadequate resourcing of cardiac services to meet the demands of the 
population at risk.  
At the time of this study, there were no published data regarding the impact of the 
NICE CG95 on outpatient cardiac investigation services and the requirement for 
outpatient CCT provision was unproven.   
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7.2 AIMS 
This retrospective study reviewed the demographic and clinical characteristics of 
patients referred to the RACPCs of two London hospitals with suspected cardiac chest 
pain, to evaluate the impact of NICE CG95 on our local population. 
Specific aims of the study were to: 
 Determine the distribution of CAD likelihood in patients attending RACPCs with 
suspected cardiac chest pain, according to NICE criteria.  
 Review the investigation burden on cardiac services if NICE CG95 were applied 
to this population. 
7.3 PATIENTS AND METHODS  
Consecutive patients attending RACPCs at Chelsea and Westminster Hospital (CWH) 
and Ealing Hospital (EH) over a six month period from September 2009 were identified 
using audit databases at both institutions.  
Using information obtained from medical records, data relating to clinical 
presentation, demographics, risk factor profiles, cardiac investigations and clinical 
course were collated for all patients. NICE CG95 was applied retrospectively to the 
population. 
Chest pain was categorised as non-anginal, atypical or typical for angina. Chest pain 
typicality was recorded at the time of consultation for EH patients but determined 
retrospectively by consensus of two researchers for CWH patients.  
Pre-test likelihood of CAD was determined using a nomogram based on NICE CG95. 
Patients were deemed eligible for investigation if they had typical or atypical anginal 
chest pain and a likelihood of CAD in the range 10-90%; those in the range 10-29% (i.e. 
low risk) were eligible for CCT; those in the range 30-60% (i.e. intermediate risk) were 
eligible for functional testing and those in the range 61-90% (i.e. high risk) were eligible 
for invasive coronary angiography in accordance with NICE CG95.  
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Cardiac investigations recommended by NICE were compared with those undertaken 
in the study population in accordance with standard practice. It should be noted that 
CCT was not available as part of standard practice at EH at the time of this study. The 
relative costs of the investigations recommended/undertaken were calculated from 
values published in NICE CG95. 
7.4 STATISTICAL ANALYSIS 
The study sample size was determined using the power calculation method of Nisen 
and Schwertman and the null hypothesis ‘no difference exists between the 
distributions of investigations undertaken in the combined hospitals versus those 
recommended by NICE{Nisen, 2008}. To achieve a power of 80% required a sample 
size of 575 patients.   
Comparisons between the CWH and EH cohorts were performed for age using the 
independent samples t-test following assessment for normality by the D'Agostino-
Pearson test. Gender, frequency of cardiac risk factors, nature of chest pain and 
likelihood of CAD and frequency of investigations were compared using Chi-square or 
Fisher’s exact tests as appropriate. Additionally, the overall distribution of the CAD 
likelihood categories between the two cohorts was compared using the Mann 
Whitney U test.  
7.5 RESULTS  
A total of 595 patients (median age 55 years, range 22-94 years, male: female ratio 
1:1) attended the RACPCs at EH (n=300) and CWH (n=295) over the six month period. 
Demographic and clinical information is shown in Table 7.1. There were no significant 
differences between the cohorts in their age, gender distribution, frequency of cardiac 
risk factors; however, the CWH cohort were significantly more likely to have non-
anginal pain (P<0.001) and had a lower likelihood of CAD (P=0.008).  
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Table 7.1: Population characteristics for patients attending CWH and EH RACPCs 
(n=595) 
CHARACTERISTIC TOTAL COHORT (%) CWH (%) EH (%) P VALUE 
No. of patients 595 295 300  
     
Gender     
  Male 302 (51%) 151 (52%) 151 (50%) 0.450 
 Female 293 (49%) 144 (49%) 149 (50%)  
     
Age     
 Mean ± s.d. 55.39 ± 13.17 54.54 ± 13.14 56.23 ± 13.16 0.125 
 Median 55 54 57  
 Range 22-94 24-94 22-87  
     
Cardiac risk factors  
 NICE risk factorsa 
 
411 (69%) 
 
203 (69%) 
 
208 (69%) 
 
0.481 
     
Nature of chest pain     
 Non-anginal 381 (64%) 220 (75%) 161 (54%) <0.001 
 Atypical angina 162 (27%) 57 (19%) 105 (35%) <0.001 
 Typical angina 52 (9%) 18 (6%) 34 (11%) 0.029 
     
Likelihood of CAD - NICE (%)     
 <10 106 (18%) 56 (19%) 50 (17%) 0.521 
 10-29 123 (21%) 71 (24%) 52 (17%) 0.044 
 30-60 175 (29%) 88 (30%) 87 (29%) 0.857 
 61-90 141 (24%) 62 (21%) 79 (26%) 0.148 
 >90 50 (8%) 18 (6%) 32 (11%) 0.054 
     
Recommended investigations - NICE     
 No investigation 443 (74%) 244 (83%) 199 (66%) <0.001 
 Exercise ECG 0 (0%) 0 (0%) 0 (0%) 1.000 
 CCT 10 (2%) 4 (14%) 6 (2%) 0.752 
 Functional testing 69 (12%) 23 (8%) 46 (15%) 0.005 
 Invasive angiography 73 (12%) 24 (8%) 49 (16%) 0.003 
aCardiac risk factors used to define patients at high risk for CAD using the NICE algorithm are any one of diabetes mellitus, 
smoking or hyperlipidaemia (total cholesterol >6.47mmol/l). 
 
The distribution of CAD likelihood according to nature of chest pain, gender, risk and 
age is shown in Table 7.2. 
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Table 7.2: Distribution of combined CWH and EH RACPC populations according to 
age, sex and nature of chest pain (n=595) 
AGE 
(YEARS) 
NON ANGINAL CHEST PAIN ATYPICAL ANGINA TYPICAL ANGINA 
M F M F M F 
LO HI LO HI LO HI LO HI LO HI LO HI 
<30 3 5 1 1 2 - - 1 - - - - 
30-39 9 17 11 8 2 4 4 4 - 2 - 1 
40-49 13 42 25 19 4 11 4 5 2 3 1 1 
50-59 14 32 21 36 10 14 2 20 1 6 1 4 
60-69 7 25 11 34 1 18 3 19 2 6 3 4 
≥70 4 18 8 17 3 15 11 5 1 6 - 8 
White:  Not routinely recommended for further investigation  
Dark grey: Likelihood of CAD 10-29% - recommended for CCT 
Mid grey: Likelihood of CAD 30-60% - recommended for functional cardiac testing 
Light grey: Likelihood of CAD 61-90% - recommended for invasive angiography if clinically indicated 
Across all categories of CAD likelihood in the range 10-90%, the proportions of patients 
were higher than predicted by NICE CG95.  As a result, the distribution of 
recommended cardiac investigations would have differed significantly from that 
predicted by NICE for EH, CWH and the combined population (P<0.001). The 
distribution of recommended cardiac investigations would also have differed 
significantly between the two cohorts (P<0.001).  
66% (n=393) of the total population would have been recommended for no routine 
cardiac investigation based pain classified as non-anginal (n=287), a likelihood of CAD 
<10% (n=12), or both (n=94).  8% (n=50) would have proceeded directly to treatment 
without further investigation, based on a likelihood of CAD >90%.  
No patients would have been recommended for ETT. 2% (n=10) of patients would have 
been recommended for CCT, 12% (n=69) for functional cardiac testing and 12% (n=73) 
for invasive coronary angiography.  
Relative to standard practice, applying NICE CG95 would have resulted in increased 
CCT testing (+43%; P=0.436), reduced functional cardiac testing (-24%, P=0.060) and a 
significant increase in invasive coronary angiography (+508%; P<0.001) (Figure 7.1). 
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The total number of investigations would have been reduced by 73% (P<0.001), 
predominantly due to the exclusion of ETT. 
Applying NICE CG95 would have resulted in a 36% reduction in investigation costs at 
CWH, a 127% increase in investigation costs at EH and a 24% increase across the two 
cohorts combined.    
Table 7.3: Cardiac investigations actually undertaken compared with those 
recommended by NICE CG95 (n=595) 
 INVESTIGATION ACTUAL RECOMMENDED % CHANGE P VALUE 
CWH None 16 244 +1425 <0.001 
 Exercise ECG 195 0 -100 <0.001 
 CCT 7 4 -43 0.361 
 Functional testing 65 23 -65 <0.001 
 ICA 12 24 +100 0.040 
 Total number  279 51 -82 <0.001 
      
EH None 17 199 +1071 <0.001 
 Exercise ECG 257 0 -100 <0.001 
 CCT 0 6 ∞ 0.031 
 Functional testing 26 46 +77 0.012 
 ICA 0 49 ∞ <0.001 
 Total number 283 101 -64 <0.001 
      
CWH & EH None 33 443 +1242 <0.001 
 Exercise ECG 452 0 -100 <0.001 
 CCT 7 10 +43 0.436 
 Functional testing 91 69 -24 0.060 
 ICA 12 73 +508 <0.001 
 Total number 562 152 -77 <0.001 
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Figure 7.1: Cardiac investigations actually undertaken compared with those 
recommended by NICE CG95 (n=595) 
 
 
 
Table 7.4: Comparison of actual investigation costs and costs based on NICE CG95 
recommendations{NICE, 2010} 
 INVESTIGATION ACTUAL 
 (COST £) 
RECOMMENDED 
(COST £) 
% CHANGE 
CWH Exercise ECG 12870 0  
 CCT 721 412  
 Functional testing 19045 6739  
 ICA 10200 20400  
 Total cost 42836 27551  
 Cost per capita 145.21 93.39 -35.7 
     
EH Exercise ECG 16962 0  
 CCT 0 618  
 Functional testing 7618 13478  
 ICA 0 41650  
 Total cost 24580 55746  
 Cost per capita 81.93 185.82 +126.8 
     
CWH & EH Exercise ECG 29832 0  
 CCT 721 1030  
 Functional testing 26663 20217  
 ICA 10200 62050  
 Total cost 67416 83297  
 Cost per capita 113.30 139.99 +23.6 
a counting either or both of CCS and CTA as single entity  
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7.6 DISCUSSION 
In our dual-site study population, NICE CG95 would have recommended no 
investigation for around two thirds of RACPC attenders. CCT would have been 
recommended for 2% of patients while functional cardiac testing and invasive 
coronary angiography would have been recommended for 12%. There would have 
been an overall reduction in the number of investigations performed but an increase 
in the cost of these investigations, relative to standard practice. 
Based on the distribution of CAD likelihood amongst the study population, it appears 
NICE may have underestimated the impact of NICE CG95 on RACPC service provision. 
Compared with predictions, a larger proportion of patients would have fallen within 
the boundaries of 10-90% likelihood of CAD and therefore been potentially eligible for 
investigation. Furthermore, the distribution was skewed towards a higher likelihood 
of CAD than predicted by NICE, suggesting a requirement for functional cardiac testing 
and invasive coronary angiography greater than predicted. 
Importantly, the study also demonstrated how subtle demographic differences 
between RACPC populations can result in markedly different patterns of referral for 
cardiac investigations to meet NICE CG95. EH and CWH both serve patients within a 
limited geographic area and their RACPC patients are similar in number, age, gender 
and risk factor profiles, yet NICE CG95 would have necessitated significantly different 
service provision for the two RACPCs (P<0.001). Differences in practice between 
clinicians categorising the nature of chest pain may also have contributed to variations 
in scoring the likelihood of CAD and thus recommended investigations. The higher 
proportion of patients with non-anginal pain in the CWH cohort would have resulted 
in more discharges without investigation. By contrast, the EH cohort, having a higher 
likelihood of CAD would have been more likely to be recommended for invasive 
angiography. 
Application of NICE CG95 would have resulted in the discharge without further cardiac 
investigation of two thirds of the study population, with pain categorised as non-
anginal or a likelihood of CAD <10%. This equates to a greater than 1000% increase in 
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discharge without investigation, relative to standard practice. Despite the recognised 
validity of pre-test probability scoring in the prediction of CAD{Pryor, 1993}, a large, 
multi-centre RACPC study has demonstrated nearly one‐third of significant cardiac 
events occur in patients diagnosed with non-cardiac chest pain, raising concern for 
potential missed diagnoses{Sekhri, 2007}. Clinicians may be justifiably unkeen to 
discharge without investigation a patient whom another clinician has deemed at risk, 
and consultation without progression to investigation may also do little to reassure 
patients who have been informed they are at risk of  CAD{Fox, 2009}.  
In the study population, exercise ECG testing was performed as a preliminary 
investigation in around 85% of EH patients and 65% of CWH patients but would have 
been recommended for none based on NICE CG95. NICE CG95 excludes exercise ECG 
testing as a first line investigation based upon its relative lack of sensitivity and 
specificity and the superior cost-effectiveness of imaging, an approach which differs 
significantly from standard UK practice and European guidance{Montalescot, 2013}. 
There is concern that cardiology services may struggle to divert resources from the 
‘ubiquitous’ treadmill to the various forms of cardiac imaging in which equipment and 
expertise is less common{Ranjani, 2011} and this readily available, inexpensive test is 
likely to continue to play a role in risk stratification. 
NICE CG95 would have recommended CCT for 2% of the study population. Despite a 
43% increase in CCT relative to standard practice, the numbers would have remained 
small.  12% of the study population would have been recommended for functional 
cardiac testing, a 24% drop relative to standard practice. Referrals for invasive 
angiography would have increased significantly, by over 500%.This may be an over-
estimation as NICE CG95 recommends angiography with the caveat that it should be 
limited to patients for whom revascularisation is a consideration and for whom the 
procedure is clinically appropriate and personally acceptable.  As it stands; however, 
NICE CG95 appears to overcommit to the use of invasive angiography, which will 
impact upon catheter lab workload, consultant availability and costs{Khan, 2014; 
Cubukcu, 2015}.   
132 
 
Based on our study findings, implementation of NICE CG95 appears likely to result in 
a reduction in the total number of patients referred for cardiac investigation relative 
to standard practice, however, costs are likely to increase due to increased reliance 
on more expensive investigations such as invasive coronary angiography over non-
invasive and less expensive tests such as exercise ECG testing and CCT. 
When considering service development to meet the demands of NICE CG95, it is 
noteworthy that a number of the diagnostic investigations recommended by NICE are 
not widely available across the NHS. While the majority of NHS hospitals with RACPCs 
have access to a CT scanner, developing a CCT service (using a minimum 64-detector 
scanner), enhancing a local functional imaging service (using stress echocardiography, 
myocardial perfusion scintigraphy or perfusion cardiac MRI) or expanding invasive 
angiographic services requires significant investment in equipment, personnel and 
training{Ranjani, 2010}. Hospitals may elect to send patients to specialist hubs for 
these investigations, delaying time to definitive diagnosis and targeted management.  
Since the primary determinant of costs is local demographic equivalence to the NICE 
CG95 model, it would appear prudent that individual hospitals audit their RACPC 
populations before investing in cardiac services to meet the guideline. Recent studies 
suggest this is now occurring across the UK {Garg, 2011; Athauda-Arachchi, 2013}. In 
hospitals where cardiac services are currently insufficient to meet NICE CG95 
requirements, the costs of establishing the pre-requisite infrastructure will have to be 
justified economically based upon predicted uptake of investigations.  
7.7 LIMITATIONS 
While the study was designed to provide a representative sample of UK RACPC 
attendances, the findings were limited by the fact that the study occurred within a 
limited geographical area and data were collected retrospectively, therefore the 
results should be generalised with caution. 
The study only analysed the impact of NICE CG95 on preliminary cardiac investigations 
and not on subsequent investigations or patient outcomes. Extrapolation of the data 
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to predict overall costs from first patient contact to discharge were therefore not 
possible. The methodology of the study reflects NICE guidelines, which are focussed 
on diagnosis rather than resultant management. Likewise, NICE economic analyses do 
not take infrastructure costs into account.  
7.8 LEARNING POINTS 
 Patients attending RACPC appear to have a greater likelihood of CAD than 
predicted by NICE CG95. 
 Adoption of NICE CG95 may result in:  
o Up to two thirds of RACPC patients recommended for discharge 
without further cardiac investigation.  
o Fewer than five percent of patients admitted with suspected cardiac 
chest pain being recommended for CCT 
o A significant increase in the proportion of RACPC patients referred for 
invasive angiography. 
 Despite fewer referrals for cardiac investigations, bias towards invasive 
angiography may result in up to a 24% increase in the average cost of 
investigation per patient with NICE CG95.  
 Differences between recommended investigations and existing practice should 
guide investment in local cardiac services.  
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CHAPTER 8: RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOMES OF CARDIAC 
OUTPATIENTS NOT INDICATED FOR FURTHER INVESTIGATION IN ACCORDANCE 
WITH NICE GUIDELINE CG95  
8.1 INTRODUCTION 
In accordance with the National Service Framework for coronary heart disease{DOH, 
2000}, RACPCs have been established across the UK to provide one stop cardiological 
assessment of patients with suspected angina. Implicit in the provision of these clinics 
is that they not only diagnose patients with CAD accurately and promptly, but that 
they also identify patients at low risk of CAD, who can be discharged without further 
investigation or treatment.  
NICE CG95 gives significant diagnostic weight to comprehensive clinical assessment of 
the patient with chest pain with a view to avoiding progression to unwarranted 
investigation. Patients with non-anginal pain, and those with atypical/typical anginal 
pain but a likelihood of CAD <10% are considered at low risk and recommended for 
discharge from care without anatomical or functional cardiac testing.  
Despite widespread awareness of the potential implications of missed CAD{Lee, 1987}, 
patients continue to be misdiagnosed with non-cardiac chest pain and, in the 
outpatient setting, up to one-third of significant cardiac events occur in patients 
previously diagnosed with non-cardiac chest pain{Sekhri, 2007}. 
Studies detailed in Chapters 5 and 7 suggest a high proportion of patients with 
suspected cardiac chest pain are recommended for discharge without investigation 
based on the application of NICE CG95 to our local acute assessment unit and RACPC 
populations.  
At the time of this study, the impact of NICE CG95 on patient outcomes and potential 
missed diagnoses had not been evaluated in the outpatient (or more specifically 
RACPC) setting.   
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8.2 AIMS  
This aims of this study were to:  
 Compare the clinical outcomes of RACPC patients for whom NICE CG95 would 
have recommended further investigation with those for whom NICE CG95 
would not recommend further investigation.  
8.3 PATIENTS AND METHODS  
Consecutive patients attending RACPCs at Chelsea and Westminster Hospital (CWH) 
and Ealing Hospital (EH) over a six month period from September 2009 were identified 
using audit databases at both institutions.  
Using information obtained from medical records, data relating to clinical 
presentation, demographics, risk factor profiles, cardiac investigations and clinical 
course were collated for all patients, as per Chapter 7. Patients were excluded from 
further analysis if their full medical notes were not available for review. NICE CG95 
was applied retrospectively to the population. 
Chest pain was categorised as non-anginal, atypical or typical for angina. Pre-test 
likelihood of CAD was determined using a nomogram based on NICE CG95. Patients 
were deemed eligible for investigation if they had typical or atypical anginal chest pain 
and a likelihood of CAD in the range 10-90%; those in the range 10-29% (i.e. low risk) 
were eligible for CCT; those in the range 30-60% (i.e. intermediate risk) were eligible 
for functional testing and those in the range 61-90% (i.e. high risk) were eligible for 
invasive coronary angiography in accordance with NICE CG95.  
Following risk stratification, patients were classified into two cohorts: NICE-Y (patients 
for whom the NICE guideline recommended further investigation) and NICE-N 
(patients not routinely recommended for cardiac investigation by NICE; i.e. those with 
non-anginal chest pain or a likelihood of CAD <10%).  
For each group, subsequent admissions with angina were recorded, and information 
from cardiac investigations, clinic letters and discharge summaries used to ascertain if 
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significant CAD had been diagnosed, excluded, or if investigations were inconclusive 
over a six month period.  The reference diagnosis was based on the judgment of 2 
physicians with access to all clinical and laboratory data, through 6 months of follow-
up. 
Major adverse cardiac events (MACE) were determined from the RACPC databases at 
six months from the time of presentation and were defined as myocardial infarction 
(MI), cerebrovascular accident (CVA), emergency revascularisation (ER) and cardiac-
related death.  
The frequencies of MACE according to the likelihood of CAD and according to the 
nature of chest pain were calculated. A descriptive analysis was also performed for 
the sub-group of patients in the NICE-N group with no previous CAD diagnosis. 
8.4 STATISTICAL ANALYSES 
Comparisons between the two groups were performed for age using the independent 
samples t-test following assessment for normality by the D'Agostino-Pearson test. 
Gender, frequency of cardiac risk factors, nature of chest pain, subsequent admissions 
with angina, likelihood of CAD, and frequency of MACE were compared using Chi-
square or Fisher’s exact tests as appropriate. Additionally, the overall distribution of 
the CAD likelihood categories between the two groups was compared using the Mann 
Whitney U test.  
8.5 RESULTS  
8.5.1 Patient population 
A total of 557 patients (median age 55 years, range 22-94 years, male: female ratio 
1:1) attending the RACPCs at CWH (n=263) and EH (n=294) over the six-month period 
were reviewed.  
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Following risk stratification according to the NICE guidelines, 187 of the 557 patients 
(33.6%) comprised the NICE-Y group, while 370 (66%) comprised the NICE-N group 
and would have been excluded from further cardiac investigation.  
The vast majority of the NICE-N group would have been excluded due to non-anginal 
chest pain (360/370 patients, 97 %), with the remainder (10/370 (3%)) excluded due 
to a CAD likelihood of <10% on risk stratification, despite presenting with atypical 
angina.  
Demographic and clinical information is shown in Table 8.1. Patients in the NICE-N 
group were, on average, significantly younger than those in the NICE-Y group, with a 
mean difference of 6.1 years (95% CI 3.8 to 8.4 years, P<0.0001), and were less likely 
to have risk factors for cardiac disease (67% versus 78%, P=0.007). There were 5% and 
17% of patients who had a previous history of CAD in the NICE-N and NICE-Y groups, 
respectively.  
Table 8.1: Study population characteristics (n=557) 
CHARACTERISTIC TOTAL COHORT (%) NICE-Y (%) NICE-N (%) P VALUE 
No. of patients 557 (100.0) 187 (100.0) 370 (100.0)  
     
Gender     
  Male 281 (50.4) 99 (52.9) 182 (49.2) 0.462 
 Female 276 (49.6) 88 (47.1) 188 (50.8)  
     
Age     
 Mean ± s.d. 55.4 ± 13.3 59.5 ± 11.9 53.4 ± 13.6 <0.001 
 Median 55 60 52  
 Range 22 - 94 23 - 87 22 - 94  
     
Cardiac risk factors  
  NICE risk factorsa 
 
396 (71.1) 
 
147 (78.6) 
 
249 (67.3) 
 
0.007 
 Hypertension 253 (45.4) 111 (59.4) 142 (38.4) <0.001 
 Reported CAD 50   (9.0) 31 (16.6) 19 (5.1) <0.001 
 Family history of CAD  213 (38.2) 71 (38.0) 142 (38.4) 0.999 
     
Nature of chest pain     
 Non-anginal 360 (64.6) 0 (0) 360 (97.3) <0.001 
 Atypical angina 148 (26.6) 138 (73.8) 10 (2.7) <0.001 
 Typical angina 49 (8.8) 49 (26.2) 0 (0) <0.001 
     
Likelihood of CAD (%)     
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 <10 97 (17.4) 0 (0) 97 (26.2) <0.001 
 10-29 112 (20.1) 8 (4.3) 104 (28.1) <0.001 
 30-60 168 (30.2) 66 (35.3) 102 (27.6) 0.064 
 61-90 130 (23.3) 63 (33.7) 67 (18.1) <0.001 
 >90 50 (9.0) 50 (26.7) 0 (0) <0.001 
     
Admissions with chest pain 24 (4.3) 10 (5.3) 14 (3.8) 0.385 
 
MACE 
    
 Total no. of cases  11 (2.0) 4 (2.1) 7 (1.9) 1.000 
 MI 6 (1.1) 3 (1.6) 3 (0.8) 0.409 
 CVA 3 (0.5) 1 (0.5) 2 (0.5) 1.000 
  ER 4b (0.7) 4 (2.1) 0 (0) 0.012 
 Death 2 (0.4) 0 (0) 2 (0.5) 0.553 
     
Adjudicated diagnosis     
CAD diagnosed 92 (16.5) 57 (30.5) 35 (9.5) <0.001 
 CAD excluded 405 (72.7) 107 (57.2) 298 (80.5) <0.001 
 Inconclusive 54 (9.7) 22 (11.8) 32 (8.6) 0.292 
 No follow-up data 6 (1.1) 1 (0.5) 5 (1.4) 0.669 
aCardiac risk factors used to define patients at high risk for CAD using the NICE algorithm are any one of diabetes mellitus, 
smoking or hyperlipidaemia (total cholesterol >6.47mmol/l). 
bAll four patients who underwent emergency revascularisation also had another MACE; three had an MI, and one had a 
CVA. 
The distribution of CAD likelihood according to nature of chest pain, gender, risk and 
age is shown in Table 8.2. Although no statistical difference was found between the 
proportions of patients in both groups that had a CAD likelihood of 30-60%, overall 
the NICE-N group had a significantly higher proportion of patients with lower 
likelihoods of CAD compared to the NICE-Y group (median CAD likelihood 10-29% 
versus 61-90% respectively, P<0.001), as would be expected.  
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Table 8.2: Distribution of RACPC population according to age, sex and nature of 
chest pain (n=557). 
AGE 
(YEARS) 
NON ANGINAL CHEST PAIN ATYPICAL ANGINA TYPICAL ANGINA 
M F M F M F 
LO HI LO HI LO HI LO HI LO HI LO HI 
<30 3 5 1 1 2 0 0 1 0 0 0 0 
30-39 9 17 10 6 1 5 4 4 0 2 0 1 
40-49 13 38 20 21 3 11 3 5 2 3 1 1 
50-59 10 35 18 35 8 11 2 20 1 6 1 3 
60-69 4 26 13 31 1 15 4 14 0 7 4 3 
≥70 3 16 7 18 3 15 10 6 0 6 0 8 
White:  Not routinely recommended for further investigation  
Dark grey: Likelihood of CAD 10-29% - recommended for CCT 
Mid grey: Likelihood of CAD 30-60% - recommended for functional cardiac testing 
Light grey: Likelihood of CAD 61-90% - recommended for invasive angiography 
8.5.2 Clinical outcomes 
The frequency of subsequent admissions with angina between the two groups was not 
significantly different (Table 8.3). 17% of the total cohort (n=92) were subsequently 
diagnosed with significant CAD, of whom over one-third were from the NICE-N group. 
10% (n=35) of patients who would have been excluded from further cardiac 
investigation were subsequently diagnosed with significant CAD within six months.  
In total, 11 patients (2%) experienced at least one MACE. Seven patients (64%) who 
experienced a MACE were from the NICE-N group and all had clinical events (MI, CVA 
or death) rather than revascularisation; nearly 2% of all patients who would have been 
denied cardiac investigation using the NICE criteria experienced a MACE. All seven 
patients had presented with non-anginal chest pain; one was subsequently diagnosed 
with significant CAD, whereas significant CAD had been excluded in four patients and 
investigations were inconclusive in the remaining two. As depicted in Table 8.1, the 
frequencies of MACE were not significantly different between the two groups. The 
distribution of MACE according to CAD likelihood is illustrated in Table 8.3. 
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Table 8.3: Distribution of patients with at least one MACE according to CAD 
likelihood (n=11). 
LIKELIHOOD OF CAD (%) NO. OF PATIENTS WITH AT LEAST ONE MACE (%) 
<10 1 (9.1) 
10-29 3 (27.3) 
30-60 2 (18.2) 
61-90 3 (27.3) 
>90 2 (18.2) 
19 patients in the NICE-N group had a history of known CAD. Even if these patients 
were excluded, 24/351 remaining patients (7%) would subsequently have been 
diagnosed with significant CAD, and with a similar frequency of MACE (Table 8.4).  
Table 8.4: Comparison of characteristics of patients in the NICE-N group when 
patients with a history of known CAD were included, versus when such patients 
were excluded. 
CHARACTERISTIC NICE-N EXCLUDING PATIENTS WITH 
KNOWN CAD (%) 
NICE-N INCLUDING PATIENTS WITH 
KNOWN CAD (%) 
No. of patients 351 (100.0) 370 (100.0) 
   
Gender   
  Male 169 (48.1) 182 (49.2) 
 Female 182 (51.9) 188 (50.8) 
   
Age   
 Mean ± s.d. 52.8 ± 13.3 53.4 ± 13.6 
 Median 51 52 
 Range 22-94 22 – 94 
   
NICE risk factors 230 (65.5) 249 (67.3) 
   
Nature of chest pain   
 Non-anginal 341 (97.2) 360 (97.3) 
 Atypical angina 10 (2.8) 10 (2.7) 
 Typical angina 0 (0) 0 (0) 
   
Likelihood of CAD (%)   
 <10 97 (27.6) 97 (26.2) 
 10-29 101 (28.8) 104 (28.1) 
 30-60 96 (27.4) 102 (27.6) 
 61-90 57 (16.2) 67 (18.1) 
 >90 0 (0) 0 (0) 
   
Admissions with chest pain 11 (3.1) 14 (3.8) 
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MACE 
  
 Total no. of cases  6 (1.7) 7 (1.9) 
 MI 2 (0.6) 3 (0.8) 
 CVA 2 (0.6) 2 (0.5) 
 ER 0 (0) 0 (0) 
 Death 2 (0.6) 2 (0.5) 
     
Adjudicated diagnosis     
 CAD diagnosed 24 (6.8) 35 (9.5) 
 CAD excluded 292 (83.1) 298 (80.5) 
 Inconclusive 30 (8.5) 32 (8.6) 
 No follow-up data 
  
5 (1.4) 5 (1.4) 
 
8.6 DISCUSSION 
The results of this study suggest that, in a population of patients attending RACPCs, 
application of NICE CG95 would result in two-thirds of patients being excluded from 
further cardiac investigations, primarily due to non-anginal chest pain. A diagnosis of 
significant CAD will subsequently be made in 10% of these patients, while a MACE will 
occur in 2%.  
The Diamond-Forrester risk stratification model is based on Bayesian analysis that 
emphasises the importance of age, gender and nature of chest pain. It has been 
validated against invasive coronary angiography for the diagnosis of obstructive CAD, 
and confirmed in multiple prospective studies{Chaitman, 1981; Genders, 2011}. 
Further risk stratification models have been developed that take into account other 
cardiovascular risk factors (including the Duke clinical score that incorporates the 
presence of diabetes mellitus, hyperlipidaemia and smoking history) while reiterating 
the strength of clinical assessment{Pryor, 1993}. In NICE CG95, NICE have essentially 
amalgamated the Diamond-Forrester and Duke models. 
NICE have acknowledged that their model may over-estimate the likelihood of CAD in 
(lower-risk) community populations, but may simultaneously also underestimate the 
likelihood of angina as a cause of chest pain (in part because it does not account for 
the cumulative effect of cardiac risk factors and ignores the risks attributable to history 
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of established CAD, history of other cardiovascular disease, hypertension and family 
history of premature CAD). A further important caveat of the model is that it is based 
on data validated for obstructive, but not non-obstructive CAD. 
Recent multicentre trial evidence reinforces the idea that CAD (whether non-
obstructive or obstructive) is prevalent amongst stable patients even when no 
modifiable risk factors are present and that an increasing burden of CAD in such 
patients is predictive of MACE{Leipsic, 2013}. These limitations may help explain why 
10% of the population excluded from further investigation in our study had a 
subsequent diagnosis of significant CAD. 
In clinical reality, RACPC patients with a prior history of known CAD (whether 
substantiated or not) would undergo further investigation even if they were 
categorised as low-risk according to NICE CG95. The guideline does make provision for 
such an approach, stating that clinical suspicion could be raised ‘based on other 
aspects of the history and risk factors’{NICE, 2010}. To test this argument, the analysis 
was repeated, excluding those with a history of known CAD. The results demonstrate 
that even allowing for this more liberal application of NICE CG95, the frequency of 
subsequent CAD diagnosis and MACE remained essentially unchanged.  
Studies documenting MACE frequency{Jespersen, 2012; Six, 2013; Body, 2014; Kelly, 
2013} have varied with respect to the type of populations studied, the durations of 
follow-up, and their clinical settings. As such, the definition of an ‘acceptable’ MACE 
rate is still a subject of debate{Brace-McDonnell, 2014}. While a 2% risk of MACE 
appears low, the financial implications of the study findings are not inconsiderable. If 
extrapolated to the 700,000 annual ED admissions for chest pain, a 2% risk of MACE 
may translate into 14,000 patients per year experiencing a major cardiac event within 
six months of presentation and up to 70,000 subsequently being diagnosed with 
significant CAD.  Not investigating these patients deemed at low risk of CAD may, in 
fact, result in patients re-presenting with cardiac events that are significantly more 
resource intensive and expensive to manage.    
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One method of improving the performance of the NICE CG95 model may be to allow 
provision for clinical assessment to be combined with one more non-invasive tests, 
even in patients with non-cardiac chest pain. Comprehensive clinical risk scores 
incorporating a demographic, clinical and diagnostic testing offer prognostic 
information in the evaluation of ACS, but have yet to be widely validated or adopted 
in the evaluation of the patient presenting with recent-onset chest pain{Morrow, 
2010}. Non-invasive functional tests provide vital information on reversible disease, 
but are not quick to perform. CT coronary angiography and coronary calcium scoring, 
with their high sensitivity for CAD{Mowatt, 2008}, are another alternative especially 
as ever improving radiation dose reduction strategies in CCT become available.  
Evidence suggests that a stepwise approach, combining an extended version of the 
Duke clinical score with coronary calcium scoring, improves the predicted probability 
of disease in lower risk populations{Genders, 2012). NICE CG95 currently recommends 
CT calcium scoring in patients with a low (10-29%) likelihood of CAD. There is emerging 
evidence that extending CT calcium scoring to patients with low and intermediate pre-
test probability of CAD, in addition to (but not in place of) clinical assessment could 
also improve CAD prediction{Genders, 2010; Mouden, 2013}. 
Coronary CTA measures of CAD severity have independent prognostic value{Chow, 
2011} and a prognostic score incorporating plaque burden and stenosis may have 
merit for risk prediction beyond clinical risk scores alone{Hadamitzky, 2013}. 
Biomarker measurement (e.g. highly sensitive Tn assays) is also showing increasing 
promise as a risk prediction tool for cardiovascular events and mortality for patients 
with stable chest pain{Omland, 2013; Lyngback 2013}, but has yet to be incorporated 
into guidelines on the diagnosis of patients with stable CAD. 
8.7 LIMITATIONS 
Due to its retrospective nature, typicality of chest pain had to be estimated from note 
review, and variable interpretations of the nature of chest pain could have resulted in 
some patients in the excluded group (particularly in the small number of patients with 
a history of known CAD) actually being recommended for further investigation.  
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The absolute number of MACE was also small, and comparisons between rates in the 
excluded and included groups should be viewed with caution, as should their 
extrapolation. The use of medical records to determine the occurrence of MACE in this 
study may have contributed to the true incidence being underestimated. Options to 
minimise this bias in future studies include corroboration via patients’ general 
practitioners or patient status tracking via the Office of National Statistics.   
Extending the period of study follow-up beyond six months may also facilitate greater 
understanding of the risks of adopting the NICE CG95 in the RACPC setting.  
8.8 LEARNING POINTS 
 Application of NICE CG95 to a RACPC population may result in up to two-thirds 
of patients being excluded from further cardiac investigation.  
 Up to 10% of patients excluded from further cardiac investigation are 
subsequently diagnosed with significant coronary artery disease, and 2% 
experience a major adverse cardiac event within six months of presentation. 
 Up to two-thirds of all major adverse cardiac events may occur in patients 
diagnosed with non-cardiac chest pain on the basis of history.  
 Information offered by the addition of an anatomical test, such as CCT, or 
cardiac-specific biomarkers (as these are increasingly validated) may allow 
more robust risk stratification and appropriate reassurance to those with 
normal or minor CAD. 
 Adherence to the NICE algorithm alone should not be used to justify excluding 
patients from further investigation if CAD is clinically suspected.  
 The results are also a reminder that guidelines are not edicts{Rastogi, 2014} 
and should not be used as a substitute for clinical judgement or experience in 
the assessment of chest pain. 
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CHAPTER 9: PROSPECTIVE ASSESSEMENT OF THE UTILITY OF CARDIOPULMONARY 
CT IN PATIENTS ADMITTED WITH DYSPNOEA TO THE ACUTE MEDICAL SETTING 
9.1 INTRODUCTION 
Dyspnoea, the subjective sensation of breathlessness, is among the most common 
causes of presentation to the acute medical services. Breathlessness may result from 
a number of independent or concurrent pathologies, most commonly respiratory or 
cardiac in origin. Evidence suggests that a proportion of diagnoses are missed by 
treating clinicians using existing assessment algorithms{Stevenson, 1989; Remes, 
1991; Pope, 2000; Mascarenhas, 2010}.  
CT is already extensively used in the investigation of suspected lung disease. Over the 
past decade there has been mounting evidence that CT may also be used to provide 
accurate, reproducible assessment of cardiac pathology, and specifically CAD. 
Technological advances in cardiac CT and intravenous contrast injection protocols 
have enabled the development of CPCT protocols that simultaneously image the 
coronary, pulmonary and aortic beds, allowing the diagnosis or exclusion of CAD, 
pulmonary embolism, aortic dissection and other clinically significant intra-thoracic 
disease. In the past, the prolonged period of breath-holding required for image 
acquisition limited the utility of CPCT in breathless patients; however, high resolution 
images can be now obtained in a single, short, breath-hold. 
The potential of CPCT as a fast and all-inclusive diagnostic study is appealing for clinical 
practice. Further to evidence that the use of CCT may increase diagnostic sensitivity 
and specificity in patients presenting to the emergency department with acute chest 
pain{Rubinshtein, 2007}, CPCT has been shown to eliminate the need for further 
diagnostic testing in over 75% of patients{Takakuwa, 2008}. In particular, CPCT has 
proven utility in the triage of patients safe for early discharge from hospital{Henzler, 
2013}.  
One small survey reported that 18% of radiology departments have protocols for 
CPCT{Thomas, 2008}. CCT and CPCT are becoming increasingly important for the 
clinical risk stratification of patients presenting to hospital with stable chest pain and 
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suspected ACS. However, studies that have considered the role of CPCT in patients 
with acute dyspnoea are lacking. To date, there is only one study looking into the 
utility of CPCT in acutely breathless patients, and this study is in the context of 
suspected CAD{Rogers, 2011}. The broad overlap between the conditions causing 
chest pain and dyspnoea would suggest CPCT may also be diagnostically useful, 
improve the efficiency and downstream clinical outcomes of acute dyspnoea 
evaluations.  
9.2 AIMS  
This aims of this study were to:  
 Evaluate the spectrum, prevalence and significance of radiological findings in 
patients attending Chelsea and Westminster Acute Assessment Unit with 
symptoms of acute dyspnoea. 
 Describe the diagnostic yield, clinical outcomes and downstream resource use 
of patients undergoing CPCT in clinical practice.  
9.3 PATIENTS AND METHODS  
Consecutive patients who presented to the acute assessment unit of Chelsea and 
Westminster Hospital with the primary complaint of new or worsening dyspnoea, over 
a fourteen month period from July 2010, were screened for entry to the study. 
Exclusion criteria, common to other studies involving CT in this thesis, are detailed in 
Chapter 2.  
Enrolled patients underwent a structured history and physical examination at 
admission. CPCT was performed once optimal heart rate had been achieved according 
to the protocol detailed in Chapter 2. CT scans were assessed by a trained clinician for 
CCS, the presence/absence of coronary artery stenoses, mediastinal, pulmonary 
vascular and pulmonary parenchymal pathology. Where the field of view permitted, 
review of the upper abdominal organs also occurred. Radiological findings were 
classified according to location and clinical importance, as detailed in Chapter 2. CT 
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reports were made available to the treating clinicians, who were solely responsible for 
further management.  
Two sub-groups were identified; those patients who achieved a diagnostic quality 
CPCT (CPCT-Y) and those patients who did not achieve a diagnostic quality CPCT (CPCT-
N). 
Data relating to clinical presentation, demographics, risk factor profiles (i.e. diabetes 
mellitus, smoking history, hyperlipidaemia and hypertension) and clinical course were 
collated for all patients. Medical records were reviewed to obtain results of all 
diagnostic tests performed during the hospital admission and in the 6 months post 
admission. Downstream investigations were defined as all cardiac and respiratory 
tests occurring from admission to completion of follow-up. Data were corroborated 
by telephone survey of patients and their general practitioners at 6 months. 
Diagnoses documented in the medical notes at initial clerking and consultant review 
and in the EPR discharge summary were collated. The diagnostic performance of CPCT 
was assessed using adjudicated discharge diagnoses as reference standards. Diagnosis 
of MACE was based on the judgment of a clinician with access to all clinical and 
laboratory data, and test results through 6 months of follow-up.  
A descriptive analysis was also performed for the sub-group of patients in the CPCT-Y 
group with a previous COPD diagnosis. 
9.4 STATISTICAL ANALYSES 
Using evidence that 35% of asymptomatic patients have evidence of pulmonary 
pathology on CT{Gil, 2007}, we performed a calculation using the one-sample z test 
for population proportion. This indicated that a sample size of 250 would yield a 95% 
confidence interval of width 13% in the prevalence of clinically significant pathology.  
Outcome data were analysed using descriptive statistics. Continuous variables were 
expressed as mean values with standard deviations, ranges and median values where 
appropriate. For non-continuous variables, counts and % frequencies were used. 
Categorical variables were compared using Chi-square or Fisher’s exact tests and the 
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Mann Whitney U test was used for the analysis of non-normally distributed continuous 
variables. Additionally, the distributions of CAD likelihood and clinical risk scores for 
patients in the CPCT-Y and CPCT-N groups were compared using the Mann Whitney U 
test.  
9.5 RESULTS 
9.5.1 Patient population 
A total of 530 patients attending the acute assessment unit at Chelsea and 
Westminster Hospital, with symptoms of dyspnoea, were screened during the 
enrolment period. It was apparent from early in the recruitment phase that the target 
of 250 study participants was unlikely to be achieved based on high exclusion rates. 
Exclusion criteria were identified in 89% (n=474). The reasons for exclusion are 
detailed in Table 9.1.  
Table 9.1: Recruitment analysis  
Number of patients screened 530 (100.0) 
Number of patients recruited 56 (10.6) 
Number of patients screened but not recruited  474 (89.4) 
Reasons for non-recruitment:  
Age <40 years 73 (13.8) 
Acutely unwell/unstable 48 (9.1) 
Previous coronary intervention 16 (3.0) 
Resting HR >70pbm 27 (5.1) 
Poorly controlled asthma 0 (0.0) 
Cardiac CT within preceding 3 months 28 (5.3) 
CI to contrast including CKD 20 (3.8) 
Palliative care 20 (3.8) 
Enrolled in parallel study 6 (1.1) 
Unable to provide written consent 65 (12.3) 
Declined written consent 
 Lack of time 
 Concerns regarding radiation 
 Contrast 
 Medical advice 
 Other 
78 (14.7) 
10 
23 
0 
2 
43 
Logistical issues 49 (9.2) 
Discharged from hospital 44 (8.3) 
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56 patients (median age 68 years, range 41-90 years, male: female ratio 1:1.5) were 
recruited to the study. 43 patients completed CPCT imaging, resulting in 35 scans of 
diagnostic quality (Figure 9.1).  Thus, the CPCT-Y group comprised 35 patients and the 
CPCT-N comprised the remaining 21 patients. Demographic and clinical information 
for both groups is detailed in Table 9.2.   
Figure 9.1: Scanning profiles for recruited patients (n=56) 
 
 
Table 9.2: Study population characteristics (n=56) 
CHARACTERISTIC  TOTAL (%) CPCT-Y (%) CPCT-N (%) P VALUE 
No. of patients 56 (100.0) 35 (100.0) 21 (100.0)  
     
Gender     
  Male 23 15 (42.9) 8 (38.1) 0.785 
 Female 33 20 13  
     
Age     
 Mean ± s.d. 68.80 ± 13.93 67.94 ± 13.19 70.24  ± 15.31 0.571 
 Median 68 66 72  
 Range 40-97 40-90 41-97  
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Cardiac risk factors  
  NICE risk factorsa  
 
43 (76.79) 
 
27 (77.1) 
 
16 (76.2) 
 
1.000 
 Hypertension 26 17 9 0.785 
  Reported CAD 4 1 3 0.143 
  Family history of CAD 10 7 3 0.727 
     
Pack year smoking history     
 Mean ± s.d. 22.95 ± 28.86 26.77 ± 31.57 16.57 ± 22.96  
 Median 11.25 20 5 0.180 
 Range 0-140 0-140 0-80  
     
NYHA     
 Mean ± s.d. 2.18 ± 0.92 2.00 ± 0.94 2.48 ± 0.81 0.051 
 Median 2 2 2  
 Range 1-4 1-4 1-4  
     
TIMI scorea     
 Mean ± s.d. 1.25 ± 0.98 1.03 ± 0.82 1.62 ± 1.12  
 Median 1 1 1 0.0615 
 Range 0-4 0-3 0-4  
     
Wells Scoreb     
 Mean ± s.d. 2.03 ± 2.18 2.01 ± 2.33 2.05 ± 1.97  
 Median 1.5 1.5 1.5 0.741 
 Range 0 -10.5 0 -10.5 0 - 7  
     
Length of stay     
 Mean ± s.d. 4.67 ±  5.04 3.61 ±  3.51 6.44 ±  6.61  
 Median 2.60 2.24 2.87 0.112 
 Range 0.32-24.13 0.32-15.13 0.97-24.13  
     
Downstream investigations      
 CXR 56 35 21 1.000 
 ECHO 22 11 11 0.161 
 Exercise ECG 1 1 0 1.000 
 Functional imaging 11 7 4 1.000 
 Invasive angiography 0 0 0 1.000 
 Doppler uss 1 1 0 1.000 
 VQ scan 0 0 0 1.000 
 CPCT 35 35 0 <0.001 
 Non-CPCT protocol CT 21 4 17 <0.001 
 Bronchoscopy 4 2 2 0.626 
 Pulmonary function test 0 0 0 1.000 
 TOTAL 151 96 55 0.773 
     
OPD clinic appointments     
 Respiratory      
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  Mean  
  Median  
  Range 
0.80 ± 1.34 
0 
0-7 
0.86 ± 1.48 
0 
0-7 
0.71 ± 1.10 
0 
0-3 
0.682 
 Cardiology  
  Mean  
  Median  
  Range 
 
0.52 ± 0.89 
0 
0-3 
 
0.46 ± 0.89 
0 
0-3 
 
0.62 ± 0.92 
0 
0-3 
 
0.522 
 General Medicine 
  Mean  
  Median  
  Range 
 
0.34 ± 0.75 
0 
0-3 
 
0.40 ± 0.88 
0 
0-3 
 
0.24 ± 0.44 
0 
0-1 
 
0.364 
 TOTAL 230 149 81 0.741 
     
Re-presentation to ED with  
dyspnoea 
17 7 10 0.039 
Re-admission with dyspnoea 15 8 7 0.534 
     
MACE 0 0 0 1.000 
aReference: Antman, 2000  
bReference: Wells, 2000  
There were no statistical differences between the groups with respect to age, gender, 
cardiac risk factor profiles or smoking history, although the CPCT-Y group tended 
towards a greater pack-year smoking history (P=0.180).  
9.5.2 Clinical outcomes (for the CPCT-Y group, n=35) 
In the CPCT-Y group, CPCT was unremarkable in 9% (n=3) of patients scanned. 
Abnormalities on CPCT were identified in 91.4% (n=32). In 65.7% (n=23), multiple 
abnormalities were identified, and in 60% (n=21), findings were defined as significant. 
A total of 120 abnormal findings were identified. Of these, 24 were classified as 
benign, 70 as indeterminate and 26 as significant (Table 9.3).  
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Table 9.3: Benign, intermediate and significant findings on CPCT (n= 35) 
CLINICAL SIGNIFICANCE  SYSTEM FINDING NUMBER % OF TOTAL 
SIGNIFICANT CARDIAC CAD >50% 7 20.0 
  Intra-cardiac thrombus 1 2.9 
 PULMONARY Pulmonary embolism 7 20.0 
  Pulmonary nodule >3cm or lesion  with 
malignant characteristics 
3 8.6 
  Pleural lesion with malignant characteristics 1 2.9 
  Unilateral pleural effusion 2 5.7 
  Pneumothorax 1 2.9 
 MEDIASTINAL Aortic aneurysm with mural thrombus 1 2.9 
 OTHER Bone lesion with malignant characteristics 1 2.9 
     
INTERMEDIATE CARDIAC CAD <50% 15 42.9 
  Valve calcification 3 8.6 
  Poorly enhancing myocardium 1 2.9 
  Pericardial effusion 1 2.9 
 PULMONARY Pulmonary nodule >0.8 and <3cm 8 22.9 
  Atelectasis 10 28.6 
  Ground glass change/consolidation 12 34.3 
  Pulmonary fibrosis 2 5.7 
  Pleural thickening 1 2.9 
  Bilateral pleural effusion 2 5.7 
 MEDIASTINAL Mediastinal mass lesion  1 2.9 
  Thyroid mass lesion/enlargement  2 5.7 
  Lymphadenopathy 6 17.1 
 OTHER Hepatic lesion/cyst  3 8.6 
  Renal lesion/cyst 2 5.7 
  Axillary fluid collection 1 2.9 
     
BENIGN CARDIAC Left ventricular hypertrophy 1 2.9 
 PULMONARY Emphysema 6 17.1 
  Bronchiectasis 4 11.4 
 OTHER Hiatus hernia 5 14.3 
  Spinal degeneration 5 14.3 
  Bone haemangioma 1 2.9 
  Bone fracture 3 8.6 
  Small volume kidneys 1 2.9 
 
9.5.2.1 Cardiovascular outcomes 
Mean CCS was 206.25 (s.d. ± 399.88; median 2; range 0-1693). 46% (n=16) of patients 
scanned had a score of zero, 40% (n=14) had a score <400 and14% (n=5) had a score 
153 
 
>400.  On CTA, 37.1% (n=13) had no evidence of CAD, 43% (n=15) had non-significant 
stenosis and 20% (n=7) had significant stenosis, based on luminal obstruction >50%.  
In patients with known COPD (n=10), 60% (n=6) had non-significant stenosis and 20% 
(n=2) had significant stenosis on CTA. 
9.5.2.2 Pulmonary vascular outcomes 
Pulmonary embolism was detected in 20% (n=7) of patients scanned. In five patients 
the emboli were acute and two were chronic. Emboli were distributed in the main 
pulmonary artery (n=2), the lobar arteries (n=1), the segmental arteries (n=2) and the 
sub segmental arteries (n=2). Emboli were identified in 20% (n=2) of the 10 patients 
with known COPD. 
9.5.2.3 Aortic outcomes 
No patients were found to have aortic dissection.  
9.5.2.4 Non-vascular chest outcomes 
Non-vascular chest disease was identified in 89% (n=31) of patients scanned. As 
detailed in Table 9.3, the most commonly identified non-vascular pathologies were 
consolidation (identified in 34%), atelectasis (29%), emphysema (17%), 
lymphadenopathy (17%) and hiatus hernia (14%).  
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Figure 9.2: Diagnostic yield with CPCT (%) 
 
9.5.2.5 Impact of CPCT on diagnosis 
A radiological diagnosis for dyspnoea was identified in 94% (n=33) of patients scanned; 
either pulmonary (54%; n=19), cardiac (20%; n=7) or both (20%; n=7). No extra-
thoracic causes of dyspnoea were identified.  
Inclusion of CPCT in the diagnostic pathway resulted in a refined diagnosis (i.e. 
modified during the course of admission in light of CPCT findings) for 49% (n=17) of 
patients scanned.   
9.5.2.6 Adverse events 
One patient undergoing CPCT experienced bronchoconstriction in response to 
intravenous contrast. All participants survived to hospital discharge and mortality was 
nil for the following six months with no major adverse cardiac events.  
9.5.3 Resource utilisation 
Over the 6 month follow-up period, there was a tendency towards an increased 
frequency of cardiopulmonary investigations in the CPCT-Y group but this was not 
statistically significant (P=0.773).  
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CPCT resulted in a reduced frequency of non-cardiopulmonary investigations 
(P=0.383). Investigations performed in the CPCT-Y cohort were abdominal uss (n=4), 
abdominal MRI (n=1), thyroid uss (n=1), bone studies (n=2) and GI endoscopy (n=2). 
Investigations performed in the CPCT-N cohort were abdominal uss (n=1), abdominal 
MRI (n=1), bone studies (n=3) and GI endoscopy (n=2). 
Although mean and median length of stay were lower in the CPCT-Y group, the 
difference was not statistically significant (P=0.112). 14 patients represented to the 
emergency department and/or were readmitted with dyspnoea on at least one 
occasion. Patients in the CPCT-Y group were significantly less likely to represent 
(P=0.039) but there was no significant difference in the likelihood of patients being re-
admitted between the two groups (P=0.534). 
9.6 DISCUSSION 
This pilot study highlighted clinical and logistical challenges to the introduction of CPCT 
in the acute medical setting. In those patients for whom a diagnostic CPCT was 
achieved, a radiological diagnosis for dyspnoea was identified in 94% and inclusion of 
CPCT in the diagnostic pathway impacted upon the diagnoses made by treating 
clinicians in 49% of patients scanned.  CPCT also revealed incidental pathology ranging 
from clinically significant to benign in 89% of patients scanned. The CPCT approach 
resulted in increased diagnostic testing but reduced hospital length of stay and re-
presentation to the emergency department without a detected increase in MACE.  
In this selected population of patients presenting with dyspnoea, the diagnostic yield 
with CPCT was equal for coronary artery disease and pulmonary embolism.  No 
patients were diagnosed with aortic dissection, making it impossible to estimate the 
performance characteristics of CPCT for this condition. The results highlight a 
difference between patients undergoing CPCT for dyspnoea and chest pain. In the 
emergency department setting, the majority of the pathology yield in patients with 
chest pain is from CAD, with a trivial contribution from new pulmonary 
embolism{Feldmann, 2013}. 
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20% of patients undergoing diagnostic CPCT demonstrated at least 50% diameter 
coronary artery stenosis, warranting further workup. The results raise concern that 
standard assessment for acute breathlessness, which does not include dedicated 
cardiac assessment, may lead to the under-diagnosis of clinically significant CAD in up 
to one fifth of patients presenting to acute assessment units.  
Dyspnoea as a marker of myocardial ischaemia was first described in 1968, when 
Phibbs identified dyspnoea alone in 26% of patients at the time of a positive exercise 
test{Phibbs, 1968}. Data from the GRACE study suggest 8% of patients with ACS 
present without chest pain{Brieger, 2004} and the EuroHeart data set has shown 
around one quarter present with breathlessness at rest{Hamaad, 2004}. A missed 
diagnosis of CAD in patients with dyspnoea or another painless presentation of 
unstable angina increases the likelihood of poor outcome in a population already 
recognised to have greater morbidity and higher mortality than patients with typical 
symptoms{Brieger, 2004; Steg, 2004}. Thus, CPCT assessment of selected breathless 
patients may be particularly useful in atypical presentations of CAD.  
Where CPCT may have the greatest potential is in the exclusion of CAD in patients with 
COPD. In this study 80% of patients scanned with COPD had evidence of CAD. COPD is 
recognised as an independent risk factor for CAD, increasing the odds of disease by a 
factor of 2.7{Finkelstein, 2009}. One-third of deaths in patients with COPD are 
attributable to cardiovascular disease and cardiovascular mortality increases by 28% 
for every 10% decrement in FEV1{Anthonisen, 2002}. Patients with COPD commonly 
exhibit an atypical presentation, reporting dyspnoea more frequently and chest pain 
less frequently than patients without COPD{Andell, 2014}. Patients with COPD are 
more likely to be misdiagnosed and undertreated, contributing to excess mortality in 
this group{Andell, 2014}.  
It has been suggested that myocardial ischaemia should be considered in every patient 
presenting an exacerbation of COPD, recognising that an ACS may coexist with another 
acute illness (Figure9.3). There is some reticence to use beta-blockers in COPD patients 
which may limit the application of CPCT in this context (although rate control will 
become less important with advances in CT technology), despite increasing evidence 
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that beta-blockers are safe and can actually be beneficial in patients with COPD{Quint, 
2013}. 
 
Figure 9.3: A suggested approach to patients with COPD presenting with 
dyspnoea{Sinha, 2014} 
 
An atypical presentation of myocardial infarction (MI) should be considered in every patient presenting with COPD exacerbation. 
Patients with COPD and MI should be urgently assessed for revascularisation and started on guideline-based therapy. Any 
hospitalisation in a patient with COPD, even in the absence of an MI, should be considered an opportunity to assess and optimise 
their coronary risk factors. 
In a previous study of patients undergoing CPCT for suspected ACS, a 1.5% prevalence 
of pulmonary embolism was detected{Takakuwa, 2008}. Based on pilot data, detailed 
in Chapter 1, we predicted a less than three percent prevalence of pulmonary 
embolism in patients admitted with acute dyspnoea. By contrast, this study identified 
pulmonary embolism in 20% of patients undergoing a diagnostic CPCT. Our figures 
correlate with the ‘acceptable’ yield of 9-19% reported with dedicated CT pulmonary 
angiography protocols{Anderson, 2007; Constantino, 2008} and with Schertler et al. 
who identified acute PE in 21% patients with suspected PE using CPCT{Schertler, 
2009}.  
Our results also correlate with studies in COPD that have shown up to twenty five 
percent of patients with an exacerbation of unknown origin have pulmonary embolism 
on CT{Rizkallah, 2009; Tillie-Leblond, 2006}, further supporting a role for CPCT in this 
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population. Identifying PE in patients with COPD is of vital importance due to the 
increased relative risk of death at one year when the conditions occur concurrently 
(RR 1.94 versus RR 1.14 with PE alone){Carson, 1996}.  
Published data suggest around 7.7% of COPD patients have aneurysmal changes of the 
aorta{Lindholt, 1998}. Genetic susceptibility to extracellular matrix degradation and 
secondary inflammation are proposed as common mechanisms in both COPD and 
aneurysm formation{Ramnath, 2014}. Although it is rare for aortic rupture to present 
with dyspnoea, there are case reports of painless left sided haemothorax with non-
catastrophic events{Poondru, 2014}. Given the low prevalence of aortic dissection in 
patients presenting with chest pain {Ayaram, 2013} and the absence of dissection 
amongst our study population of patients with dyspnoea, CPCT may not be justified in 
the diagnosis of this condition. 
Data from chest pain studies suggest that CPCT detects up to a 45% prevalence of 
undiagnosed non-cardiac pathology{Lehman, 2009; Machaalany, 2009; Burt, 2008}, 
although not all pathology is of clinical significance. In a study of 197 patients at low 
to moderate risk of ACS, CPCT provided a non-coronary diagnosis in 11% of 
patients{Takakuwa, 2007}. In our study population we identified non-vascular chest 
disease in 89% of patients undergoing a diagnostic CPCT, which explained 
breathlessness in 49% of patients scanned. The CT findings were predominantly 
consolidation and atelectasis, which it may be argued can be diagnosed by x-ray with 
a lower radiation dose; however, around one in five patients were noted to have 
pulmonary nodularity that would not have been detected by x-ray and one patient 
was diagnosed with new lung adenocarcinoma as a result.  
In the absence of guidelines constraining the tendency to follow-up incidental non-
coronary findings, the use of CPCT may increase costs for the work-up of individual 
patients and lead to patient anxiety without proven benefit{Budoff, 2007}. However, 
early identification of some incidental findings may allow early intervention, improve 
health outcomes and reduce overall costs for the treatment of more advanced 
disease{Gruettner, 2013}.  In this study, assessment involving CPCT resulted in an 
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increased frequency of diagnostic testing but fewer non-cardiopulmonary 
investigations, indicating CPCT may have facilitated more targeted test selection.  
In contrast to CPCT performed to investigate chest pain{Rogers, 2011}, this study 
suggested the use of CPCT reduced length of stay in patients presenting with 
undifferentiated dyspnoea. This is particularly relevant give our observation in 
Chapter 3 that patients with undifferentiated dyspnoea remain in hospital for around 
three days longer than those with chest pain. The effect is likely to have been 
underestimated as not all CCT reports were available to responsible clinicians prior to 
patient discharge (whereas pulmonary imaging was reported directly). Early discharge 
following CPCT occurred without an increase in MACE, suggesting there were no 
significant missed diagnoses as a result.  
Although this study supports the use of CPCT to facilitate early discharge in patients 
with acute dyspnoea, there is justifiable concern regarding high exposure to ionising 
radiation and intravenous contrast, exceeding that for dedicated pulmonary and 
cardiac angiographic protocols. Furthermore, the incidence of poor/uninterpretable 
image quality, noted in around one fifth of scans performed in this study, has been 
found to be greater with CPCT (CPCT 10% vs. coronary CTA 8%, P<0.01){Burris, 2013}.  
 
It has been proposed that dedicated angiographic protocols should be performed as a 
first line when there is a significant pre-test likelihood of CAD/ PE/aortic dissection. 
Where there is diagnostic uncertainty, particularly amongst groups at increased risk 
of atypical presentation, this study confirms a high diagnostic yield using CPCT. Given 
the low frequency of findings in aortic dissection, CPCT may be best utilised for 
patients with suspected pulmonary embolism{Schertler, 2009} or in COPD where it is 
important to exclude CAD and occult PE. CPCT should ideally be reserved for older 
patients who have relatively lower risk of lifelong radiation-induced cancer.  
9.7 LIMITATIONS 
The relatively small study population limits the significance of the data; however, this 
is the first study that has specifically addressed the role of CPCT in dyspnoeic patients 
and it provides a baseline for further prospective, potentially multi-centre, trials. 
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Larger studies may also allow comparison of risk scores (e.g. NYHA, TIMI, Wells) and/or 
smoking history with radiographic findings.  
In the course of this study, cardiac CT reports were not always available for the 
treating clinicians prior to discharge although they received the results at a later point. 
This limits the impact of the investigation on hospital length of stay and may have 
contributed to the relatively low levels of downstream functional cardiac testing and 
invasive coronary angiography despite a 20% prevalence of significant CAD on CPCT. 
Failure of timely reporting is also likely to have minimised differences between the 
CPCT-Y and CPCT-N groups and therefore underplayed the impact of CPCT on 
outcomes and downstream resource use.  
Extending the period of study follow-up beyond six months and more broadly 
exploring the downstream effects of CPCT (e.g. the composite financial contribution 
of evaluation, monitoring, full investigation and therapy and the impact on quality-
adjusted-life-years) may have facilitated greater understanding of the risks and 
benefits of CPCT and the recognition of scenarios in which CPCT does, and does not, 
add ‘value’. 
9.8 LEARNING POINTS 
 CPCT is feasible in selected patients presenting with acute dyspnoea and 
reveals a wide range of vascular and non-vascular chest disease.  
 20% of patients with undifferentiated dyspnoea have evidence of CAD on 
CPCT; in those patients with known COPD the prevalence is 80% 
 20% of patients with undifferentiated dyspnoea have pulmonary embolism; 
prevalence is the same in patients with known COPD 
 Inclusion of CPCT in the diagnostic pathway of patients with undifferentiated 
dyspnoea results in a refined diagnosis for up to half of those scanned.   
 The use of CPCT does not result in increased adverse patient events, suggesting 
the technique may be useful to aid early discharge of patients presenting with 
undifferentiated dyspnoea. 
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 CPCT reduces re-presentation to the emergency department with acute 
dyspnoea and with improved and prompt diagnosis, may contribute to 
reduced risk of hospital readmission. 
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CHAPTER 10: CONCLUSION 
10.1 REVIEW OF FINDINGS 
The studies within this thesis sought to explore a potential role for cardiopulmonary 
assessment with multi-detector CT and provide insights into the potential clinical role 
for this evolving new technology.  
At the inception of this thesis, there was a body of evidence demonstrating good to 
excellent diagnostic accuracy of cardiac CT for the non-invasive visualisation of 
coronary arteries {Meijer, 2008} with high negative predictive values for the presence 
of stenotic disease{Mowatt, 2008; Marano, 2009}. From 2008 onwards, there was also 
increasing evidence to support the diagnostic utility of comprehensive CPCT in 
patients with acute chest pain, via the simultaneous evaluation of the coronary 
arteries, pulmonary arteries, thoracic aorta and other intra-thoracic 
structures{Rubinshtein, 2007; Gallagher, 2008}.  
Where the evidence was more sparse was in the clinical utility of these techniques, 
particularly outside the emergency department setting e.g. in acute medical 
admissions and rapid access chest pain clinics. At the time, there was debate regarding 
whether cardiac CT should be limited to patients with chest pain at low risk of CAD 
{NICE, 2010} and CPCT was being evaluated in patients at low-intermediate risk of CAD 
with possible aortic/pulmonary arterial pathology{Halpern, 2009}. Until this thesis, the 
concept of using CPCT in patients presenting with acute dyspnoea had not been 
introduced.  
10.1.1 Chapter 3 
The inadequacy of existing diagnostic pathways for undifferentiated chest pain and 
dyspnoea were highlighted in this retrospective survey of patients admitted to Chelsea 
and Westminster Hospital over a 5 year period. Of these patients, between 30% and 
40% of patients were discharged without a documented diagnosis. Considering the 
potential of cardiopulmonary CT as a rapid, all-inclusive diagnostic test, we identified 
that CT was performed in only 10% of patients admitted with acute chest pain, 
although uptake was higher in patients admitted with acute dyspnoea(32%; P=0.047). 
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10.1.2 Chapter 4 
This prospective pilot study assessing the feasibility and clinical utility of cardiac CT 
within a diagnostic pathway for acute medical admissions with symptoms of chest pain 
highlighted clinical and logistical challenges.  
Despite broad inclusion criteria to recruit patients with low to moderate risk of CAD 
(likelihood 10-90%), the study recruitment rate was less than 10%. Over 50% of 
individuals screened were ineligible for CCT due to clinical reasons (i.e. known CAD 
with previous intervention, high likelihood of CAD, features of acute myocardial 
infarction). The proportion of ineligible patients would have been still higher if NICE 
CG95 criteria, which restrict CCT to low risk patients, been applied.  
There was patient reticence to undergo CCT. One third of patients offered CCT 
declined the investigation. Although radiation and contrast burden were contributing 
factors, most patients declined CCT to expedite hospital discharge. The non-
availability of CCT outside routine working hours limited our ability to scan patients 
within 24 hours of admission and for CCT to add benefit to the data available to 
clinicians, investment to provide an out of hours service should be considered.  
In the recruited cohort of 14 patients, diagnostic yield for significant CAD was 21%. 
Compared with standard practice in a historical cohort, a diagnostic pathway involving 
CCT resulted in a greater proportion of patients for whom CAD was diagnosed or 
excluded (100% versus 79%; P=0.222). Following CCT there was a 100% increase in 
functional imaging but a 100% decrease in invasive angiography (although absolute 
numbers were small and should be extrapolated with caution). Despite a greater 
number of investigations performed in patients undergoing CCT, costs per capita were 
13.6% lower than with standard care.  
Inclusion of CCT in the diagnostic pathway for acute chest pain admissions had no 
significant impact on hospital length of stay, hospital re-attendance or re-admission 
with chest pain over a three month follow-up but an absolute rate of MACE of zero 
confirmed no detrimental cardiovascular effects with the CCT pathway.  
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10.1.3 Chapter 5 
In the future, it is likely that the diagnostic investigations undertaken for medical 
admissions with suspected cardiac chest pain will be aligned to those recommended 
by NICE CG95. This retrospective study analysed the impact of NICE CG95 on referrals 
for cardiac investigation for the population of medical admissions with acute chest 
pain described in Chapter 4.  
Using NICE criteria, 51% of study population would have been excluded from further 
cardiac testing based on pain deemed non-anginal or a likelihood of CAD <10%. 
Exercise ECG would not have been recommended in this context. 1% of the study 
population would have been recommended for CCT, 6 % for functional testing and 9% 
for invasive coronary angiography. Based on NICE criteria, all patients aged 70 years 
or older with typical or atypical angina symptoms would have been assigned a 
likelihood of CAD whereby they would have been referred for angiography or 
presumed to have angina.  
The results raise concern that adoption of NICE CG95 may result in missed cardiac 
diagnoses and therefore increase mortality risk. NICE CG95 also appears to undervalue 
CCT despite favouring anatomical diagnosis over functional assessment.   
Overall, the results do not support local investment in inpatient CCT services to meet 
NICE CG95 and resources may be better directed towards functional and invasive 
coronary angiography facilities. If NICE expand their recommendations for CCT to 
include patients at intermediate risk of CAD, investment may be better justified.  
10.1.4 Chapter 6 
Prior to this thesis, there was no literature evidence to support the use of CCT in the 
risk stratification of outpatients with stable chest pain. This prospective pilot study 
assessed the feasibility and clinical utility of cardiac CT within a diagnostic pathway for 
RACPC patients with suspected CAD.  
The study recruitment rate was less than 20%. The main barriers to recruitment were 
logistic, relating to CCT or patient non-availability prior to RACPC attendance 
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compounded by a short turn-around time between RACPC referrals being accepted 
and seen.  
In the cohort of 40 patients randomised to CCT, diagnostic yield for significant CAD 
was 13%. Compared with a cohort of 45 patients randomised to standard practice, a 
diagnostic pathway involving CCT resulted in a greater proportion of patients for 
whom CAD was diagnosed or excluded (97% versus 89%; P=0.207).  
Following CCT there were decreases in functional imaging (48%) and in invasive 
angiography (19%) but disappointingly, no significant reduction in the proportion of 
negative functional studies or catheterisations. Despite a greater number of 
investigations performed in patients undergoing CCT, costs per capita were 10% lower 
than with standard care. Inclusion of CCT in the diagnostic pathway for RACPC patients 
resulted in fewer clinic follow-up appointments, further supporting the potential of 
CCT to be a cost effective addition to the RACPC diagnostic armamentarium.  
A low absolute rate of MACE across the entire study population suggests patient 
randomised to CCT were no more likely to experience detrimental cardiovascular 
effects and the trend towards earlier discharge did not result in missed diagnoses. CCT 
had no significant impact on the frequency of hospital attendance or admission with 
chest pain over a six month follow-up. 
10.1.5 Chapter 7 
In the future, it is likely that the diagnostic investigations undertaken in RACPCs will 
be aligned to those recommended by NICE CG95. This retrospective study analysed 
the impact of NICE CG95 on referrals for cardiac investigation, relative to existing 
practice, for patients attending the RACPCs of two central London district general 
hospitals (Chelsea and Westminster Hospital and Ealing Hospital).  
Using NICE criteria, 66% of study population would have been excluded from further 
cardiac testing based on pain deemed non-anginal or a likelihood of CAD <10%. 
Exercise ECG would not have been recommended in this context. 2% of the study 
population would have been recommended for CCT, 12% for functional testing and 
12% for invasive coronary angiography. All patients aged 70 years or older with typical 
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or atypical angina symptoms would have been referred for angiography or presumed 
to have angina.  
Relative to existing practice, there would have been a >1000% increase in discharge 
without investigation, a 43% increase in CCT, a 24% decrease in functional cardiac 
testing and a 500% increase in invasive coronary angiography. The results raise 
concern that NICE CG95 appears to place unprecedented diagnostic weight on clinical 
assessment yet also overcommit to invasive angiography. As noted in acute 
admissions (Chapter 5), CCT and functional testing appear to have been undervalued 
as first line investigations. 
Despite fewer patients undergoing investigation, the bias towards more expensive 
investigations such as invasive angiography over non-invasive and less expensive tests 
such as exercise ECG testing and CCT means that adoption of NICE CG95 would have 
resulted in a 24% increase in the cost of investigation per capita. 
Differences in population demographics, existing and recommended practice at the 
two RACPC sites highlight the risks of service development without prior evaluation of 
NICE compliant local practice. 
10.1.6 Chapter 8 
The high proportion of patients identified for discharge without further cardiac 
investigation in accordance with NICE CG95 (Chapters 5 and 7) prompted analysis of 
the clinical outcomes in these individuals against the outcomes of patients 
recommended for further investigation. This retrospective study compared the 
outcomes for a subgroup of the population attending the RACPCs of two central 
London district general hospitals, described in Chapter 7. 
Amongst the patients recommended for discharge without investigation, a diagnosis 
of significant CAD was subsequently made in 10%, and a MACE occurred within six 
months of presentation in 2%. Two thirds of MACE occurred in patients diagnosed 
with non-anginal chest pain on the basis of history.  
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The results highlight the risk of deferring investigation in accordance with NICE CG95, 
leading to potential missed diagnoses and a significant proportion of patients likely to 
re-present with hard cardiac events (i.e. more resource intensive and expensive to 
manage).  
10.1.7 Chapter 9 
This prospective pilot study assessed the feasibility and clinical utility of CPCT within a 
diagnostic pathway for acute medical admissions with symptoms of dyspnoea.  
The recruitment rate for the study was 11%, due a combination of logistic and clinical 
challenges. 23% of the 56 patients recruited failed to complete scanning and 14% of 
scans were partially or non-diagnostic.  
Amongst the 35 patients for whom a diagnostic CPCT was achieved, a radiological 
diagnosis for dyspnoea was identified in 94%. The diagnostic yield of CPCT was 20% 
for significant CAD, 20% for pulmonary embolism, zero for aortic dissection and 89% 
for non-vascular chest disease. CPCT also revealed incidental pathology ranging from 
clinically significant to benign in 89% of patients scanned.  
For the subset of patients achieving a diagnostic CPCT with a history of COPD, 80% had 
evidence of significant CAD and 20% had evidence of pulmonary embolism on CPCT.  
Inclusion of CPCT in the diagnostic pathway impacted upon the diagnoses made by 
treating clinicians in 49% of patients scanned.  The CPCT approach resulted in 
increased diagnostic testing but reduced hospital length of stay and re-presentation 
to the emergency department, without a detected increase in MACE.  
The potential strength of CPCT in the diagnosis of patients with acute dyspnoea for 
whom there is diagnostic uncertainty, or amongst groups with an increased likelihood 
of atypical presentation such as those with COPD, in whom CAD and occult PE are 
often overlooked.  
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10.1.8 Summary overview 
Overall, these studies suggest that there are significant obstacles to the widespread 
adoption of CCT and CPCT in the acute and outpatient settings. A number of these are 
logistical and may be remedied by investment in infrastructure, personnel and training 
to provide an accessible and responsive CT service if the financial implications can be 
justified. Patient factors, particularly in the acute setting where tachycardia, 
orthopnoea and renal impairment are more prevalent, also limit uptake of the 
technology at present. 
Inclusion of CCT in diagnostic pathways in both acute medical admissions and RACPC 
attenders with chest pain appears to result in fewer patients discharged without a 
diagnosis, fewer invasive angiography procedures and reduced diagnostic costs 
relative to standard practice, suggesting CCT may be a clinically and cost-effective 
addition to the diagnostic investigations currently available.  
In acute medical admissions with dyspnoea, CPCT demonstrates relevant cardiac, 
pulmonary and incidental pathology and provides value to clinicians making 
diagnoses. The strength of the technique is likely to be in the assessment of patients 
in whom there is diagnostic uncertainty. Prompt diagnosis will allow timely initiation 
of targeted management and CCT appears to support early discharge without 
detrimental outcomes.  
Ultimately, the idea that CT may provide a one stop diagnostic capability for all 
patients with acute chest pain and dyspnoea is contrary to the increasing trend for 
personalised medicine. Appropriate patient selection for CCT and CPCT is key to 
achieving both a diagnostic result and one which can be interpreted in the context of 
pre-test probability.  In the future, it is likely that CCT will be targeted to patients with 
chest pain in the narrow cohorts recommended by NICE CG95, despite the fact that 
the strict criteria imposed by NICE potentially undervalue the investigation in both the 
inpatient and outpatient settings.  
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10.2 THE FUTURE 
Significant advances in CT technology have occurred during the period of investigation 
for this thesis. Multi-detector computed tomography (MDCT) has rapidly evolved from 
4-detector row systems in 1998 to 320 and 640-detector row CT systems in clinical use 
today. Wide-area detector coverage and dual-source acquisition strategies have 
further contributed to dramatic reductions in temporal resolution and there is now 
the option for simultaneous dual-energy investigation in a single study. Future 
innovations focused on faster gantry rotation speeds and reductions in radiation 
dosing will facilitate greater spatial resolution, allowing CT to match invasive 
angiography.  
At present, CCT is the only non-invasive investigation able to evaluate robustly the 
presence and extent of CAD, the anatomical severity of CAD, coronary plaque 
characteristics and global atherosclerotic burden but the investigation has recognised 
limitations in its ability to predict the functional relevance of stenoses. Methods are 
emerging to estimate the functional significance of CAD using CCT. The first, CT 
perfusion (CTP), allows evaluation of myocardial ischaemia induced by 
pharmacological stress, but is disadvantaged by its requirement for contrast, 
radiation, and image acquisition beyond standard CCT. The second, transluminal 
contrast attenuation gradient (TAG), identifies lesion-specific ischaemia using manual 
or semi-automated techniques to measure a falloff in contrast in the coronary vessel 
corresponding to coronary blood flow. The third, CT fractional flow reserve (FFR-CT), 
uses anatomic and physiologic data combined with fluid dynamics observed on CCT to 
identify lesion-specific ischaemia. Published data suggest that CT perfusion and FFR-
CT improve accuracy and discrimination versus CT alone for the diagnosis of 
hemodynamically significant CAD{Rocha-Filho, 2010; Min, 2012}. The incremental 
diagnostic value of TAG is less clear{Stuijfzand, 2014}. The potential to provide non-
invasive anatomic and functional assessment in a single scan is likely to enhance the 
clinical utility of CCT and improve the yield of invasive angiography.  
Technological advances to date have prompted stepwise phases of research with an 
academic focus on validation of the technology rather than its potential capability. 
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Seeking to address the following research questions, including those raised by 
Hoffman in 2009{Hoffman, 2009}, will inform future debate regarding the appropriate 
use of CCT and CPCT. 
1. Can a combination of clinical assessment and CCT enhance the diagnosis of 
patients at low risk of CAD? 
2. Can CCT replace functional testing as the initial diagnostic investigation for 
suspected CAD, with or without the addition of CTP, TAG or FFR-CT? 
3. Will CCT lead to an increase in percutaneous intervention on lesions that would 
not have been detected as physiologically significant on functional imaging 
studies?  
4. Will the detection of non-obstructive plaque on CCT prompt medical therapy 
and result in a decrease in future MACE?  
5. Can CPCT reduce the incidence of missed diagnoses in patients with 
unexplained dyspnoea, particularly amongst those patients at risk of atypical 
presentation of CAD? 
6. Will the detection of incidental findings in the CCT or CPCT field of view result 
in increased diagnostic testing and will the benefits of these investigations 
outweigh the risks? 
7. Is there a minimal event rate that justifies the use of CCT or CPCT? 
8. Will advances in MRI offer comparable outcomes to CT angiography and 
perfusion imaging, without the associated radiation burden? 
Further, larger, longer term, outcome studies are necessary to delineate the roles for 
both CCT and CPCT, to optimise clinical and cost-effectiveness, and to allow the 
generation of robust national and international guidance.  
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APPENDIX 
Table App 1.2: Read codes compatible with symptoms of dyspnoeaa 
READ CODE ICD 10 TEXT 
R0606 R060 [D]RESPIRATORY DISTRESS 
R060600 R060 [D]RESPIRATORY DISTRESS 
R0608 R060 [D]SHORTNESS OF BREATH 
R060800 R060 [D]SHORTNESS OF BREATH 
R060A R060 [D]DYSPNOEA 
R060A00 R060 [D]DYSPNOEA 
R061. R061 [D]STRIDOR 
R061.00 R061 [D]STRIDOR 
R0609 R062 [D]WHEEZING 
R060900 R062 [D]WHEEZING 
R060E00 R062 [D]MILD WHEEZE 
R060F00 R062 [D]MODERATE WHEEZE 
R0605 R063 [D]CHEYNE-STOKES RESPIRATION 
R0601 R064 [D]HYPERVENTILATION 
R060100 R064 [D]HYPERVENTILATION 
R04z2 R065 [D]MOUTH BREATHING 
R04z200 R065 [D]MOUTH BREATHING 
R060B R065 [D]SNORING 
R060B00 R065 [D]SNORING 
R068.00 R066 [D]HICCOUGH 
R04z0 R068 [D]CHOKING SENSATION 
R04z000 R068 [D]CHOKING SENSATION 
R0603 R068 [D]TACHYPNOEA 
R060300 R068 [D]TACHYPNOEA 
R0604 R068 [D]APNOEA 
R060400 R068 [D]APNOEA 
R0607 R068 [D]RESPIRATORY INSUFFICIENCY 
R060700 R068 [D]RESPIRATORY INSUFFICIENCY 
R060D R068 [D]BREATHLESSNESS 
R060D00 R068 [D]BREATHLESSNESS 
R060z R068 #MULTIVALUE 
R060z00 R068 [D]RESPIRATORY ABNORMALITIES NOS 
R060z11 R068 [D]MOUTH BREATHER 
R06z. R068 [D]OTHER RESPIRATORY SYSTEM AND CHEST SYMPTOMS 
215 
 
R06z0 R068 [D]BREATH-HOLDING SPELL 
R06z.00 R068 [D]OTHER RESPIRATORY SYSTEM AND CHEST SYMPTOMS 
R06z000 R068 [D]BREATH-HOLDING SPELL 
R06zz00 R068 [D]RESPIRATORY SYSTEM AND CHEST SYMPTOMS NOS 
Ryu03 R068 [X]OTHER AND UNSPECIFIED ABNORMALITIES OF BREATHING 
Ryu0300 R068 [X]OTHER AND UNSPECIFIED ABNORMALITIES OF BREATHING 
R041.00 R070 [D]THROAT PAIN 
R041.11 R070 [D]THROAT DISCOMFORT 
R065300 R071 [D]PAINFUL RESPIRATION NOS 
H00.. J00X #MULTIVALUE 
H00..11 J00X COMMON COLD 
H00..12 J00X CORYZA - ACUTE 
H00..13 J00X FEBRILE COLD 
H00..15 J00X PYREXIAL COLD 
H00..16 J00X RHINITIS - ACUTE 
H010.00 J010 ACUTE MAXILLARY SINUSITIS 
H010.11 J010 ANTRITIS - ACUTE 
H011. J011 ACUTE FRONTAL SINUSITIS 
H011.00 J011 ACUTE FRONTAL SINUSITIS 
H013.00 J013 ACUTE SPHENOIDAL SINUSITIS 
H01y.00 J018 OTHER ACUTE SINUSITIS 
H01yz00 J018 OTHER ACUTE SINUSITIS NOS 
H01z. J019 ACUTE SINUSITIS NOS 
H01z.00 J019 ACUTE SINUSITIS NOS 
H01.. J01X #MULTIVALUE 
H01..11 J01X SINUSITIS 
A340. J020 STREPTOCOCCAL SORE THROAT 
A340.00 J020 STREPTOCOCCAL SORE THROAT 
A3402 J020 STREPTOCOCCAL PHARYNGITIS 
A340200 J020 STREPTOCOCCAL PHARYNGITIS 
A340z J020 STREPTOCOCCAL SORE THROAT NOS 
A340z00 J020 STREPTOCOCCAL SORE THROAT NOS 
H024. J028 ACUTE VIRAL PHARYNGITIS 
H024.00 J028 ACUTE VIRAL PHARYNGITIS 
H022.00 J029 ACUTE ULCERATIVE PHARYNGITIS 
H023z00 J029 ACUTE BACTERIAL PHARYNGITIS NOS 
H02z. J029 ACUTE PHARYNGITIS NOS 
H02z.00 J029 ACUTE PHARYNGITIS NOS 
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H02.. J02X #MULTIVALUE 
H02..11 J02X SORE THROAT NOS 
A3403 J030 STREPTOCOCCAL TONSILLITIS 
A340300 J030 STREPTOCOCCAL TONSILLITIS 
H035z00 J038 ACUTE BACTERIAL TONSILLITIS NOS 
H030.00 J039 ACUTE ERYTHEMATOUS TONSILLITIS 
H031. J039 ACUTE FOLLICULAR TONSILLITIS 
H031.00 J039 ACUTE FOLLICULAR TONSILLITIS 
H03..11 J039 THROAT INFECTION - TONSILLITIS 
H03..12 J039 TONSILLITIS 
H036. J039 ACUTE VIRAL TONSILLITIS 
H036.00 J039 ACUTE VIRAL TONSILLITIS 
H037. J039 RECURRENT ACUTE TONSILLITIS 
H037.00 J039 RECURRENT ACUTE TONSILLITIS 
H03z. J039 ACUTE TONSILLITIS NOS 
H03z.00 J039 ACUTE TONSILLITIS NOS 
H03.. J03X #MULTIVALUE 
H040. J040 ACUTE LARYNGITIS 
H040w J040 ACUTE VIRAL LARYNGITIS UNSPECIFIED 
H040w00 J040 ACUTE VIRAL LARYNGITIS UNSPECIFIED 
H041. J041 ACUTE TRACHEITIS 
H041z00 J041 ACUTE TRACHEITIS NOS 
H042z J042 ACUTE LARYNGOTRACHEITIS NOS 
H043211 J050 CROUP 
H044. J050 CROUP 
H044.00 J050 CROUP 
H0430 J051 ACUTE EPIGLOTTITIS WITHOUT OBSTRUCTION 
H043100 J051 ACUTE EPIGLOTTITIS WITH OBSTRUCTION 
H043z00 J051 ACUTE EPIGLOTTITIS NOS 
H05..00 J068 OTHER ACUTE UPPER RESPIRATORY INFECTIONS 
H051. J069 ACUTE UPPER RESPIRATORY TRACT INFECTION 
H051.00 J069 ACUTE UPPER RESPIRATORY TRACT INFECTION 
H05z. J069 #MULTIVALUE 
H05z.00 J069 UPPER RESPIRATORY INFECTION NOS 
H05z.11 J069 UPPER RESPIRATORY TRACT INFECTION NOS 
H05z.12 J069 VIRAL UPPER RESPIRATORY TRACT INFECTION NOS 
H270100 J100 INFLUENZA WITH PNEUMONIA, INFLUENZA VIRUS IDENTIFIED 
Hyu04 J101 [X]FLU+OTH RESPIRATORY MANIFESTATIONS,'FLU VIRUS IDENTIFIED 
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Hyu0400 J101 [X]FLU+OTH RESPIRATORY MANIFESTATIONS,'FLU VIRUS IDENTIFIED 
Hyu0500 J108 [X]INFLUENZA+OTHER MANIFESTATIONS,INFLUENZA VIRUS 
IDENTIFIED 
H270.00 J110 INFLUENZA WITH PNEUMONIA 
H270z00 J110 INFLUENZA WITH PNEUMONIA NOS 
H27.. J111 INFLUENZA 
H27..00 J111 INFLUENZA 
H271. J111 INFLUENZA WITH OTHER RESPIRATORY MANIFESTATION 
H27z. J111 #MULTIVALUE 
H27z.00 J111 INFLUENZA NOS 
H27z.11 J111 FLU LIKE ILLNESS 
Hyu0600 J111 [X]INFLUENZA+OTH RESPIRATORY MANIFESTATNS,VIRUS NOT 
IDENTIFD 
Hyu0700 J118 [X]INFLUENZA+OTHER MANIFESTATIONS, VIRUS NOT IDENTIFIED 
H200.00 J120 PNEUMONIA DUE TO ADENOVIRUS 
H201.00 J121 PNEUMONIA DUE TO RESPIRATORY SYNCYTIAL VIRUS 
H202. J122 PNEUMONIA DUE TO PARAINFLUENZA VIRUS 
H202.00 J122 PNEUMONIA DUE TO PARAINFLUENZA VIRUS 
H20y.00 J128 VIRAL PNEUMONIA NEC 
H20..00 J129 VIRAL PNEUMONIA 
H20..11 J129 CHEST INFECTION - VIRAL PNEUMONIA 
H20z. J129 VIRAL PNEUMONIA NOS 
H20z.00 J129 VIRAL PNEUMONIA NOS 
H21.. J13X #MULTIVALUE 
H21..00 J13X LOBAR (PNEUMOCOCCAL) PNEUMONIA 
H21..11 J13X CHEST INFECTION - PNEUMOCOCCAL PNEUMONIA 
H222. J14X PNEUMONIA DUE TO HAEMOPHILUS INFLUENZAE 
H222.00 J14X PNEUMONIA DUE TO HAEMOPHILUS INFLUENZAE 
H222.11 J14X PNEUMONIA DUE TO HAEMOPHILUS INFLUENZAE 
H220.00 J150 PNEUMONIA DUE TO KLEBSIELLA PNEUMONIAE 
H221. J151 PNEUMONIA DUE TO PSEUDOMONAS 
H221.00 J151 PNEUMONIA DUE TO PSEUDOMONAS 
H224. J152 PNEUMONIA DUE TO STAPHYLOCOCCUS 
H224.00 J152 PNEUMONIA DUE TO STAPHYLOCOCCUS 
H223000 J153 PNEUMONIA DUE TO STREPTOCOCCUS, GROUP B 
H223. J154 PNEUMONIA DUE TO STREPTOCOCCUS 
H223.00 J154 PNEUMONIA DUE TO STREPTOCOCCUS 
H22y000 J155 PNEUMONIA DUE TO ESCHERICHIA COLI 
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H22y011 J155 E.COLI PNEUMONIA 
H22yX00 J156 PNEUMONIA DUE TO OTHER AEROBIC GRAM-NEGATIVE BACTERIA 
Hyu0900 J156 [X]PNEUMONIA DUE TO OTHER AEROBIC GRAM-NEGATIVE BACTERIA 
H231. J157 PNEUMONIA DUE TO MYCOPLASMA PNEUMONIAE 
H231.00 J157 PNEUMONIA DUE TO MYCOPLASMA PNEUMONIAE 
H28.. J157 ATYPICAL PNEUMONIA 
H28..00 J157 ATYPICAL PNEUMONIA 
H22..00 J158 OTHER BACTERIAL PNEUMONIA 
H22..11 J158 CHEST INFECTION - OTHER BACTERIAL PNEUMONIA 
H22y. J158 PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA 
H22y.00 J158 PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA 
Hyu0A J158 [X]OTHER BACTERIAL PNEUMONIA 
Hyu0A00 J158 [X]OTHER BACTERIAL PNEUMONIA 
H22yz J159 PNEUMONIA DUE TO BACTERIA NOS 
H22yz00 J159 PNEUMONIA DUE TO BACTERIA NOS 
H22z. J159 BACTERIAL PNEUMONIA NOS 
H22z.00 J159 BACTERIAL PNEUMONIA NOS 
H23..11 J168 CHEST INFECTION - PNEUMONIA ORGANISM OS 
H23z.00 J168 PNEUMONIA DUE TO SPECIFIED ORGANISM NOS 
Hyu0B00 J168 [X]PNEUMONIA DUE TO OTHER SPECIFIED INFECTIOUS ORGANISMS 
Hyu0F J173* [X]PNEUMONIA IN PARASITIC DISEASES CLASSIFIED ELSEWHERE 
H25.. J180 #MULTIVALUE 
H25..00 J180 BRONCHOPNEUMONIA DUE TO UNSPECIFIED ORGANISM 
H25..11 J180 CHEST INFECTION - UNSPECIFIED BRONCHOPNEUMONIA 
H260. J181 LOBAR PNEUMONIA DUE TO UNSPECIFIED ORGANISM 
H260.00 J181 LOBAR PNEUMONIA DUE TO UNSPECIFIED ORGANISM 
H260000 J181 LUNG CONSOLIDATION 
H261. J181 BASAL PNEUMONIA DUE TO UNSPECIFIED ORGANISM 
H261.00 J181 BASAL PNEUMONIA DUE TO UNSPECIFIED ORGANISM 
H5400 J182 HYPOSTATIC PNEUMONIA 
Hyu0H00 J188 [X]OTHER PNEUMONIA, ORGANISM UNSPECIFIED 
H26.. J189 #MULTIVALUE 
H26..00 J189 PNEUMONIA DUE TO UNSPECIFIED ORGANISM 
H26..11 J189 CHEST INFECTION - PNEMONIA DUE TO UNSPECIFIED ORGANISM 
H262.00 J189 POSTOPERATIVE PNEUMONIA 
H263.00 J189 PNEUMONITIS, UNSPECIFIED 
H060800 J201 ACUTE HAEMOPHILUS INFLUENZAE BRONCHITIS 
H060C J204 ACUTE BRONCHITIS DUE TO PARAINFLUENZA VIRUS 
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H060C00 J204 ACUTE BRONCHITIS DUE TO PARAINFLUENZA VIRUS 
H060D00 J205 ACUTE BRONCHITIS DUE TO RESPIRATORY SYNCYTIAL VIRUS 
H060E00 J206 ACUTE BRONCHITIS DUE TO RHINOVIRUS 
H0605 J209 ACUTE TRACHEOBRONCHITIS 
H060w00 J209 ACUTE VIRAL BRONCHITIS UNSPECIFIED 
H060z J209 ACUTE BRONCHITIS NOS 
H060z00 J209 ACUTE BRONCHITIS NOS 
H060. J20X #MULTIVALUE 
H060.00 J20X ACUTE BRONCHITIS 
H0615 J210 ACUTE BRONCHIOLITIS DUE TO RESPIRATORY SYNCYTIAL VIRUS 
H061500 J210 ACUTE BRONCHIOLITIS DUE TO RESPIRATORY SYNCYTIAL VIRUS 
H061600 J218 ACUTE BRONCHIOLITIS DUE TO OTHER SPECIFIED ORGANISMS 
Hyu1100 J218 [X]ACUTE BRONCHIOLITIS DUE TO OTHER SPECIFIED ORGANISMS 
H061.00 J219 ACUTE BRONCHIOLITIS 
H061000 J219 ACUTE CAPILLARY BRONCHIOLITIS 
H061100 J219 ACUTE OBLITERATING BRONCHIOLITIS 
H061z J219 ACUTE BRONCHIOLITIS NOS 
H061z00 J219 ACUTE BRONCHIOLITIS NOS 
H061. J21X ACUTE BRONCHIOLITIS 
H062. J22X ACUTE LOWER RESPIRATORY TRACT INFECTION 
H062.00 J22X ACUTE LOWER RESPIRATORY TRACT INFECTION 
H06z0 J22X #MULTIVALUE 
H06z000 J22X CHEST INFECTION NOS 
H06z011 J22X CHEST INFECTION 
H06z1 J22X #MULTIVALUE 
H06z100 J22X LOWER RESP TRACT INFECTION 
H06z111 J22X RESPIRATORY TRACT INFECTION 
H06z112 J22X ACUTE LOWER RESPIRATORY TRACT INFECTION 
H06z200 J22X RECURRENT CHEST INFECTION 
H0z..00 J22X ACUTE RESPIRATORY INFECTION NOS 
SP132 J22X POST OPERATIVE CHEST INFECTION 
SP13200 J22X POST OPERATIVE CHEST INFECTION 
H172.11 J304 HAY FEVER - UNSPECIFIED ALLERGEN 
H17z. J304 ALLERGIC RHINITIS NOS 
H17z.00 J304 ALLERGIC RHINITIS NOS 
H120. J310 #MULTIVALUE 
H120.00 J310 CHRONIC RHINITIS 
H120300 J310 CHRONIC ATROPHIC RHINITIS 
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H120z J310 CHRONIC RHINITIS NOS 
H120z00 J310 CHRONIC RHINITIS NOS 
H121. J312 #MULTIVALUE 
H121.11 J312 SORE THROAT - CHRONIC 
H130. J320 #MULTIVALUE 
H1y8. J393 UPPER RESPIRATORY TRACT HYPERSENSITIVITY REACTION NOS 
H1y8.00 J393 UPPER RESPIRATORY TRACT HYPERSENSITIVITY REACTION NOS 
H5y12 J398 STENOSIS OF TRACHEA 
H5y1200 J398 STENOSIS OF TRACHEA 
Hyu2A00 J398 [X]OTHER SPECIFIED DISEASES OF UPPER RESPIRATORY TRACT 
H3... J40X #MULTIVALUE 
H30.. J40X #MULTIVALUE 
H3...00 J40X CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
H300. J40X TRACHEOBRONCHITIS NOS 
H30..00 J40X BRONCHITIS UNSPECIFIED 
H300.00 J40X TRACHEOBRONCHITIS NOS 
H301. J40X LARYNGOTRACHEOBRONCHITIS 
H30..12 J40X RECURRENT WHEEZY BRONCHITIS 
H302.00 J40X WHEEZY BRONCHITIS 
H30z. J40X BRONCHITIS NOS 
H30z.00 J40X BRONCHITIS NOS 
H310. J410 SIMPLE CHRONIC BRONCHITIS 
H31.. J42X CHRONIC BRONCHITIS 
H31..00 J42X CHRONIC BRONCHITIS 
H31z. J42X CHRONIC BRONCHITIS NOS 
H31z.00 J42X CHRONIC BRONCHITIS NOS 
H321.00 J431 PANLOBULAR EMPHYSEMA 
H322.00 J432 CENTRILOBULAR EMPHYSEMA 
Hyu3000 J438 [X]OTHER EMPHYSEMA 
H32.. J439 EMPHYSEMA 
H32..00 J439 EMPHYSEMA 
H32z. J439 EMPHYSEMA NOS 
H32z.00 J439 EMPHYSEMA NOS 
H3y0.00 J440 CHRONIC OBSTRUCT PULMONARY DIS WITH ACUTE LOWER RESP 
INFECTN 
H3122 J441 ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE 
H312200 J441 ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE 
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H3y1. J441 CHRON OBSTRUCT PULMONARY DIS WTH ACUTE EXACERBATION, 
UNSPEC 
H3y1.00 J441 CHRON OBSTRUCT PULMONARY DIS WTH ACUTE EXACERBATION, 
UNSPEC 
H061400 J448 OBLITERATING FIBROUS BRONCHIOLITIS 
H312. J448 OBSTRUCTIVE CHRONIC BRONCHITIS 
H3120 J448 #MULTIVALUE 
H312.00 J448 OBSTRUCTIVE CHRONIC BRONCHITIS 
H312000 J448 CHRONIC ASTHMATIC BRONCHITIS 
Hyu3100 J448 [X]OTHER SPECIFIED CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
H36..00 J449 MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
H38..00 J449 SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
H39..00 J449 VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
H3z.. J449 #MULTIVALUE 
H3z..00 J449 CHRONIC OBSTRUCTIVE AIRWAYS DISEASE NOS 
H3z..11 J449 CHRONIC OBSTRUCTIVE PULMONARY DISEASE NOS 
H3y.. J44X #MULTIVALUE 
H3y..00 J44X OTHER SPECIFIED CHRONIC OBSTRUCTIVE AIRWAYS DISEASE 
H330. J450 #MULTIVALUE 
H33..00 J450 ASTHMA 
H3300 J450 #MULTIVALUE 
H330.00 J450 EXTRINSIC (ATOPIC) ASTHMA 
H330011 J450 HAY FEVER WITH ASTHMA 
H330.11 J450 ALLERGIC ASTHMA 
H330.12 J450 CHILDHOOD ASTHMA 
H330.13 J450 HAY FEVER WITH ASTHMA 
H330z J450 EXTRINSIC ASTHMA NOS 
H330z00 J450 EXTRINSIC ASTHMA NOS 
H331. J451 #MULTIVALUE 
H331.11 J451 LATE ONSET ASTHMA 
H331z J451 INTRINSIC ASTHMA NOS 
H333. J459 ACUTE EXACERBATION OF ASTHMA 
H333.00 J459 ACUTE EXACERBATION OF ASTHMA 
H334.00 J459 BRITTLE ASTHMA 
H33z. J459 #MULTIVALUE 
H33z.00 J459 ASTHMA UNSPECIFIED 
H33z1 J459 #MULTIVALUE 
H33z100 J459 ASTHMA ATTACK 
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H33z111 J459 ASTHMA ATTACK NOS 
H33z200 J459 LATE-ONSET ASTHMA 
H33zz J459 #MULTIVALUE 
H33zz00 J459 ASTHMA NOS 
H33zz12 J459 ALLERGIC ASTHMA NEC 
H33zz13 J459 ALLERGIC BRONCHITIS NEC 
H330100 J46X EXTRINSIC ASTHMA WITH STATUS ASTHMATICUS 
H331100 J46X INTRINSIC ASTHMA WITH STATUS ASTHMATICUS 
H33z0 J46X #MULTIVALUE 
H33z000 J46X STATUS ASTHMATICUS NOS 
H33z011 J46X SEVERE ASTHMA ATTACK 
H34.. J47X BRONCHIECTASIS 
H34..00 J47X BRONCHIECTASIS 
H340.00 J47X RECURRENT BRONCHIECTASIS 
H34z. J47X BRONCHIECTASIS NOS 
H34z.00 J47X BRONCHIECTASIS NOS 
H41.. J61X ASBESTOSIS 
H41..00 J61X ASBESTOSIS 
H41z. J61X ASBESTOSIS NOS 
H41z.00 J61X ASBESTOSIS NOS 
H434.00 J634 SIDEROSIS 
H45..00 J64X PNEUMOCONIOSIS NOS 
H357.00 J677 "VENTILATION" PNEUMONITIS 
H35.. J679 EXTRINSIC ALLERGIC ALVEOLITIS 
H35..00 J679 EXTRINSIC ALLERGIC ALVEOLITIS 
H35z100 J679 HYPERSENSITIVITY PNEUMONITIS NOS 
H460.00 J680 BRONCHITIS AND PNEUMONITIS DUE TO CHEMICAL FUMES 
H460100 J680 ACUTE PNEUMONITIS DUE TO CHEMICAL FUMES 
H462. J682 UPPER RESPIRATORY INFLAMMATION DUE TO CHEMICAL FUMES 
H470. J690 #MULTIVALUE 
H470.00 J690 PNEUMONITIS DUE TO INHALATION OF FOOD OR VOMITUS 
H470000 J690 PNEUMONITIS DUE TO INHALATION OF REGURGITATED FOOD 
H470100 J690 PNEUMONITIS DUE TO INHALATION OF GASTRIC SECRETIONS 
H470.11 J690 ASPIRATION PNEUMONIA 
H4702 J690 #MULTIVALUE 
H4703 J690 #MULTIVALUE 
H470311 J690 VOMIT INHALATION PNEUMONITIS 
H470312 J690 ASPIRATION PNEUMONIA DUE TO VOMIT 
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H470z J690 PNEUMONITIS DUE TO INHALATION OF FOOD OR VOMITUS NOS 
H470z00 J690 PNEUMONITIS DUE TO INHALATION OF FOOD OR VOMITUS NOS 
H47.. J698 #MULTIVALUE 
H47..00 J698 PNEUMONITIS DUE TO INHALATION OF SOLIDS OR LIQUIDS 
H47..11 J698 ASPIRATION PNEUMONITIS 
H47y.00 J698 PNEUMONITIS DUE TO INHALATION OF OTHER SOLID OR LIQUID 
H47yz J698 PNEUMONITIS DUE TO INHALATION OF SOLID OR LIQUID NOS 
H47yz00 J698 PNEUMONITIS DUE TO INHALATION OF SOLID OR LIQUID NOS 
H47z. J698 PNEUMONITIS DUE TO INHALATION OF SOLID OR LIQUID NOS 
H47z.00 J698 PNEUMONITIS DUE TO INHALATION OF SOLID OR LIQUID NOS 
Hyu4700 J698 [X]PNEUMONITIS DUE TO INHALATION OF OTHER SOLIDS AND 
LIQUIDS 
H4y0.00 J700 ACUTE PULMONARY RADIATION DISEASE 
H4y10 J701 CHRONIC PULMONARY FIBROSIS FOLLOWING RADIATION 
H4y1.00 J701 CHRONIC PULMONARY RADIATION DISEASE 
H5850 J80X PULMONARY INSUFFICIENCY FOLLOWING SHOCK 
H5853 J80X ADULT RESPIRATORY DISTRESS SYNDROME 
H585300 J80X ADULT RESPIRATORY DISTRESS SYNDROME 
H585z J80X TRAUMA AND POST-OPERATIVE PULMONARY INSUFFICIENCY NOS 
H54.. J81X PULMONARY CONGESTION AND HYPOSTASIS 
H54..00 J81X PULMONARY CONGESTION AND HYPOSTASIS 
H541000 J81X CHRONIC PULMONARY OEDEMA 
H541z J81X PULMONARY OEDEMA NOS 
H541z00 J81X PULMONARY OEDEMA NOS 
H584. J81X #MULTIVALUE 
H5840 J81X POSTOPERATIVE PULMONARY OEDEMA 
H584.00 J81X ACUTE PULMONARY OEDEMA UNSPECIFIED 
H584000 J81X POSTOPERATIVE PULMONARY OEDEMA 
H584.11 J81X ACUTE OEDEMA OF LUNG, UNSPECIFIED 
H584z J81X ACUTE PULMONARY OEDEMA NOS 
H584z00 J81X ACUTE PULMONARY OEDEMA NOS 
H583. J82X PULMONARY EOSINOPHILIA 
H583.00 J82X PULMONARY EOSINOPHILIA 
H5831 J82X TROPICAL EOSINOPHILIA 
H583z00 J82X PULMONARY EOSINOPHILIA NOS 
H562.00 J840 PULMONARY ALVEOLAR MICROLITHIASIS 
H55..11 J841 CIRRHOSIS OF LUNG 
H563. J841 #MULTIVALUE 
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H563.00 J841 IDIOPATHIC FIBROSING ALVEOLITIS 
H5631 J841 DIFFUSE PULMONARY FIBROSIS 
H563100 J841 DIFFUSE PULMONARY FIBROSIS 
H563.12 J841 CRYPTOGENIC FIBROSING ALVEOLITIS 
H563z00 J841 IDIOPATHIC FIBROSING ALVEOLITIS NOS 
Hyu50 J841 [X]OTHER INTERSTITIAL PULMONARY DISEASES WITH FIBROSIS 
Hyu5000 J841 [X]OTHER INTERSTITIAL PULMONARY DISEASES WITH FIBROSIS 
H58y3 J848 INTERSTITIAL LUNG DISEASE NEC 
H58y300 J848 INTERSTITIAL LUNG DISEASE NEC 
Hyu51 J848 [X]OTHER SPECIFIED INTERSTITIAL PULMONARY DISEASES 
Hyu5100 J848 [X]OTHER SPECIFIED INTERSTITIAL PULMONARY DISEASES 
H56y1 J849 INTERSTITIAL PNEUMONIA 
H56y100 J849 INTERSTITIAL PNEUMONIA 
H530200 J850 GANGRENOUS PNEUMONIA 
H5303 J851 ABSCESS OF LUNG WITH PNEUMONIA 
H530. J852 ABSCESS OF LUNG 
H530.00 J852 ABSCESS OF LUNG 
H530100 J852 MULTIPLE LUNG ABSCESS 
H530z00 J852 ABSCESS OF LUNG NOS 
H531.00 J853 ABSCESS OF MEDIASTINUM 
H5000 J860 EMPYEMA WITH BRONCHOCUTANEOUS FISTULA 
H500.00 J860 EMPYEMA WITH FISTULA 
H500z00 J860 EMPYEMA WITH FISTULA NOS 
J10y2 J860 TRACHEO-OESOPHAGEAL FISTULA 
J10y200 J860 TRACHEO-OESOPHAGEAL FISTULA 
H50.. J869 EMPYEMA 
H50..00 J869 EMPYEMA 
H501100 J869 THORAX ABSCESS NOS 
H5012 J869 PLEURAL EMPYEMA 
H501200 J869 PLEURAL EMPYEMA 
H5013 J869 LUNG EMPYEMA NOS 
H5016 J869 PYOTHORAX 
H501600 J869 PYOTHORAX 
H50z. J869 EMPYEMA NOS 
H50z.00 J869 EMPYEMA NOS 
H5109 J90X PNEUMOCOCCAL PLEURISY 
H511.00 J90X BACTERIAL PLEURISY WITH EFFUSION 
H51y.00 J90X OTHER PLEURAL EFFUSION EXCLUDING MENTION OF TUBERCULOSIS 
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H51yz J90X OTHER PLEURAL EFFUSION 
H51z. J90X PLEURAL EFFUSION NOS 
H51z.00 J90X PLEURAL EFFUSION NOS 
H51zz J90X PLEURAL EFFUSION NOS 
H51zz00 J90X PLEURAL EFFUSION NOS 
H410.00 J920 PLEURAL PLAQUE DISEASE DUE TO ASBESTOSIS 
H510100 J929 THICKENING OF PLEURA 
H520. J930 SPONTANEOUS TENSION PNEUMOTHORAX 
H520.00 J930 SPONTANEOUS TENSION PNEUMOTHORAX 
H52y.00 J931 OTHER SPONTANEOUS PNEUMOTHORAX 
H52yz J931 #MULTIVALUE 
H52yz00 J931 OTHER SPONTANEOUS PNEUMOTHORAX NOS 
H52yz11 J931 SPONTANEOUS PNEUMOTHORAX NOS 
Hyu7100 J931 [X]OTHER SPONTANEOUS PNEUMOTHORAX 
H52y000 J938 ACUTE PNEUMOTHORAX NOS 
Hyu7200 J938 [X]OTHER PNEUMOTHORAX 
H52.. J939 PNEUMOTHORAX 
H52..00 J939 PNEUMOTHORAX 
H52z. J939 PNEUMOTHORAX NOS 
H52z.00 J939 PNEUMOTHORAX NOS 
H51y500 J940 CHYLOUS EFFUSION 
H51y1 J942 HAEMOPNEUMOTHORAX 
H51y100 J942 HAEMOPNEUMOTHORAX 
H51y200 J942 HAEMOTHORAX 
H510200 J948 CALCIFICATION OF PLEURA 
H51y000 J948 ENCYSTED PLEURISY 
H51y300 J948 HYDROPNEUMOTHORAX 
H51y400 J948 HYDROTHORAX 
H5X.. J949 PLEURAL CONDITION, UNSPECIFIED 
H5y0.00 J950 TRACHEOSTOMY COMPLICATION 
H5y0000 J950 TRACHEOSTOMY HAEMORRHAGE 
H5y0300 J950 TRACHEOSTOMY OBSTRUCTION 
H5y0z00 J950 TRACHEOSTOMY COMPLICATION NOS 
H5851 J952 PULMONARY INSUFFICIENCY FOLLOWING SURGERY 
Hy03.00 J955 POSTPROCEDURAL SUBGLOTTIC STENOSIS 
Hy04.00 J958 POSTPROCEDURAL RESPIRATORY FAILURE 
Hyu8000 J958 [X]OTHER POSTPROCEDURAL RESPIRATORY DISORDERS 
SP131 J958 OTHER ASPIRATION PNEUMONIA AS A COMPLICATION OF CARE 
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SP13100 J958 OTHER ASPIRATION PNEUMONIA AS A COMPLICATION OF CARE 
SP13. J959 RESPIRATORY COMPLICATIONS OF CARE 
SP13.00 J959 RESPIRATORY COMPLICATIONS OF CARE 
SP13z J959 RESPIRATORY COMPLICATION OF CARE NOS 
SP13z00 J959 RESPIRATORY COMPLICATION OF CARE NOS 
H590. J960 ACUTE RESPIRATORY FAILURE 
H590.00 J960 ACUTE RESPIRATORY FAILURE 
H591.00 J961 CHRONIC RESPIRATORY FAILURE 
H593.00 J961 CHRONIC TYPE 2 RESPIRATORY FAILURE 
H59.. J969 RESPIRATORY FAILURE 
H59..00 J969 RESPIRATORY FAILURE 
R2y1. J969 [D]RESPIRATORY FAILURE 
R2y1.00 J969 [D]RESPIRATORY FAILURE 
R2y1z J969 [D]RESPIRATORY FAILURE NOS 
R2y1z00 J969 [D]RESPIRATORY FAILURE NOS 
H58y. J980 OTHER LUNG DISEASE NEC 
H58y0 J980 BRONCHOLITHIASIS 
H5y1. J980 #MULTIVALUE 
H5y1.00 J980 OTHER DISEASES OF TRACHEA AND BRONCHUS NEC 
H5y1100 J980 CALCIFICATION OF BRONCHUS 
H5y1.11 J980 OTHER BRONCHUS DISEASE 
H5y1300 J980 STENOSIS OF BRONCHUS 
H5y1600 J980 BRONCHOSPASM 
H5y1z J980 DISEASES OF TRACHEA AND BRONCHUS NEC NOS 
H5y1z00 J980 DISEASES OF TRACHEA AND BRONCHUS NEC NOS 
H580. J981 #MULTIVALUE 
H5800 J981 POST OPERATIVE ATELECTASIS 
H580.00 J981 PULMONARY COLLAPSE WITH ATELECTASIS 
H580000 J981 POST OPERATIVE ATELECTASIS 
H580.11 J981 ATELECTASIS 
H580.12 J981 COLLAPSE OF LUNG 
H581. J982 #MULTIVALUE 
H581.11 J982 PNEUMOMEDIASTINUM 
H58.. J984 OTHER DISEASES OF LUNG 
H58..00 J984 OTHER DISEASES OF LUNG 
H58yz00 J984 OTHER LUNG DISEASE NEC NOS 
H58z. J984 LUNG DISEASE NOS 
H58z.00 J984 LUNG DISEASE NOS 
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Hyu8100 J984 [X]OTHER DISORDERS OF LUNG 
H5y2.00 J985 MEDIASTINITIS 
H5y3.00 J985 OTHER DISEASES OF MEDIASTINUM, NEC 
H5y3z00 J985 DISEASES OF MEDIASTINUM, NEC NOS 
H5y4.00 J986 DISORDERS OF DIAPHRAGM 
H5y4000 J986 DIAPHRAGMATITIS 
H5y41 J986 PARALYSIS OF DIAPHRAGM 
H5y4z00 J986 DISORDERS OF DIAPHRAGM NOS 
H5C.. J988 CHOKING DUE TO AIRWAYS OBSTRUCTION 
H5C..00 J988 CHOKING DUE TO AIRWAYS OBSTRUCTION 
H5y.. J988 OTHER SPECIFIED DISEASES OF RESPIRATORY SYSTEM 
H5y..00 J988 OTHER SPECIFIED DISEASES OF RESPIRATORY SYSTEM 
H5yy. J988 #MULTIVALUE 
H5yy.00 J988 OTHER DISEASES OF RESPIRATORY SYSTEM NEC 
H5yy.11 J988 RESPIRATORY INFECTION NOS 
Hyu82 J988 [X]OTHER SPECIFIED RESPIRATORY DISORDERS 
Hyu8200 J988 [X]OTHER SPECIFIED RESPIRATORY DISORDERS 
H5yz. J989 OTHER DISEASES OF RESPIRATORY SYSTEM NOS 
H5yz.00 J989 OTHER DISEASES OF RESPIRATORY SYSTEM NOS 
H5z..00 J989 RESPIRATORY SYSTEM DISEASES NOS 
aNo cases of cardiac failure, PE or malignancy recorded 
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Table App 1.2: Number of patients discharged with respiratory diagnoses (Feb 2008 
- Feb 2012; n=4600) 
 DESCRIPTOR NUMBER OF PATIENTS  
(% OF TOTAL) 
Infection Upper respiratory tract infection 
Chest/Lower respiratory tract infection 
Pneumonia 
Aspiration pneumonia/pneumonitis 
Lung abscess 
Viral infection 
Respiratory infection NOS 
178 (3.9) 
838 (18.2) 
1134 (24.7) 
204 (4.3) 
2 (0.04) 
59 (1.3) 
24 (0.5) 
Atopic disease Hay fever/rhinitis 3 (0.07) 
Obstructive lung 
disease 
Upper airway obstruction 
Bronchitis 
Asthma/bronchospasm 
COPD/emphysema 
2 (0.04) 
15 (0.3) 
441 (9.6) 
985 (21.4) 
Bronchiectasis Bronchiectasis 34 (0.7) 
Interstitial lung disease Interstitial lung disease/radiation associated 36 (0.8) 
Pulmonary vascular 
disease 
Pulmonary embolism  
Pulmonary oedema 
0 (0.0) 
39 (0.9) 
Disorders of the 
mediastinum and 
pleura 
Pneumothorax/pneumomediastinum 
Pleural effusion 
Empyema 
130 (2.8) 
126 (2.7) 
10 (0.2) 
Respiratory failure Respiratory failure 124 (2.7) 
Other Symptoms not attributed to disease process 168 (3.7) 
 Radiologic features not attributed to 
disease process  
39 (0.9) 
 Unspecified respiratory disease 9 (0.2) 
Total  4600 (100) 
 
 
